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Abstract 
 
The INK4A tumour suppressor gene is negatively regulated by the Polycomb Group 
(PcG)  complexes,  which  plays  an  important  role  in  stem  cell-  and  cancer  biology. 
Polycomb Repressive Complex 1 (PRC1) members posterior sex comb protein BMI1 
and polycomb proteins CBX7 and CBX8 have been shown to be directly involved in 
repression of INK4A and delay of senescence, whereas evidence from mouse genetics 
suggests that polyhomeotic protein Ph2 is also required. However, it is still unknown 
why the mammalian PRC1 complex has so many possible permutations compared to the 
basic system in Drosphila and how this relates to the regulation of a single target gene. 
The  aim  was  therefore  to  define  the  requirement  and  function  of  the  three  human 
polyhomeotic members, HPH1, -2 and -3, for INK4A repression. It was found that 
depletion  of  all  HPH  proteins  by  shRNA-mediated  knockdown  in  primary  human 
fibroblasts  results  in  derepression  of  INK4A  and  premature  senescence.  In  contrast, 
overexpression of HPH proteins leads to activation of INK4A accompanied by loss of 
PRC1 binding and PcG-associated histone H3K27 trimethylation at the locus. These 
diametrically opposite findings suggest that  a fine balance in HPH protein levels is 
required for PcG repression. Furthermore, biochemical investigation of the interaction 
between  CBX  and  HPH  proteins  did  not  demonstrate  any  level  of  specificity,  but 
emphasised the RNA binding capacity of both proteins, which was further investigated. 
In addition, by tandem affinity purification and mass spectrometry analysis it was found 
that  HPH2  interacts  with  both  PRC1  components  and  novel  proteins,  which  were 
studied for involvement in INK4A repression. In summary, this thesis demonstrates an 
essential  role  for  the  HPH  proteins  in  the  regulation  of INK4A  and  provides  novel 
insights into their functional contribution to PcG repression.   4 
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1  Introduction 
 
1.1  The Polycomb Group Family 
 
The Polycomb Group (PcG) represents a family of transcriptional repressors that play 
an  important  role  in  maintaining  the  repressed  state  of  genes  in  the  developmental 
regulatory transcription programs. PcG proteins are considered to be part of the cellular 
memory  system,  which  ensures  the  transmission  of  cellular  identities  through  cell 
division. Moreover, deregulated expression of PcG proteins has important implications 
in cancer and stem cell self-renewal (discussed in more detail in section 1.2). Most of 
the  fundamental  knowledge  about  PcG  repression  was  derived  from  research  in 
Drosophila. 
 
1.1.1  Drosophila Polycomb Biology 
 
PcG genes were initially discovered in the fruitfly Drosophila melanogaster. Mutations 
in the PcG genes were found to cause multiple homeotic transformations, which were 
similar to gain-of-function mutations of the homeotic selector genes. The first mutant 
had a phenotype of disrupted segmentation displaying multiple sex combs, and hence 
was  named  Polycomb  (Sandler  et  al.,  1968).  The  Polycomb  gene  was  subsequently 
discovered  to  be  part  of  a  gene  family,  the  polycomb  group  (PcG),  controlling 
segmentation by repression of the homeotic genes (Lewis, 1978). The homeobox or Hox 
genes are a set of transcription factors that are expressed in a spatially restricted manner 
along the anteroposterior axis during development, which results in the morphological 
differences  between  segments  from  head  to  tail  (Krumlauf,  1994).  Consequent 
identification of the trithorax group (TrxG) that activate homeotic genes has led to a 
concept  of  a  balance  between  silencing  and  activating  factors  that  together  provide 
cellular memory at different stages of development (Kennison and Tamkun, 1988; Shao 
et al., 1999). In early stage embryonic development Hox genes are initially regulated by 
transiently  expressed  segmentation  genes,  but  later  PcG  and  TrxG  are  required  to 
maintain the correct pattern of Hox gene expression.    16 
Subsequently identified genetic interactions and biochemical studies indicated 
that both the members of the PcG and TrxG groups form large multiprotein complexes 
(reviewed in (Schuettengruber et al., 2007)). These complexes interact directly with the 
chromatin at their target gene. In Drosophila, specific DNA regulatory elements, named 
Polycomb and Trithorax response elements (PRE and TRE respectively) were found to 
be necessary and sufficient for recruitment of both PcG and TrxG complexes. Although 
these elements serve a common function throughout the Drosophila genome, the PREs 
and TREs do not carry any consensus sequence (reviewed in (Schwartz and Pirrotta, 
2007)). Recently, the first example of a vertebrate PRE was discovered in mouse (Sing 
et al., 2009). Nevertheless, it is important to note that there are substantial differences 
between  the  Drosophila  and  the  mammalian  mechanism  of  PcG  repression.  For 
example, four of the DNA binding elements important in Drosophila PcG recruitment, 
GAF,  Pipsqueak,  Zeste  and  DSP1,  are  not  conserved  in  vertebrates  (reviewed  in 
(Sparmann  and  van  Lohuizen,  2006)).  It  is  therefore  important  to  be  cautious  in 
generalising  mechanistic  findings  about  PcG-mediated  repression  across  species. 
Perhaps  one  of  the  most  striking  differences  between  Drosophila  and  mammalian 
Polycomb  biology  is  the  expansion  in  the  number  and  diversity  of  proteins  that 
constitute the Polycomb complexes. 
 
1.1.2  Polycomb Complexes 
 
The textbook version of PcG-mediated repression holds that the PcG proteins function 
through  the  combined  activity  of  two  Polycomb  repressive  complexes  (PRC);  the 
initiator  complex,  PRC2,  and  the  maintenance  complex,  PRC1  (reviewed  in 
(Schuettengruber  et  al.,  2007)).  Although  biochemical  analysis  of  both  complexes 
suggests that they are independent entities with separate functions and timing (Ng et al., 
2000; Sewalt et al., 1998; Shao et al., 1999; Tie et al., 2001; van Lohuizen et al., 1998), 
a transient interaction between components of both complexes has been observed in 
early  embryonic  development  (Poux  et  al.,  2001;  van  Lohuizen  et  al.,  1998). 
Furthermore,  it  has  been  reported  that  complex  formation  is  important  for  the 
stabilization  of  PcG  proteins  both  in  vivo  and  in  vitro  (Leeb  and  Wutz,  2007; 
Montgomery et al., 2005; Pasini et al., 2004). It was found that if one protein is lost, the 
others are also affected post-transcriptionally (Montgomery et al., 2005). This would   17 
suggest that PcG proteins not incorporated into complexes may be degraded (reviewed 
in (Schwartz and Pirrotta, 2008)). 
It  has  also  been  observed  that  PcG  complexes  form  subnuclear  silencing 
compartments, or Polycomb/PcG bodies, that may play a role in the stable repression of 
transcription (Saurin et al., 1998). Immunofluorescence of PcG proteins shows clear 
speckles, but the number of speckles decrease  during development (Grimaud et al., 
2006). It was shown that that the formation of these Polycomb bodies in Drosophila, 
requires  colocalisation  of  components  of  the  RNA  interference  (RNAi)  machinery 
(Grimaud et al., 2006). This is particularly interesting due to the increasing observations 
of  RNA  involvement  in  PcG-mediated  repression,  which  will  be  discussed  in  more 
detail in section 1.1.3.5. 
 
1.1.2.1  The PRC1 Complex 
 
The PRC1 complex was first purified from Drosophila where it was found to actively 
inhibit the activity of TrxG complexes (Shao et al., 1999). PRC1 was found to consist of 
four  conserved  core  components,  Polycomb  (Pc),  Polyhomeotic  (Ph),  Posterior  sex 
combs (Psc) and Sex combs extra (Sce). Over recent years, it has been established that 
the mammalian PcG family has multiple paralogues for each Drosophila component, 
with five polycombs (CBX2/4/6/7/8), three polyhomeotic (HPH1/2/3), six posterior sex 
combs (PSC1-6) and two sex combs extra (RING1A/1B) proteins (Francis et al., 2001; 
Levine et al., 2002; Whitcomb et al., 2007). At present, there is no universally accepted 
nomenclature for these proteins. For completeness, all the names used for Drosophila, 
mouse and human PcG proteins are listed in Table 1, where the names in bold will be 
those used in this thesis. The functional basis of this evolutionary expansion of PRC1 
genes  is  unknown,  but  within  the  context  of  a  core  complex  of  four  subunits,  this 
diversity  could  render  a  large  number  of  permutations  of  the  PRC1  complex  in 
mammalian  cells  (reviewed  in  (Gil  and  Peters,  2006;  Whitcomb  et  al.,  2007)).  In 
addition  to  the  four  core  subunits  of  PRC1,  a  number  of  other  proteins  have  been 
reported  to  associate  with  the  complex.  Although  the  Drosophila  sex-comb  on  the 
midleg (Scm) protein is generally considered to be part of PRC1, it has only been found 
to associate with PRC1 in sub-stoichiometric amounts (Levine et al., 2002; Saurin et al., 
2001; Shao et al., 1999). For this reason, Scm is not considered to be a core component 
of PRC1. In addition, our laboratory has not been able to co-purify either of the two   18 
human homologues of SCM, SCMH1 and SCMH2, with either Cbx7, MEL18 or BMI1 
(Maertens et al., 2009).  
 
1.1.2.2  The PRC2 Complex 
 
In comparison to PRC1, evolution has only provided a modest expansion of the genes 
that  contribute  to  the  formation  of  PRC2  and  so  the  human  complex  is  largely 
constituted of direct homologues of the Drosophila core components. As summarised in 
Table  1,  these  include  two  homologous  of  the  enhancer  of  zeste  (EZH1/2),  the 
homologue  of  extra  sex  combs  embryonic  ectoderm  development  (EED)  and  the 
homologue  of  suppressor  of  zeste  (SUZ12)  (Cao  et  al.,  2002;  Satijn  et  al.,  2001). 
Genetic  experiments  in  mice  have  illustrated  the  importance  of  an  integral  PRC2 
complex, as ablation of any of the PRC2 genes was found to produce early embryonic 
lethality (O'Carroll et al., 2001; Pasini et al., 2004; Schumacher et al., 1996; Tie et al., 
2007). This can be attributed to the fact that all proteins are required for targeted and 
efficient  methyltransferase  activity  in  vivo  (see  below).  Additional  components 
associated  with  the  PRC2  complex  are  the  retinoblastoma  binding  proteins  4 
(RBBP4/RBAP48/NURF55) and -7 (RBBP7/RBAP46). Together with SUZ12, these 
two proteins were shown to be required for the association of EZH2 with nucleosomes 
(Kuzmichev  et  al.,  2002;  Nekrasov  et  al.,  2005).  Additional  variation  in  complex 
formation is established by the different isoforms of EED or expression level of EZH2, 
which play a role in directing the enzymatic activity of the complex (Kuzmichev et al., 
2004; Kuzmichev et al., 2005). This variability in the PRC2 complex has also been 
observed in Drosophila based on alternative Esc subunits (Ohno et al., 2008). 
 
1.1.2.3  The Pho/YY1 complex 
 
In  Drosophila,  a  third  PcG  complex  has  been  proposed,  termed  PhoRC.  PhoRC 
includes  the  PRE-binding  proteins  Pleiohomeotic  (Pho)  or  Pho-like  (Phol)  that  are 
involved  in  the  recruitment  of  the  PRC2  and  PRC1  complexes  to  target  genes  by 
providing  sequence-specific  DNA  binding  ((Wang  et  al.,  2004b),  reviewed  in 
(Schuettengruber et al., 2007)). Homologues of Pho and Phol have been identified in 
human,  where  they  have  been  called  Yin-yang  1  and  2  (YY1/YY2)  respectively   19 
(Nguyen et al., 2004; Shi et al., 1991). However, no YY1-based complex has yet been 
identified in mammals and until very recently the existence of a mammalian PRE was 
questioned, which together have limited the understanding of the role of these proteins 
in the mammalian mechanism of PcG-mediated repression. 
 
 PRC1 (Maintenance)     
 Drosophila  Mouse  Human 
 Polycomb (Pc)   Cbx2/M33/pc   CBX2/M33/PC 
   Cbx4/Pc2/PC2   CBX4/PC2/hPC2 
   Cbx6   CBX6 
   Cbx7   CBX7 
   Cbx8/Pc3   CBX8/PC3/HPC3 
 Polyhomeiotic (Ph)   Mph1/Phc1/Rae28/Edr1   HPH1/PHC1/EDR1/RAE28 
   Mph2/Phc2/Edr2   HPH2/PHC2/EDR2/PH2 
   Mph3/Phc3/Edr3   HPH3/PHC3/EDR3 
 Sex combs extra (Sce)   Ring1a/Ring1   RING1A/RING1/RNF1 
   Ring1b/Ring2   RING1B/RING2/RNF2 
 Posterior sex combs (Psc)   Pcgf1/Nspc1   PCGF1/NSPC1/RNF68 
   Pcgf2/Mel18/Rnf110/Zfp144   PCGF2/MEL18/RNF110 
   Pcgf3/Rnf3/RNF3A   PCGF3/RNF3/RNF3A 
   Pcgf4/Bmi1/Rnf51   PCGF4/BMI1/RNF51 
   Pcgf5/Rnf159   PCGF5/RNF159 
   Pcgf6/Mblr/Rnf134   PCGF6/MBLR/RNF134 
 
 PRC2 (Initiation)     
 Drosophila   Mouse   Human 
 Extra sex combs (Esc)   Eed/I7Rn5/lusk   EED/WAIT1 
 Enhancer of zeste (E(z))   Ezh1   EZH1 
   Ezh2/Enx-1/KMT6   EZH2/ENX-1/KMT6 
 Suppressor of zeste (Su(z))   Suz12   SUZ12/CHET9/JJAZ1 
 
Table 1. PcG proteins representing the core components of PRC1 and PRC2 in 
Drosophila, mouse and human. The names commonly used in this thesis are in 
bold.   20 
1.1.3  Mechanism of PcG-mediated Repression 
 
1.1.3.1  Introduction to Chromatin and Transcription 
 
In eukaryotes, genomic DNA is packaged into a chromatin fiber, which involves the 
wrapping of the DNA double strand around an octamer of four pairs of the core histones 
H2A, H2B, H3 and H4. The chromatin fiber is a highly dynamic structure, which is 
altered in a number of fundamental DNA-based processes, including replication, DNA 
repair,  cell  division  and  transcription.  Around  150bp  of  DNA  is  wrapped  around  a 
single nucleosome, but the density and locations of nucleosomes varies. This density 
determines the consequent openness or compaction of regions of chromatin and this has 
an important regulatory role for transcription. In addition, enzymatic modification of the 
amino terminal tails of the histone proteins, which include acetylation, methylation, 
phosphorylation,  ubiquitination,  sumoylation,  citrullination,  deimination,  ADP-
ribosylation  and  proline  isomerisation,  play  an  important  part  in  the  regulation  of 
transcription. Of these the small covalent modifications acetylation, methylation and 
phosphorylation are best characterised. It has become increasingly evident that different 
combinations of histone modifications influence transcriptional regulation of genes and 
therefore it has been suggested that they constitute an epigenetic- or histone code, which 
is superimposed on the genetic code (reviewed in (Goldberg et al., 2007)). 
Transcription
 of RNA consists of distinct phases during
 which RNA polymerase 
II (Pol II) is recruited to a gene promoter,
 initiates transcription, elongates the RNA 
transcript, and finally terminates
 transcription. Transcription starts with the formation of 
the preinitiation complex (PIC) at promoters of activated genes. The PIC is composed 
of three categories of transcription factors, being transactivators, cofactors and basal 
factors,  which  work  coordinately  to  recruit  PolII  and  trigger  RNA  synthesis.  An 
important level of regulation of transcription is the rate of PIC formation, which is also 
influenced by enhancers at more distal sites of chromatin. In the transcription initiation 
process, the cofactor and basal factors are generally viewed as the universal machinery, 
whereas the transactivators are the positive or negative regulators that can work in a 
cell- or gene-specific manner. Nevertheless, an increasing number of studies suggest 
that there are also cell type-specific cofactors and basal factors (reviewed in (D'Alessio 
et al., 2009)).   21 
  Over recent years it has been found that for transcription factors to access and 
bind their target sequences in promoters, local reorganisation of nucleosomal structures 
is required, and that this is a dynamic and continuous process (reviewed in (Hager et al., 
2009)).  This  reorganisation  is  orchestrated  by  the  combined  effort  of  chromatin 
remodelers and chromatin modifiers, of which the latter can be directly recruited by 
transcription factors. The traditional view that promoters are either in an open or closed 
chromatin state has been superseded by observations that most promoters are in fact 
found to be in a wide spectrum of intermediate chromatin states, between these two 
contrasting extremes (reviewed in (Cairns, 2009)). 
Also during transcription elongation, the PolII complex needs to pass through 
nucleosome structures and therefore recruits chromatin remodelling enzymes that can 
temporarily disassemble and reform the chromatin structures (Carrozza et al 2005). In 
addition, different histone modifications are correlated with either active or repressed 
transcription and can influence the elongation ability of the PolII complex and thereby 
stall  transcription  before  this  phase  (Core  and  Lis,  2008;  Stock  et  al.,  2007).  The 
acetylation of histone H3 on lysine 9 (H3K9ac), the di- or trimethylation of histone H3 
on  lysine  4  (H3K4me2  or  –me3),  the  dimethylation  of  histone  H3  on  lysine  36 
(H3K36me2) and the ubiquitination of histone H2B at lysine 120 (H2BK120ub) are 
generally correlated with active transcription. In contrast, trimethylation of histone H3 
on lysine 9 and 27 (H3K9me3 and H3K27me3), trimethylation of histone H4 on lysine 
20 (H4K20me3) and ubiquitination of H2A on lysine 119 (H2AK119ub) are all linked 
to transcriptional repression and the possible formation of heterochromatin. However, it 
is important to recognise that the meaning of these modifications is highly dependent on 
the context of other modifications. As such, H3K9 methylation for example can both 
have  an  active  or  repressive  effect  (Vakoc  et  al.,  2005).  PcG-mediated  repression 
involves the recognition and establishment of a number of these key chromatin marks, 
as will be discussed in more detail below. 
 
1.1.3.2  Classical Model of PcG Repression 
 
In  the  current  models  of  PcG-mediated  repression  (Figure  1.1),  the  PRC2  complex 
interacts with histone deacetylases (HDAC) via EED to remove the acetylated H3K9 
mark from transcriptionally active chromatin (Kuzmichev et al., 2002; Tie et al., 2001; 
van der Vlag and Otte, 1999). In addition, the histone methyltransferase activity of   22 
PRC2  converts  the  lysine  27  of  histone  H3  (H3K27)  to  a  trimethylated form.  This 
constitutes a unique enzymatic property of the PRC2 complex and is therefore widely 
regarded as the hallmark of PcG-mediated repression (Cao et al., 2002; Czermin et al., 
2002; Muller et al., 2002). This mark is then recognized by the chromodomain of the 
Polycomb protein(s) and facilitates binding of the PRC1 complex (Czermin et al., 2002; 
Fischle  et  al.,  2003;  Min  et  al.,  2003).  Following  binding,  PRC1  catalyses  the 
ubiquitination of histone H2A on lysine 119 (H2AK119ub), an essential modification 
for  transcriptional  repression  (Wang  et  al.,  2004a).  In  mice,  it  was  shown  that  the 
Ring1B E3 ligase protein is the main catalytic subunit, whereas both Ring1A and Bmi1 
have been identified as important enhancers of enzymatic activity (Buchwald et al., 
2006; Cao et al., 2005). 
This model has however been challenged by the observations of PRC1 binding 
to  nucleosomal  arrays  without  histone  tails,  by the  absence  of  nucleosomes  at  PcG 
binding  sites  and  by  the  PRC2-independent  function  of  PRC1  in  X-chromosome 
inactivation  (Francis  et  al.,  2004;  Papp  and  Muller,  2006;  Schoeftner  et  al.,  2006). 
Furthermore, this model does not explain how PRC2 is recruited in the mammalian 
system, nor how the binding of PRC1 results in stable repression. Therefore, to get a 
more precise understanding of PcG-mediated repression, it is important to consider the 
various elements of PcG repression in more detail and in the context of recent findings. 
 
1.1.3.3  Histone Methylation in PcG-mediated repression 
 
Histone  H3K27  trimethylation  is  the  hallmark  of  PcG-mediated  repression  and  is 
assumed to function as the landing platform for PRC1 recruitment. Binding of PRC1 to 
chromatin  is  indeed  lost  following  depletion  of  PRC2,  and  the  interaction  between 
Polycomb  and  H3K27me3  can  be  competed  away  from  Drosophila  polytene 
chromosomes, at least in part, by using a H3K27me3 peptide (Bracken et al., 2007; 
Ringrose et al., 2004). Moreover, genome-wide binding studies in Drosophila, mouse 
and human have found that H3K27me3 is generally correlated with PcG protein binding 
(Boyer et al., 2006; Bracken et al., 2006; Schwartz et al., 2006; Tolhuis et al., 2006). 
These studies found that the H3K27me3 mark is highly localised to gene promoters at 
some loci, but spread over large domains at others, such as observed for the HOX gene 
clusters.  However,  PRC1  was  not  found  to  follow  the  same  distribution  pattern 
(Schwartz et al., 2006).   23 
 
 
Figure 1.1 Classical model of PcG-mediated repression. 
Actively  transcribed  chromatin  typically  has  acetylated  H3K9  (H3K9ac)  and  di-  or 
trimethylated H3K4 (H3K4me2/me3). Upon initiation of PcG-mediated repression, the 
PRC2  complex  recruits  a  histone  deacetylase  (HDAC)  to  the  target  chromatin  to 
catalyse  the  removal  of  the  H3K9ac  mark.  In  addition,  PRC2  catalyses  the 
trimethylation of H3K27 (H3K27me3). In the next step, the PRC1 complex recognises 
and binds the H3K27me3 mark. The ubiquitin E3 ligase activity of the complex then 
mediates the ubiquitination of H2AK119 (H2AK119ub). It is proposed that H3K4me2/3 




In fact, in Drosophila only a fraction of the H3K27me3 domains are bound by PcG, 
whereas the overlap in mammals was found to be much higher (reviewed in (Schwartz 
and Pirrotta, 2008)). Even more so, PRC1 has been reported to be recruited to certain 
targets in the absence of any H3K27 methylation (Schoeftner et al., 2006; Vincenz and 
Kerppola, 2008). These observations thus undermine the direct link between methylated 
H3K27 and PRC1 chromatin binding.  
Conversely,  the  methylation  of  H3K27  could  also  be  involved  in  functions 
independent of PRC1. It has been shown that mono- and dimethylation of H3K27 are 
also  mediated  by  PRC2  proteins,  although  the  function  of  these  modifications  is 
unknown, as they are not strongly bound by the chromodomain of CBX proteins (Ebert 
et al., 2004). Ezh2 and Suz12 are only required for the di- and trimethylated forms of   24 
H3K27, whereas Eed is necessary for all stages of H3K27 methylation (Montgomery et 
al., 2005; Pasini et al., 2004). Interestingly, Ezh1 was found to be responsible for the 
mono-methylated form of H3K27, and PRC2 complexes incorporating Ezh1 are mainly 
active  in  non-proliferating  cells  and  have  a  robust  ability  to  compact  chromatin 
(Margueron et al., 2008; Shen et al., 2008).  
The methylation of H3K27 can also be reversed by the action of the Jumonji C-
domain  histone  demethylases,  such  as  UTX  and  JMJD3  (reviewed  in  (Swigut  and 
Wysocka,  2007)).  The  association  of  UTX  with  the  Trithorax  MLL  H3K4 
methyltransferases,  the  localisation  of  UTX  at  HOX  gene  promoters  and  the  direct 
involvement in HOX gene expression strongly suggest that H3K27 demethylation acts 
to counteract PcG repression (Cho et al., 2007; Issaeva et al., 2007; Lan et al., 2007; 
Lee et al., 2007). It is thus believed that the balance between TrxG activation and PcG 
repression  is  in  part  executed  by  opposing  activities  of  the  PRC2  complex  and  the 
JmjC-domain demethylases (Swigut and Wysocka, 2007). 
PRC2 variants also methylate other target sites than H3K27. It was found that a 
different isoform of the EED protein of PRC2 directs the methyltransferease activity of 
the complex to the trimethylation of histone H1 on K26. This mark is recognised by 
heterochromatin protein 1 (HP1) and could be important for higher order chromatin 
organisation (Daujat et al., 2005; Kuzmichev et al., 2004). Trimethylation of H3K9 and 
H4K20 have been found to accompany H3K27me3 on PcG-repressed genes and these 
marks  are  involved  in  the  formation  of  constitutive  pericentric  heterochromatin 
(Czermin  et  al.,  2002;  Papp  and  Muller,  2006; Schotta  et  al.,  2004).  Although,  the 
trimethylation  of  H3K9  is  normally  catalysed  by  the  SUV39H1  methyltransferase, 
PRC2  has  also  been  found  to  trimethylate  H3K9  in  vitro  (Bannister  et  al.,  2001; 
Czermin et al., 2002; Kuzmichev et al., 2002; Lachner et al., 2001; Rea et al., 2000). It 
has also been shown that the chromodomains of a number of murine Pc/Cbx proteins 
have high affinity for H3K9me3 in vitro (Bernstein et al., 2006b). This mark might 
therefore  be  involved  in  a  connection  between  PcG-mediated  repression  and  the 
induction of heterochromatin formation (Fischle et al., 2003). 
 
1.1.3.4  Ubiquitination in PcG-mediated repression 
 
Although,  purified  PRC1  complexes  have  demonstrable  ubiquitin  ligase  activity 
specific for histone H2A, it is clear that the main components are Psc and Sce or its   25 
homologues that all carry the characteristic RING domain. In the mammalian system, 
RING1B is widely accepted as the main catalyst of PRC1-mediated ubiquitination of 
histone H2A (Wang et al., 2004a). However, it was shown that Ring1A can substitute 
for Ring1B E3 ligase activity (de Napoles et al., 2004; Endoh et al., 2008; Leeb and 
Wutz, 2007). Further evidence has indicated that there are distinct complexes consisting 
of  only  Ring1B  and  co-factor  BMI1  or  Mel18,  which  can  directly  catalyse  the 
ubiquitination of H2A (Buchwald et al., 2006; Elderkin et al., 2007; Li et al., 2006). A 
similar complex, also including the KDM2 histone demethylase, was recently found in 
Drosophila and human cells (Gearhart et al., 2006; Lagarou et al., 2008). It is therefore 
unclear whether ubiquitination of histone H2A is performed by the PRC1 complex or 
by derivatives of it. 
In addition to the ubiquitination of histone H2A, deubiquitination of histone 
H2B has also been shown to contribute to PcG-mediated repression (van der Knaap et 
al.,  2005).  Ubiquitinated  histone  H2B  is  required  to  establish  the  activating  mark 
H3K4me3 and in Arabidopsis it was found that deubiquitination of H2B is required for 
the  methylation  of  H3K9  and  important  for  the  maintenance  of  heterochromatic 
silencing (Sridhar et al., 2007). This would thus suggest that the deubiquitination of 
H2B might be an important link between PcG-mediated repression and more stable 
silencing by the formation of heterochromatin. 
 
1.1.3.5  Non-coding RNA in PcG-mediated repression 
 
Several observations have implicated non-coding RNA (ncRNA) molecules in PcG-
mediated repression, but mechanistic concepts about how ncRNA is employed still need 
to be elucidated. Firstly, X-inactivation, needed to equal the X-chromosome dosage 
between sexes, involves both PcG-mediated repression silencing and ncRNA (Silva et 
al.,  2003).  Interestingly,  X-inactivation  requires  the  ncRNA  X  inactive-specific 
transcript (XIST) (Brown et al., 1991). Based on the recent identification that Xist binds 
to the PRC2 complex, it was postulated that XIST thereby recruits PcG complexes to the 
X-chromosome destined for inactivation (Zhao et al., 2008). However, it was recently 
shown that initiation, but not maintenance, of X-inactivation can occur in the absence of 
XIST (Kalantry et al., 2009). This would thereby suggest that PcG-mediated repression 
would be involved as a secondary mechanism in X-inactivation, possibly facilitating 
stable silencing of the X chromosome.   26 
In contrast, studies in Drosophila report that non-coding transcription through 
the  PRE  is  required  to  counteract  silencing  (Schmitt  et  al.,  2005).  A  mammalian 
counterpart  was  also  found  by  investigation  of  intergenic  ncRNA  transcription  that 
accompanies  co-linear  activation  of  the  human  HOXA  cluster  (Sessa  et  al.,  2007). 
Another  report  studying  all  four  human  HOX  clusters  identified  and  using  the 
H3K4me3 and H3K36me2 marks as a signature for active transcription identified many 
conserved regions of ncRNA transcription that co-ordinately expressed with respect to 
their 3’ proximal HOX gene (Rinn et al., 2007). This approach also led to the discovery 
of a transcript regulating the repression of a distal HOX gene in trans by interacting 
with the PRC2 complex. Genome-wide follow up studies in different cell types have 
now identified several thousand of these long ncRNAs of which more than a quarter 
were found to interact with PRC2 (Guttman et al., 2009; Khalil et al., 2009). 
Further  work  in  Drosophila  has  established  that  components  of  the  RNAi 
machinery are involved in PcG silencing. It was demonstrated that AGO1, an essential 
component  of  the  RNAi  machinery,  recruits  EZH2  to  mediate  the  transcriptional 
silencing of promoters targeted by small interfering RNA (siRNA) (Kim et al., 2006). 
Furthermore,  another  study  showed  that  RNAi  components  are  required  for  long-
distance interactions of interchromosomal regions silenced by PcG complexes, but that 
mutations of key components of the RNAi machinery did not find an essential role in 
the PcG mechanism (Grimaud et al., 2006). In line with a structural role of RNA in PcG 
silencing, the ncRNA Kcnq1 overlapping transcript 1 (Kcnq1ot1) and PcG proteins are 
required for the formation of discrete repressive nuclear compartments for imprinting of 
the  Kcnq1  locus  (Pandey  et  al.,  2008;  Terranova  et  al.,  2008).  Similarly,  ncRNA 
involvement in the imprinting of the Igf2r/h19 domain by long-range interchromosomal 
looping of PcG proteins has been observed (Li et al., 2008; Sleutels et al., 2002). It thus 
remains to be established whether ncRNA plays a general role in preventing promoter 
access to PcG complexes, in directing PcG silencing or in establishing higher order 
chromatin structures, or all of the above. 
 
1.1.3.6  Repression by stable binding of PRC1 
 
It was long believed that the stable binding of PRC1 to genomic loci blocks the access 
to transcription factors and the transcriptional machinery and would thereby repress its 
expression (Cao et al., 2002). However, this has been contrasted by observations in   27 
Drosophila that components of the general transcription factor TFIID can still bind to 
PcG-repressed genes and interact with PRC1 proteins (Breiling et al., 2001; Saurin et 
al.,  2001).  Examination  of  the  regulation  of  Ubx,  a  Drospophila  Hox  gene,  also 
concluded that PRC1 binding does not prevent transcription factor binding, but prevents 
the activation of these factors (Dellino et al., 2004). Both the PcG and TrxG complexes 
were found to bind the the Ubx promoter, irrespective of its transcriptional state (Papp 
and Muller, 2006). This study also observed that Ubx activation leads to the loss of 
H3K27me3 from the promoter and coding region, where it was replaced by H3K4me3, 
which  suggests  that  only  local  chromatin  marks  correlate  with  transcription.  These 
findings therefore suggest that the mediators of transcription are closely linked with 
transcriptional repression by PcG. 
 
1.1.3.7  DNA Hypermethylation 
 
In addition to histone modifications, one of the well-known mechanisms of stable gene 
repression is the methylation of the DNA itself, specifically of CpG islands associated 
with gene promoters. Methylation-dependent silencing of tumour suppressor genes is 
commonly  observed  in  and  contributes  to  the  development  of  cancer  (reviewed  in 
(Ballestar  and  Esteller,  2008).  Recently,  DNA  hypermethylation  has  been  directly 
linked to PcG-mediated repression. DNA methyltransferases (DNMTs) interact directly 
with EZH2 (Vire et al., 2006) and the presence of both these proteins and EED are 
required for recruitment of BMI1 to Polycomb bodies (Hernandez-Munoz et al., 2005). 
In addition, the methylated DNA binding protein (MBD1) interacts with CBX4 and 
RING1B  at  heterochromatin  foci  and  these  interactions  are  required  for  HOXA 
repression (Sakamoto et al., 2007), whereas CBX4 also sumoylates DNMT3a (Li et al., 
2007).  It  has  also  been  found  that  PcG-mediated  methylation  of  H3K27me3  marks 
genes for de novo methylation in cancer cells, leading to permanent silencing of target 
genes (Bracken et al., 2006; Schlesinger et al., 2007).  
It thus remains to be determined how these various aspects of the PcG-mediated 
repression  mechanism  fit  together,  what  their  contribution  is  and  how  they  are 
regulated. There is thus a need for further biochemical and functional characterisation of 
the  PRC  complexes  and  their  components.  Increased  understanding  of  the  PcG-
repression mechanism will lead to a better appreciation of the roles of these proteins in 
development, as well as tissue homeostasis and malignancy.   28 
1.2  PcG in Stem Cells and Cancer 
 
Although a number of PcG target genes were already known from classical genetic 
studies,  more  recent  genome-wide  screens  of  PcG  protein  binding  sites  in  mouse 
embryonic stem (ES) cells and human embryonic fibroblasts identified more than a 
thousand potential target genes (Boyer et al., 2006; Bracken et al., 2006; Lee et al., 
2006).  Functionally,  these  genes  are  related  to  cell  proliferation,  cancer,  genomic 
imprinting and X-inactivation, but the most important concept to emerge was that PcG 
proteins are important for maintaining pluripotency of embryonic stem cells and the 
identity and self-renewal capacity of somatic stem cells (reviewed in (Ringrose, 2007). 
On the other hand, disrupted levels of PcG proteins have increasingly become linked to 
aberrant  proliferation  in  cancer  (reviewed  in  (Gil  et  al.,  2005;  Sparmann  and  van 
Lohuizen, 2006; Valk-Lingbeek et al., 2004). The morphological defects resulting from 
PcG mutations can be directly connected to defective stem cell maintenance, whereas 
expression of PcG proteins is found to be upregulated in cancer cells. The PcG proteins 
therefore  may  represent  an  important  element  in  the  ‘cancer  stem  cell  hypothesis’, 
which holds that the driving subpopulation of cells in a tumor has stem cell properties 
(reviewed in (Gupta et al., 2009; Reya et al., 2001)). 
 
1.2.1  PcG proteins in stem cell self-renewal 
 
The first indications that PRC1 proteins play a role in stem cell maintenance came from 
studies  on  Bmi1-deficient  mice.  These  animals  display  haematopoietic-  and 
neurological defects that are caused by a failure in self-renewal of the corresponding 
stem-  and  progenitor  cell  populations  (Lessard  and  Sauvageau,  2003;  Leung  et  al., 
2004; Molofsky et al., 2003; Park et al., 2003; van der Lugt et al., 1994). In addition to 
Bmi1,  Mel18,  Mph1  and  Cbx2/M33  are  also  highly  expressed  in  haematopoietic 
progenitor cells and their mutation gives rise to various defects in the haematopoietic 
system (Akasaka et al., 1997; Core et al., 1997; Ohta et al., 2002; Park et al., 2003; 
Takihara et al., 1997). The fact that the observed effects on haematopoiesis are different 
between these mutants, may suggest that the proteins have distinct roles in this process.  
Due to the early embryonic lethality of PRC2  mutants, their involvement in 
adult stem cells has not been well characterised, although Ezh2 was found to control B 
cell  development  in  conditional  knockout  mice  (Su  et  al.,  2003).  However,  recent   29 
studies indicate that ES cells lacking Ezh2 or Suz12 are viable and proliferate in culture 
(Chamberlain et al., 2008; Pasini et al., 2007). Even though the lack of core PRC2 
components  leads  to  the  global  loss  of  H3K27  methylation,  H3K27me3  and  PcG 
silencing were maintained at a select number of key developmental target genes by the 
activity of Ezh1 (Shen et al., 2008). The interaction between Ezh1 and Eed can maintain 
ES cell self-renewal, but not pluripotency, which additionally equires Suz12 and Ezh2 
(Ezhkova et al., 2009; Pasini et al., 2007). 
Genome-wide analyses of histone modifications of mouse and human ES cells 
has  found  that  key  regulatory  genes  of  developmental  pathways  are  bound  by  PcG 
complexes,  have  broad  H3K27me3  domains  and  the  active  H3K4me3  mark  at  the 
transcription start sites (Boyer et al., 2006; Lee et al., 2006). This epigenetic state has 
been termed bivalent and is thought to be characteristic of genes poised for expression 
(Bernstein et al., 2006a). Upon ES cell differentiation, either the repressive or active 
mark  is  lost  as  a  consequence  of  activation  or  silencing  of  the  respective  gene. 
Nevertheless, a number of bivalent domains are sustained after differentiation (Barski et 
al., 2007; Mikkelsen et al., 2007). It was recently discovered that bivalent domains are 
maintained by a low level of basal transcription, of which elongation is restricted by 
Ring1b-mediated  ubiquitination  of  H2A  (Stock  et  al.,  2007).  This  thus  strongly 
implicates the PcG proteins in controlling the bivalency of genes. 
  PcG-mediated repression thus has an important role in ES cells by maintaining 
self-renewal,  pluripotency  and  priming  differentiation,  whereas  they  are  required 
maintaining the identity and self-renewal of somatic stem cells. The significance of PcG 
proteins in pluripotency is further supported by the fact that SOX2 and OCT3/4, two of 
the four ‘Yamanaka factors’ used to derive induced pluripotent stem (iPS) cells, and the 
downstream  self-renewal  factor  NANOG  are  co-localised  with  PcG  proteins  on  the 
promoters  of  target  genes  (Boyer  et  al.,  2006;  Lee  et  al.,  2006;  Takahashi  and 
Yamanaka, 2006), and OCT3/4 was shown to direct the binding of PRC1 in ES cells 
(Endoh et al., 2008).   30 
PcG proteins in cancer 
 
The first link between PcG and cancer was drawn from the discovery of Bmi1 as a 
target of insertional mutagenesis in murine leukaemia virus-induced lymphomas (Haupt 
et al., 1991; van Lohuizen et al., 1991). The name Bmi1 (B-cell Moloney Integration) 
reflects these observations and it was shown that the gene collaborates with oncogenic 
Myc (Eµ-Myc) in tumourigenesis. Human BMI1 has since been found to be highly 
expressed in leukaemia and lymphoma, colorectal cancer, liver cancer, breast cancer, 
medulloblastoma  and  glioma,  and  non-small  cell  lung  cancer  (Bea  et  al.,  2001; 
Bruggeman et al., 2007; Dimri et al., 2002; Haupt et al., 1991; Leung et al., 2004; van 
Lohuizen et al., 1991; Vonlanthen et al., 2001). Other PcG proteins have since also been 
implicated in tumourigenesis. Increased levels of CBX7 have been found to be involved 
in lymphomas and prostate cancer (Bernard et al., 2005). Whereas EZH2 is commonly 
found overexpressed in various types of cancer, including leukaemia, prostate cancer 
and breast cancer and is regarded as a potential marker of advanced aggressive cancer 
with poor prognosis (Bracken et al., 2003; Kleer et al., 2003; Varambally et al., 2002). 
SUZ12 is also found to be upregulated in various cancers, including colon, breast and 
liver cancer (Kirmizis et al., 2003). 
The  dual  role  of  PcG  proteins  in  cancer  and  stem  cells  is  unlikely  to  be 
coincidental. Over recent years there has been emerging evidence that tumours contain a 
subset of cancer cells that display numerous properties of stem cells, particularly the 
ability  to  self-renew  and  to  spawn  differentiated  progeny.  Pioneering  studies  on 
leukaemia demonstrated the existence of a small subset of leukaemic cells that carry 
specific cell surface markers and are able to seed new tumors (Lapidot et al., 1994). 
Further studies identified similar cells from solid breast and brain tumours (Al-Hajj et 
al., 2003; Singh et al., 2003). These findings have provided the basis for the cancer stem 
cell hypothesis, which holds that the origin of tumours are based on stem cell properties, 
either  as  a  basis  (somatic  stem  cells  or  progenitor  cells)  or  acquired  (terminally 
differentiated cells) in the process of transformation. The increased understanding of 
what governs the plasticity of cellular identity and the transcriptional events to achieve 
pluripotency,  in  the  form  of  iPS  cells,  has  shed  light  on  the processes  involved  in 
reversing differentiation and acquiring self-renewal capacity. The role of PcG proteins 
in resetting the repression of differentiation-specific genes is likely to be an important 
topic ((Endoh et al., 2008), reviewed in (Jaenisch and Young, 2008)). Therefore, the   31 
role of PcG proteins in stem cells and differentiation and the possible contribution to 




Figure 1.2 Model for PcG involvement in normal differentiation and opportunities 
for tumourigenesis 
PcG  repression  is  involved  at  various  stages  of  differentiation.  In  ES  cells  (white 
circles)  PcG  complexes  are  responsible  for  the  maintenance  of  pluripotency  by 
repression  of  differentiation-specific  genes.  PcG  binding  at  these  genes  creates  a 
bivalent state, from which either activation or silencing can be quickly achieved upon 
differentation.  1)  differentiation  to  a  multipotent  or  oligopotent  somatic  stem-  or 
progenitor cell (light green, blue and orange circles) results in the loss of pluripotency, 
which  is  mediated  by  loss  of  PcG  repression  at  differentiation-related  genes. 
Differentiation also activates more profound cell cycle control, including the activation 
of  the  G1  checkpoint,  and  PcG  repression  is  needed  to  repress  the  genes  limiting 
proliferation in order to maintain the self-renewal capacity. 2) when the cell becomes 
terminally differentiated (dark green, blue and orange circles), self-renewal is lost and 
the  cells  become  quiescent,  unless  stimulated  in  culture.  3)  however,  due  to  the 
accumulation of mutations over time a differentiated cell may acquire properties that 
will allow it to become susceptible to transformation and therefore a pre-cancerous cell   32 
(light red circle). 4) complete tumourigenesis would require unlimited proliferation and 
therefore could involve de-differentiation to acquire the self-renewal properties of adult 
stem-/progenitor cells to become a cancer stem cell (red circle). 5) alternatively, somatic 
stem- or progenitor cells could directly acquire the transforming mutations to become a 
cancer stem cell. 
 
1.3  PcG proteins in regulation of the INK4A tumour suppressor 
 
So far, the focus has been on the role of PcG-mediated repression for the control of 
developmentally regulated genes. However, one of the critical targets identified in the 
Bmi1 knockout mice was the Ink4a/Arf locus (Jacobs et al., 1999a). This section aims to 
introduce the products of the INK4B-ARF-INK4A locus, their known properties and 
functions,  and  their  involvement  in  the  implementation  of  senescence,  the  state  of 
permanent growth arrest activated in response to various types of cellular stress, which 
represents an important barrier in tumourigenesis and sustained somatic stem cell self-
renewal. 
 
1.3.1  The INK4B-ARF-INK4A locus and its products 
 
The  INK4B-ARF-INK4A  locus  on  human  chromosome  9p21,  and  the  corresponding 
locus  on  mouse  chromosome  4,  comprises  two  annotated  genes,  officially  termed 
CDKN2B  and  CDKN2A,  but  more  commonly  referred  to  as  INK4B  and  INK4/ARF 




Arf  in  mice)  and  p16
INK4A  (see  Figure  1.3).  The  p15
INK4B  and  p16
INK4A 
proteins are cyclin-dependent kinase (CDK) inhibitors that bind directly to CDK4 and 
CDK6 and thereby prevent their interaction with regulatory D-type cyclins. Inhibition 
of CDK4 and CDK6 blocks the hyperphosphorylation of the RB tumour suppressor 
protein. In its hypophophorylated and active form, RB functions as a negative regulator 
of  the  E2F  transcription  factors  (reviewed  in  (Classon  and  Harlow,  2002)).  E2F 
activates a series of genes involved in DNA replication and nucleotide metabolism that 
are required for cell cycle progression into S-phase (Dyson, 1998).  
  The p16
INK4A and p15
INK4B proteins are closely related (85% similarity in primary 
sequence)  and  it  is  believed  that INK4A  arose  in  evolution  via  gene  duplication  of   33 
INK4B (Gil and Peters, 2006; Kim and Sharpless, 2006). In contrast, the ARF protein 
has no structural or functional counterpart conserved throughout evolution. It is encoded 
by  an  exon,  designated  exon  1β,  that  is  located  between  INK4A  and  INK4B  and 
becomes  spliced  to  exon  2  of  INK4A.  The  acronym  ARF  reflects  the  fact  that  it 
incorporates amino acids encoded by the shared exon in an alternative reading frame 
relative to INK4A (Quelle et al., 1995). ARF is thought to interact with a wide variety of 
cellular proteins. Its best understood property is that it can stabilise and activate the p53 
tumour  suppressor  protein  by  inhibiting  its  ubiquitination  by  HDM2  (reviewed  in 
(Vousden and Prives, 2009)).  
 
 
Figure 1.3 The human INK4B-ARF-INK4A locus and its products 
The  INK4/ARF  locus  encodes  two  genes CDKN2A  and  CDKN2B  that  encode  three 
coding transcripts; two highly related genes INK4A and INK4B, and an unrelated gene 
ARF. The product of the latter, p14
ARF
 protein is a potent inhibitor of HDM2, which in 
its turn is an inhibitor the p53 tumour suppressor protein. Stabilisation of p53 leads to 
the transactivation of a wide array of genes, including p21
CIP1 that can arrest the cell 
cycle at multiple stages by inhibiting the respective cyclin-dependent kinases (CDKs). 
P16
INK4A  also  inhibits  cell  cycle  progression  at  G1/S  phase  through  the  specific 
inhibition of CDK4 and CDK6. This blocks the phosphorylation of pRb and allows it to 
inhibit the E2F transcription factors, which are essential for cell cycle progression to S 
phase. P15
INK4B
 works through the same mechanism as p P16
INK4A.    34 
One of the most important downstream targets of activated p53 is the CDK inhibitor 
p21
CIP1,  which  is  crucial  for  p53-dependent  cell  cycle  arrest  in  response  to  DNA 
damage (Brown et al., 1997). Interestingly, ARF also forms a connection between the 
p53- and RB pathways as it is transcriptionally activated by E2F (Bates et al., 1998).  
Thus, agents, such as viral oncoproteins, that inactivate RB will inevitably invoke a p53 
response via ARF. 
 
1.3.2  Role of the INK4A-ARF-INK4B locus in senescence 
 
It  is  evident  that  by  activating  the  RB  and  p53  pathways,  all  three  of  the  proteins 
encoded by the INK4B-ARF-INK4A locus have the ability to cause cell cycle arrest.  
However, there is no evidence that they are involved in the regulation of the normal cell 
cycle.  Their  levels  do  not  fluctuate  significantly  as  cells  progress  through  different 
phases and at least in the case of the INK4 genes, the encoded proteins are extremely 
stable. They also appear to be expressed at very low, essentially undetectable levels in 
most normal tissues. The one process however in which all three proteins appear to 
have an important role is the implementation of senescence. 
The term "senescence", derived from senex, Latin for old man or old age, refers 
to a state of irreversible growth arrest that is now recognised as a hallmark of tumour 
suppression and ageing. The concept of senescence was originally proposed by Hayflick 
and colleagues who found that primary human  diploid fibroblasts (HDFs) grown in 
tissue culture achieve a specific but finite number of population doublings (Hayflick 
and  Moorhead,  1961).  In  the  following  decades,  these  observations  have  been 
developed and extended to other cell types but HDFs remain the system of choice for 
experimental studies on senescence.  Importantly, when the cells reach the end of their 
finite lifespan, they adopt a characteristic phenotype that distinguishes them from cells 
arresting in response to growth factor withdrawal or contact inhibition. These include an 
enlarged  and  flattened  appearance,  failure  to  respond  to  proliferative  stimuli,  and 
resistance  to  apoptosis.  They  also  develop  single  prominent  nucleoli,  senescence-
associated  heterechromatin  foci  (SAHF)  and  -DNA  damage  foci  (SDF),  and  stain 
positively  for  senescence-associated  β-galactosidase  activity  (SA-βgal)  (reviewed  in 
(Campisi and d'Adda di Fagagna, 2007)).  
Another  important  feature  of  senescent  cells  is  altered  patterns  of  gene 
expression, including the upregulation of secretory proteins involved in changing the   35 
extracellular matrix or in local inflammation, such as IL6, IL8 and the IL8 receptor 
CXCR2 (Acosta et al., 2008; Kuilman et al., 2008; Rodier et al., 2009). However, from 
the perspective of this thesis, the most noteworthy aspect of the senescence phenotype is 
the near uniform increase in expression of the p16
INK4A and p21
CIP1 CDK inhibitors and 
various lines of evidence have confirmed that these proteins are instrumental in bringing 
cell proliferation to a halt (reviewed in (Besson et al., 2008; Campisi and d'Adda di 
Fagagna, 2007)). 
 
1.3.3  Different Types of Senescence 
 
The classical studies on senescence in human fibroblasts suggested that there must be 
an  intrinsic  counting  mechanism  that  pre-determines  the  lifespan  of  particular  cell 
strains. The accepted explanation is that this counting mechanism is provided by the 
progressive erosion of telomeric repeats that occurs with each cell division, due to the 
inability  of  the  replication  machinery  to  copy  the  ends  of  linear  DNA  molecules 
(reviewed in (Deng et al., 2008)). Complete loss or uncapping of the telomeric DNA 
produces  the  equivalent  of  a  double  strand  break,  which  triggers  the  DNA  damage 
response (DDR) and activation of p53 (d'Adda di Fagagna et al., 2003). This form of 
senescence, commonly referred to as replicative senescence, can be prevented by the 
activation of telomerase, the enzyme responsible for maintaining telomere length. In 
general, this enzyme is either not expressed or present at insufficient levels in normal 
somatic  cells  (Bodnar  et  al.,  1998;  Masutomi  et  al.,  2003).  (Blasco  et  al.,  1997; 
Masutomi et al., 2003). However, telomerase is frequently activated in cancer cells, 
enabling them to avoid senescence (reviewed in (Stewart and Weinberg, 2006)).  
Importantly, there are other scenarios in which cells develop the characteristics 
of  senescence,  irrespective  of  telomere  status.  Two  typical  examples  are  human 
epithelial cells, which undergo a senescence-like arrest in tissue culture after only a few 
population doublings, and mouse embryonic fibroblasts (MEFs), which have a limited 
lifespan despite having exceptionally long telomeres.  The explanation is that standard 
conditions of tissue culture can be sufficiently stressful to engage telomere-independent 
senescence, sometimes referred to as ‘culture shock’. The effects of culture shock can 
be alleviated by growing cells on feeder layers (Ramirez et al., 2001) or, in the case of 
MEFs,  by  growing  the  cells  in  reduced  oxygen  concentrations  that  are  closer  to 
physiological levels (Parrinello et al., 2003). This is thought to reduce the oxidative   36 
DNA damage caused by reactive oxygen species (ROS) and thereby reduce the chances 
of activating the DDR and engaging senescence (reviewed in (Lu and Finkel, 2008)).  
From the perspective of tumour suppression, the most significant type of stress 
that can elicit a senescence response is aberrant signalling from an activated oncogene. 
Oncogene-induced senescence (OIS) was first reported in primary fibroblasts exposed 
to oncogenic RAS (RAS
V12) and was shown to be associated with elevated levels of 
p16
INK4A and p53 (Serrano et al., 1997). Similar findings were recorded with activated 
RAF and MEK, downstream components of the RAS signalling pathway (Lin et al., 
1998; Zhu et al., 1998). The mechanisms underlying OIS and how they impact on the 
INK4B-ARF-INK4A  locus  remain  poorly  understood  but  one  common  denominator 
could be the DDR that results from increased DNA replication caused by these aberrant 
mitogenic stimuli (Bartkova et al., 2006; Di Micco et al., 2006).  
 
1.3.4  INK4B-ARF-INK4A, senescence and tumour suppression 
 
The involvement of INK4A in the implementation of OIS would provide an attractive 
explanation for its role as a tumour suppressor. It was first identified as such from 
studies showing that predisposition to melanoma could in certain families be linked to 
markers  on  chromosome  9p21  and  ultimately  to  inactivating  mutations  in  INK4A 
(Kamb et al., 1994). It has subsequently been shown that INK4A is frequently mutated, 
deleted or epigenetically silenced in a large variety of primary cancers and tumour cell 
lines  (reviewed  in  (Ruas  and  Peters,  1998;  Sharpless,  2005)).  Indeed,  it  has  been 
claimed that p16
INK4A is second only to p53 in the frequency with which it is inactivated 
in  human  cancers.  However,  many  of  the  homozygous  deletions  that  occur  on 
chromosome 9p21 encompass ARF and INK4B making it difficult to determine what 
contributions these two genes might have in tumour suppression.  Missense mutations 
in ARF and INK4B are extremely rare but there are circumstances in which they appear 
to have been selectively inactivated by deletion or methylation (Peters, 2008). 
Curiously, a very different picture has emerged from studies on the mouse locus. 
Mice  that  are  defective  for  Arf  specifically  are  highly  tumour  prone  and  the 
corresponding MEFs are immortal and sensitive to transformation by RAS (Kamijo et 
al., 1997). In contrast, mice that specifically lack Ink4a have a relatively low incidence 
of spontaneous tumours, unless challenged with a chemical carcinogen, and the Ink4a -
/- MEFs undergo senescence (Krimpenfort et al., 2001; Sharpless et al., 2001). Thus, all   37 
the evidence suggests that the Arf/p53 pathways is critical for tumour suppression in 
mice.  In line with this, RAS activates the expression of mouse Arf but has little effect 
on  human  ARF.  Studies  in  mice  have  also  confirmed  a  role  for  p15
Ink4b in  tumour 
suppression. Although the single knockout of Ink4b displays only very subtle tumour 
predisposition, the combinatorial deletion of all three genes at the locus implies that loss 
of  Ink4b  significantly  exacerbates  the  tumour  prone  phenotype  of  the  Ink4a/Arf 
knockout (Krimpenfort et al., 2007).  It is noteworthy that p15
INK4B was identified as 
one of the most robust markers for OIS in human fibroblasts exposed to oncogene RAS 
(Collado et al., 2005).  
Importantly, several related studies demonstrated that OIS is not confined to the 
artificial conditions of tissue culture but is clearly observed in benign and pre-malignant 
tumours in vivo, both in mouse models and in humans (Braig et al., 2005; Chen et al., 
2005;  Collado  et  al.,  2005;  Michaloglou  et  al., 2005).  One  of the  most  compelling 
examples is the accumulation of p16
INK4A and SA-βgal in benign melanocytic naevi that 
have an activated allele of B-RAF (Michaloglou et al., 2005).  
 
1.3.5  Senescence and ageing 
 
As an intrinsic limit on the proliferative capacity of cells, senescence is on the one hand 
seen as an important tumour suppressive mechanism, limiting unscheduled proliferation 
and the accumulation of mutations. On the other hand, limited proliferation of mitotic 
cells, especially somatic stem- and progenitor cells, will limit the self-renewal ability of 
tissues  and  thereby  contribute  to  organismal  ageing.    In  evolutionary  terms,  these 
opposing roles are referred to as antagonistic pleiotropy. Senescence has evolved from a 
time when longevity was highly constrained by a multitude of environmental factors, 
such as bacterial or viral infection, starvation and predation, and hence the negative 
contributions of senescence to ageing was never subject to strong selective pressure. 
Several studies have reported increased numbers of senescent cells in ageing 
tissue, as judged by SA-βgal (Dimri et al., 1995) and p16
INK4A staining (Krishnamurthy 
et al., 2004; Ressler et al., 2006). It has been suggested that the secretory programme of 
senescent cells could have an impact on the wider tissue environment and thereby affect 
age-related decrements in tissue structure and function (Kuilman and Peeper, 2009). 
Furthermore, senescence occurs at sites of age-related disorders, including osteoarthtitis 
and  artherosclerosis  (reviewed  in  (Campisi  and  d'Adda  di  Fagagna,  2007).  Recent   38 
association studies have identified genetic variants near the INK4/ARF locus linked to 
age-related disorders, including type II diabetes, coronary artery disease and general 
frailty (Helgadottir et al., 2007; McPherson et al., 2007; Saxena et al., 2007; Scott et al., 
2007b; Zeggini et al., 2007). Although it is not known how these variants affect the 
expression of the INK4/ARF locus, the putative contribution to the ageing phenotype 
provides an interesting link. 
  As  well  as  these  correlative  studies,  there  is  experimental  evidence  linking 
increased p16
INK4A levels with age-related disorders in mice engineered to have an extra 
copy of the Ink4a/Arf locus (Krishnamurthy et al., 2006; Matheu et al., 2004). Although 
these  mice  did  not  show  any  decrease  in  longevity,  the  self-renewal  capacity  of 
pancreatic β islet cells was clearly impaired, leading to diabetes. These findings are 
consistent  with  earlier  observations  that  Cdk4  null  mice  are  diabetic.  Conversely, 
deletion of Ink4a delays the age-related loss of islet cell plasticity although these mice 
were  more  prone  to  developing  tumours.  In  addition,  p16-independent  loss  of  self-
renewal has been observed, suggesting that there must be other contributors to ageing, 
with ARF and its action on the p53 pathway being an attractive candidate (reviewed in 
(Kim and Sharpless, 2006).  
It is interesting to speculate how and when the repression of INK4A/ARF needs to 
be established in embryonic development. Due to the high rate of proliferation needed 
for the expanding embryo, ES cells have been found to have a significantly shortened 
cell  cycle  without  a  classical  G1  checkpoint  (Orford  and  Scadden,  2008).  This  is 
illustrated by high levels of Cyclin D3 and pRbm and the irresponsiveness of Cyclin 
D3-Cdk6 complexes to ectopic expression of Ink4a (Faast et al., 2004). In addition, 
genome-wide  binding  assays  of  PcG  proteins  in  ES  cells  did  not  detect  binding  to 
Ink4a/Arf ((Boyer et al., 2006)). It could therefore be that the repression of INK4A/ARF 
only becomes relevant at later stages in development when other, p16-sensitive Cdk-
Cyclin  D  complexes  become  active.  Repression  of INK4A/ARF  may  therefore  be  a 
common part of the differentiation program initiated through PcG. Interestingly, the 
activation of p16
INK4A and p21
CIP1 acts as a barrier in the reprogramming of somatic 
cells to become induced pluripotent stem (iPS) cells (Banito et al., 2009; Li et al., 2009; 
Marion et al., 2009; Mikkelsen et al., 2008). This would suggest that PcG-mediated 
repression of INK4A/ARF is an important event in the acquisition of pluripotency. 
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1.3.6  PcG-mediated regulation of INK4A 
 
As alluded to earlier, studies on Bmi1 null mice provided the first evidence for a link 
between PcG proteins and the regulation of Ink4a/Arf and a clear inference was that the 
impaired  proliferation  of  Bmi1-/-  MEFs  reflected  derepression  of  Ink4a/Arf  and 
premature senescence (Jacobs et al., 1999a). Conversely, overexpression of Bmi1 could 
downregulate expression of p16
Ink4a and p19
Arf in MEFs, leading to immortalization 
(Jacobs et al., 1999a). These ideas were subsequently confirmed and extended by a 
variety  of  genetic  crosses  that  showed  that  features  of  the  Bmi1  null  phenotype, 
including  the  neurological  and  haematological  stem  cell  defects,  can  be  rescued  by 
simultaneous  ablation  of  Ink4a/Arf  (Molofsky  et  al.,  2003;  Park  et  al.,  2003). 
Conversely, it was found that up-regulated Bmi1 expression leads to enhanced β islet 
regeneration by enhanced repression of Ink4a (Dhawan et al., 2009). The further use of 
mice that are selectively defective for either Ink4a or Arf suggested a role for both these 
genes in specific subsets of stem and progenitor cells (Janzen et al., 2006; Lewis et al., 
2001; Molofsky et al., 2006). However, analogous experiments in human fibroblasts 
using shRNA-mediated knockdown or retrovirally transduced cDNA suggests that the 
effects of Bmi1 are limited to INK4A and do not extend to ARF (Bracken et al., 2007; 
Maertens et al., 2009). In the remainder of this thesis, the emphasis will be on the 
effects of PcG proteins on the human INK4A locus. 
  As Bmi1 is believed to act as part of the multicomponent PRC1 complex, it 
would be logical to expect other PRC1 proteins to have a similar influence on INK4A. 
Studies of a number of PcG gene knockouts in mice indeed reported that some of the 
defects  associated  with  ablation  of  Mel18,  Mph2,  Ring1B  were,  at  least  in  part, 
attributable to derepression of Ink4a (Cales et al., 2008; Isono et al., 2005a; Jacobs et 
al., 1999a; Miki et al., 2007; Voncken et al., 2003). Similar implications were drawn for 
Ezh2 (Chen et al., 2009; Krishnamurthy et al., 2006), but not for PcG genes Eed and 
Mph1 (Lessard et al., 1999; Ohta et al., 2002). Extending these studies to human cells, it 
has been shown that shRNA-mediated knockdown of CBX7, CBX8, MEL18 and BMI1 
results  in  elevated  expression  of  INK4A  and  premature  senescence  (Bracken  et  al., 
2007; Dietrich et al., 2007; Gil et al., 2004; Jacobs et al., 1999a; Maertens et al., 2009) 
whereas  overexpression  of  the  mouse  homologues  Cbx7,  Cbx8  and  Bmi1,  used  for 
technical reasons, in human cells can repress INK4A and delay senescence (Dietrich et 
al., 2007; Gil et al., 2004; He et al., 2009).   40 
Given these observations, it is evident that the role of PcG proteins in cancer can 
be  largely  attributed  to  the  repression  of  INK4A.  For  example,  EZH2,  which  is 
overexpressed in a variety of tumours, was shown to repress INK4A directly and to be 
responsible for additional repression by de novo methylation of INK4A in intrahepatic 
cholangiocarcinoma (Bracken et al., 2003; Sasaki et al., 2008). Interestingly, a number 
of cancer types that overexpress PcG proteins were found to have an intact INK4A locus 
(Bernard et al., 2005; Scott et al., 2007a), suggesting that PcG-mediated represson of 
INK4A provides an alternative to deletion or mutation of the locus as a step to bypass 
senescence (reviewed in (Valk-Lingbeek et al., 2004)). 
However, as PcG proteins repress a large number of target genes in addition to 
INK4A, it is of course feasible that they promote tumorigenesis in other ways. Indeed it 
has been shown that Bmi1 can engage EGFR-induced transformation (Bruggeman et 
al., 2007; Kang et al., 2007; Liu et al., 2006) and that the enhanced self-renewal of 
haematopoietic stem cells (HSCs) caused by Bmi1 overexpression is manifested in the 
absence  of  Ink4a/Arf.    Moreover,  gene  expression  profiling  of  Bmi1
-/-  HSCs  found 
increased expression of stem cell associated genes, cell survival genes and transcription 
factors  as  well  as  Ink4a/Arf  (Iwama  et  al.,  2004;  Park  et  al.,  2003).  Also,  the  key 
developmental signalling pathways operated by the SHH, WNT and NOTCH proteins 
are increasingly implicated in PcG regulation in cancer (reviewed in (Sparmann and van 
Lohuizen, 2006).  
  Recently, it has also been reported that the induction of INK4A (and Ink4a/Arf in 
mice) by oncogenic RAS involves the JMJD3 histone demethylase (Agger et al., 2009; 
Barradas et al., 2009). RAS was found to downregulate EZH2 and upregulate JMJD3, 
which  facilitates  the  demethylation  of  the  H3K27me3  mark  and  removal  of  PcG 
complexes from the locus. Knockdown of JMJD3 was found to delay senescence and 
immortalise  MEFs.  Taken  together,  these  findings  suggest  that  JMJD3  is  a  clear 
antagonist of PcG-mediated repression of INK4A and might act as a tumour suppressor. 
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1.4   Characterising PRC1 complexes that regulate INK4a 
 
At the start of this work, it was already known that several core components of the 
PRC1 complex are implicated in the regulation of INK4A, as described in the previous 
section.  Importantly, these included two members of the Pc family, CBX7 and CBX8, 
and two Psc proteins, BMI1 and MEL18. There were also indications from the analyses 
of  affinity-purified  complexes,  that  the  mammalian  PRC1  complexes  contain  single 
representatives  of  the  Pc,  Psc,  Ph  and  Sce  families,  in  line  with  the  Drosophila 
paradigm. In principle, therefore, the mammalian PcG proteins described in Table 1.1 
have the potential to form 180 different permutations of PRC1 complex.  
One  way  to  try  to  resolve  some  of  these  issues  would  be  conduct  a 
comprehensive  survey  to  identify  all  of  the  PcG  proteins  that  are  involved  in  the 
regulation of INK4A.  However, as a starting point, it was decided to focus on the HPH 
proteins for a number of reasons. First, they are arguably the least well characterised of 
the PRC1 proteins in terms of their structural or functional contribution to the complex. 
Second, of the three known Ph proteins in mammalian cells, only one has thus far been 
shown to influence expression of Ink4a in mice, namely Mph2, whereas family member 
Mph1 did not (Isono et al., 2005a; Ohta et al., 2002). Finally, preliminary findings in 
the laboratory identified HPH2 as the only member of the family that co-purified with 
mouse Cbx7 that is known to regulate INK4A. 
 
1.4.1  HPH Family overview 
 
As for all other PcG genes, polyhomeotic was initially discovered in mutant screens in 
Drosophila, where there are two nearly identical copies, Ph proximal and Ph distal 
(Dura  et  al.,  1985;  Dura  et  al.,  1987).  Early  analyses  already  provided  clues  about 
functional domains and suggested a putative role as a transcription factor, as part of a 
protein  complex  (Deatrick  et  al.,  1991).  As  these  domains  have  been  conserved  in 
evolution, they provide a basis for seeking functions common to all members of the 
family (Nomura et al., 1994). The mammalian polyhomeotic family is composed of 
three genes, which products are smaller in size than the Drosophila protein (Figure 1.4). 
In addition, Mph2 has also been reported to have a short isoform (Yamaki et al., 2002). 
Consistent  with  the  Drosophila  genes,  the  conserved  domains  are  located  in  the 
carboxy-terminal  third  of  each  protein.  These  are  designated  homology  domain  1   42 
(HD1), the (Cys)4-type Zn coordination- or FCS domain, and the homology domain II 
(HD2)  or  sterile  alpha  motif  (SAM)  domain.  Since,  the  conserved  domains  only 
comprise a small part of each protein and as the PH proteins are considerably larger 
than other PRC1 proteins there would in principle be ample opportunity for additional, 




Figure 1.4 Conservation of polyhomeotic family in different species 
Schematic  representation  of  the  polyhomeotic  proteins  in  Drosophila  melanogaster, 
Mus musculus and Homo sapiens, indicating their molecular weights and the relative 
locations  of  the  HD1,  FCS  and  SAM  converved  C-terminal  functional  domains  (as 
derived from the Uniprot database). 
 
1.4.1.1  SAM Domain Oligomerisation 
 
The sterile alpha motif (SAM) domain has been shown to mediate binding between two 
polyhomeotic  proteins,  even  when  originating  from  two  distinct  species  (Kyba  and 
Brock, 1998b). It was found that the resulting oligomer of purified Drosophila Ph SAM 
domains forms an alpha helical structure, with 6 subunits per turn (Kim et al., 2002). In 
addition to homotypic SAM interactions between polyhomeotic proteins, heterotypic 
SAM interactions with the non-core polycomb protein SCM have been observed, again 
forming a helical polymer (Kim et al., 2005; Kyba and Brock, 1998b; Peterson et al., 
1997). In addition, binding studies with HPH1 and HPH2 reported that the HD1 domain 
of one protein interacts with the SAM domain of the other (Gunster et al., 1997).  
The  self-association  of  the  different  Phs  could provide  a  mechanism  for  the 
spreading of Polycomb complexes along the chromatin of their target genes or to bridge 
between loci from different intra- or interchromosomal locations. In addition, it was 
suggested that the structure of the chromatin fiber wrapped around the helical polymer   43 
of SAM domains would be thermodynamically stablilised by protein-DNA and protein-
histone  interactions  (Kim  et  al.,  2002).  Although  there  is  in  vitro  binding  data  that 
suggests Psc and Pc can also self-associate under certain conditions (Kyba and Brock, 
1998a; Min et al., 2003), oligomerisation properties of the polyhomeotics make it a 
strong suspect for chromatin spreading of PRC1 complexes,  
 
1.4.1.2  Association with MAPKAP and ATM/ATR Kinases 
 
The  polyhomeotic  proteins  have  been  shown  to  interact  with  the  mitogen  activated 
protein  kinases-associated  protein  kinases  (MAPKAP  or  MK).  MKs  function 
downstream of the ERK pathway following mitogen stimulation and the p38 MAPK 
cascade in response to stress signals. MK2, MK3 and MK5 are involved in multiple 
cellular functions, including cell-cycle control, cellular differentiation and chromatin 
repression and remodelling (reviewed in (Gaestel, 2006)). MK2 was found to interact 
with HPH2 in the context of PRC1 and to co-localise to Polycomb bodies (Schwermann 
et al., 2009; Yannoni et al., 2004). HPH2 binding of MK2 was required to rescue the 
reduced  self-renewal  capacity  of  MK2
-/-  HSCs,  associated  with  increased  levels  of 
p19
Arf, by ectopic MK2 (Schwermann et al., 2009). This study also reported in vitro 
interactions between HPH1 and MK2, and between HPH2 and MK3, but not MK5. 
HPH1 and BMI1 were also identified as substrates for MK3 phosphorylation and MK3 
overexpression results in the release of PRC1 proteins from chromatin and reduced 
proliferation accompanied by a loss of PcG-mediated repression of p14
ARF (p16
INK4A 
was not tested) (Voncken et al., 2005). This however opposes the findings for loss of 
MK2  in  HSCs  or  other  phosphorylation  events  of  BMI1  needed  for  its  chromatin 
association (Schwermann et al., 2009; Voncken et al., 1999).  
  In addition, HPH2 and HPH3 were found to be substrates for the DNA damage 
response  kinases  ATM  (ataxia  telangiectasia  mutated)  and  ATR  (ATM  and  Rad3-
related) in a large proteomic screen in 293T cells (Matsuoka et al., 2007). Interestingly, 
the phosphorylation sites, S733 in HPH2 and S229 in HPH3, are in largely distinct 
locations and do not correspond to conserved motifs among the HPH proteins. Upon 
closer inspection, however, there are multiple PQ and SQ motifs in HPH1 and HPH2 in 
the regions aligning with S229 of HPH3. Additionally, the Swissprot database lists three 
other predicted phosphoserines in the vicinity of S733 in HPH2.  
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1.4.1.3  Nucleic Acid Binding 
 
As previously mentioned, there is a compelling link between RNA and PcG-mediated 
repression but it is not clear which PcG proteins are involved in the interaction with 
RNA. Although the chromodomains of the CBX and SCM proteins have been shown to 
interact with RNA (Akhtar et al., 2000; Bernstein et al., 2006b), there is also evidence 
ascribing nucleic acid interactions to the functional repertoire of the polyhomeotics. In 
vitro  RNA  binding  studies  with  Mph1  identified  the  conserved  zinc  finger  domain 
(CX2C...CX3C type), often referred to as the FCS finger, as the region of interaction 
with  both  RNA  and  DNA  (Zhang  et  al.,  2004).  The  binding  was  found  not  to  be 
sequence-specific and both single- and double-stranded RNAs (but not tRNA) were 
bound by the domain. A recent structure of the FCS domain from L3(MBT)-like shows 
an RNA binding pocket formed by the conserved cysteines (Lechtenberg et al., 2009) 
and  mutation  of  the  cysteine  residues  perturbs  RNA  binding.    Similar  observations 
apply to the C. elegans protein SOP2, which is a distant relative of Ph and Scm. SOP2 
RNA  binding  mutants  were  shown  to  display  homeotic  transformations  and  loss  of 
nuclear  localisation,  suggesting  an  essential  role  for  RNA  in  guiding  Polycomb-
mediated repression (Zhang et al., 2004; Zhang et al., 2006). 
 
1.4.1.4  Interaction with Transcription Factors 
 
Whereas genetic ablation of Mph2 leads to impaired proliferation, a recent report has 
suggested that loss of heterozygosity (LOH) of HPH3, which is frequently observed in 
osteosarcoma, contributes to tumorigenesis by disrupting quiescence (Deshpande et al., 
2007). HPH3 has been shown to interact with E2F6, which is believed to induce a G0 
arrest by acting as a dominant negative regulator of the E2F family of transcription 
factors (Ogawa et al., 2002). Along similar lines, E2F6 had previously been shown to 
interact with the PcG proteins RING1A, RING1B, MEL18 in human, and Bmi1 and 
Mph1 in mouse, at E2F- and Myc-responsive proteins (Deshpande et al., 2007; Ogawa 
et al., 2002; Trimarchi et al., 2001). It is conceivable, therefore, that loss of HPH1 or 
HPH3 and associated PcG function could lead to derepression of the E2F- and Myc-
responsive genes.  
On the contrary, HPH2 was found to interact with the activation domains of the 
transcription factor Sp1 in a yeast two-hybrid screen (Gunther et al., 2000). Sp1 is   45 
widely  involved  in  transcriptional  regulation  and  interacts  both  with  general 
transcription  factors  that  constitute  the  transcription  machinery  and  a  wide  array  of 
DNA binding regulatory factors, including RB, p107, p53, E2F and YY1, and the basal 
transcription machinery (reviewed in (Wierstra, 2008)). Furthermore, in Drosophila Sp1 
has been found at PREs and therefore might be a co-factor for PcG recruitment to target 
genes (Brown et al., 2005). The interaction between Sp1 and HPH2 was validated by in 
vitro binding and involved the first 266 amino acids (Gunther et al., 2000). This is of 
interest, as this region does not include any of the conserved domains of polyhomeotics, 
suggesting that this interaction could indeed be unique to HPH2. 
In summary, the HPH proteins thus present a number of interesting properties and 
interactions  in  the  context  of  PcG-mediated  repression,  some  of  which  present  a 
putative connection to the wider domain of INK4A function.   46 
1.5  Thesis Aims 
 
The general aim of this thesis was to investigate the potential role of the HPH proteins 
in the regulation of INK4A and more specifically to address the following questions: 
 
1.  Is there any evidence for specificity in the interaction between HPH2 and other 
PRC1  components  that  can  be  used  as  a  foundation  for  defining  the  PRC1 
complexes that regulate INK4A? 
 
2.  Is  HPH2  and/or  other  members  of  the  HPH  family  directly  involved  in  the 
regulation of INK4A? 
 
3.  What functions does HPH2 contribute to the regulation of INK4A? 2  Materials and Methods 
 
2.1  Solutions 
 
Versene, PBS-A, LB, LB-Agar and clean glassware were provided by the LRI Media 
Services. Chemicals were generally purchased from Sigma-Aldrich. Water was purified 
using a Millipore reverse osmosis system. Solutions were made up in water (unless 
stated otherwise) and either sterilised through autoclaving or filtered through a 0.22 µm 




PBS-A         8.06 mM Na2HPO4 
          0.8% (w/v) NaCl 
1.47 mM KH2PO4 
    0.025% (w/v) KCl (pH 7.2) 
 
Bacterial Culture & Lysis 
 
Luria broth (LB)      1% (w/v) NaCl 
          0.5% yeast extract 
          1% (w/v) bacto-tryptone 
 
SOC medium        2% (w/v) tryptone 
          0.05% (w/v) yeast extract 
          0.006% (w/v) NaCl 
          0.002% (w/v) KCl 
          0.002% (w/v) MgCl2 
          0.036% (w/v) D-glucose 
 
GST Lysis buffer      10 mM TRIS HCl pH 7.6 
          1 M NaCl 
          0.1 mM PMSF   48 
 
GST elution buffer      10 mM reduced glutathione 
          50 mM TRIS HCl pH 8.0 
 
HIS purification buffer    50 mM NaH2PO4 pH 8.0   
          0.5 M NaCl 
 
HIS imidazole buffer      3 M imidazole 
          0.5 M NaCl 




2x HBS        200 mM NaCl 
1.5 mM Na2PO4 
          50 mM HEPES (pH 7.1) 
 
Versene        0.02% (w/v) EDTA in PBS-A 
          0.0015% (w/v) phenol red 
 
SDS-PAGE and Western blotting: 
 
RIPA lysis buffer      25 mM TRIS HCl pH 7.6 
          150 mM NaCl 
          1% (v/v) NP40 
          1% (v/v) sodium deoxycholate 
          0.1% (v/v) SDS 
          0.1 mM PMSF 
          1x Protease Inhibitor Cocktail (Sigma) 
 
Protein running buffer     25 mM TRIS base 
          192 mM glycine 
          0.1% (w/v) SDS 
 
Protein transfer buffer     Protein running buffer   49 
          20% (v/v) methanol 
 
5x Laemmli buffer      0.375 M TRIS HCl pH 6.8 
10% (v/v) SDS 
50% (v/v) glycerol 
0.01% (w/v) bromophenol blue 
25% (v/v) 2-mercaptoethanol 
 
WB washing buffer      PBS-A 
0.1% (v/v) Tween-20 
 
WB blocking buffer      WB washing buffer 
          5% dried milk (Marvel) 
 
Western stripping buffer    0.5 M TRIS HCl pH 6.8 
20% (v/v) SDS 
0.5% (v/v) 2-mercaptoethanol 
 
Fixing/Destain solution    50% (v/v) methanol 
          10% (v/v) acetic acid 
 
Coomassie staining solution    0.1% (w/v) Coomassie blue R250 
          50% (v/v) methanol 




NP40 lysis buffer      50 mM TRIS HCl pH 8.0 
150 mM NaCl 
          1 mM EDTA 
          1% (v/v) NP40 
          0.1 mM PMSF 
          1x Complete EDTA free (Roche), or; 
          1x Protease Inhibitor Cocktail (Sigma) 
   50 
ChIP buffer        50 mM TRIS HCl pH 7.5 
150 mM NaCl 
          5 mM EDTA 
          1% (v/v) NP40 
          1% (v/v) Triton X-100 
0.1 mM PMSF 
          1x Complete EDTA free (Roche) 
 
ChIP elution buffer      50 mM NaHCO3 





Buffer A (with or without NP40)  5 mM PIPES pH 8.0 
          85 mM KCl 
          1X Complete EDTA free (Roche) 
50 U/ml SUPERase in (Ambion) 
          0.5% (v/v) NP40 
 
Buffer B        1% (v/v) SDS 
          10 mM EDTA 
          50 mM TRIS HCl pH 8.1 
          1X Complete EDTA free (Roche) 
50 U/ml SUPERase in (Ambion) 
 
IP buffer        0.01% (v/v) SDS 
          1.1% (v/v) Triton X-100 
          1.2 mM EDTA 
          16.7 mM TRIS HCl pH 8.1 
          167 mM NaCl 
          1X Complete EDTA free (Roche) 
50 U/ml SUPERase in (Ambion) 
 
                                                 
1 www.epigenetics-noe.net/researchtools/protocol.php?/protid=28reagents   51 
 
Low-salt wash buffer     0.1% (v/v) SDS 
          1% (v/v) Triton X-100 
          2 mM EDTA 
          20 mM TRIS HCl pH 8.1 
          150 mM NaCl 
 
Low-salt wash buffer     0.1% (v/v) SDS 
          1% (v/v) Triton X-100 
          2 mM EDTA 
          20 mM TRIS HCl pH 8.1 
          500 mM NaCl 
 
LiCl wash        0.25 M LiCl 
          1% (v/v) NP40 
          1% (v/v) deoxycholate 
          1 mM EDTA 
          10 mM TRIS HCl pH 8.1 
 
Elution buffer       1% SDS 
0.1 M NaHCO3 
50 U/ml SUPERase in (Ambion) 




Primer annealing buffer    100 mM K-acetate 
30 mM hepes-KOH pH 7.4 
2 mM Mg-acetate 
 
DNA loading buffer      60% (v/v) sucrose 
          0.1% (w/v) bromophenol blue 
 
DNA running buffer      40 mM TRIS-acetate (pH 7.6) 
          5 mM sodium acetate   52 
          1 mM EDTA 
 
Tandem Affinity Purification: 
 
Lysis buffer        50 mM TRIS HCl pH 8.0 
0.3 M NaCl 
          1 mM EDTA 
1.02 mM ZnCl2 
          1% (v/v) NP40 
          0.1 mM PMSF 
          1x Complete EDTA free (Roche) 
 
TEV cleavage buffer      50 mM TRIS HCl pH 8.0 
0.3 M NaCl 
          0.5 mM EDTA 
0.52 mM ZnCl2 
          0.1% (v/v) NP40 
0.1 mM PMSF 
1 mM DTT 
 
Calmodulin binding buffer    50 mM TRIS HCl pH 8.0 
0.3 M NaCl 
0.1% (v/v) NP40 
1 mM MgOAc 
2 mM CaCl2 
1 mM imidazole 
          10 mM 2-mercaptoethanol 
 
EDTA elution buffer      50 mM TRIS HCl pH 8.0 
0.3 M NaCl 
0.1% (v/v) NP40 
5 mM EDTA   
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GST Pull-down assay: 
 
Binding buffer       25 mM HEPES pH 7.5 
          12.5 mM MgCl2 
          20% (v/v) glycerol 
          0.1% (v/v) NP40   
 
Wash buffer        20 mM TRIS HCl  pH 8.0 
          100 mM NaCl 
          1 mM EDTA 
          0.5% NP40 
 
Senescence-associated β-Galactosidase (SAβ-Gal) Staining 
 
SAβ-Gal fixing solution    2% formaldehyde 
          0.2% glutaraldehyde 
          97.8% PBS-A 
 
SAβ-Gal staining solution (fresh)  1 mg/ml X-Gal 
          40 mM citric acid/Na3PO4 solution 
          5 mM K ferrocyanide (K4[Fe(CN)6]•3H2O) 
          5 mM K ferricyanide (K3[Fe(CN)6]) 
          150 mM NaCl 
          2 mM MgCl2 
 
Citric acid/Na3PO4 solution    36.85 mM citric acid solution 
          126.3 mM Na3PO4 
 
2.2  DNA techniques 
 
Plasmid  vectors  were  obtained  from  the  laboratory’s  stock  or  provided  by  other 
laboratories  (as  acknowledged).  cDNAs  were  obtained  from  the  Medical  Research 
Council Geneservice. 
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2.2.1  Plasmid vectors 
 
The following vectors were used in this work for the following applications; 
 
pCR2/pCR4  TOPO TA cloning of new cDNAs 
pcDNA6  cDNA expression 
pRSET A  HIS-fusion protein bacterial expression 
pGEX 6P1  GST-fusion protein bacterial expression 
pBABE  retroviral cDNA expression 
pMARX  retroviral cDNA expression 
pRS    retroviral shRNA knockdown 
pMLP   retroviral shRNA knockdown 
pLKO.1  lentiviral shRNA knockdown 
 
2.2.2  PCR 
 
In  order  to  attach  the  desired  restriction  sites  to  an  existing  cDNA  for  subsequent 
ligation into a different vector, PCR was performed using primers including the new 
restriction sites. PCR was also performed with de novo cDNA produced by using the 
Superscript  III  reverse  transcription  (RT)  kit  (Invitrogen).  The  Pfu  Ultra  DNA 
polymerase (Stratagene) was used for its high fidelity. The general reaction includes 1X 
Pfu Ultra reaction buffer, 50 ng of DNA template, 0.2 mM dNTP mix, 1 µM of each 
primer and 2.5 U of Pfu Ultra and water up to 50 µl total volume. The general PCR 
cycle programme was: 
 
1.  95 °C for 2 min (denaturation) 
2.  95 °C for 30 sec (cyclical denaturation) 
3.  (primers Tm – 4) °C for 30 sec (primer annealing) 
4.  68 °C for 1 min/kb of template (extension) 
5.  cycle to step 2 for 29-34 times 
 
Generally after the PCR, Taq DNA polymerase was added and incubated at 72°C for 
one hour to create a poly A tail on the PCR product. This was needed for ligation into 
either  the  pCR2  or  pCR4  vectors  (Invitrogen)  depending  on  the  restriction  sites   55 
required.  By  using  these  vectors  the  PCR  product  was  amplified  to  generate  larger 
amount of cut insert for ligation.  
In addition, PCR was used for site-directed mutagenesis of cDNAs. For this an 
existing plasmid was amplified using primers containing the altered base(s) and the 
following PCR cycle programme was used: 
 
1.  95 °C for 1 min (denaturation) 
2.  95 °C for 50 sec (cyclical denaturation) 
3.  (primers Tm – 4)°C for 50 sec (primer annealing) 
4.  68 °C for 2 min/kb of template (extension) 
5.  cycle to step 2 for 17 times 
 
Following the PCR program, the reaction was treated with Dpn1, which only digests 
dam methylated DNA that has been isolated from E. coli and therefore specifically 
removes the original template plasmid. 5 µl of this reaction was then used to transform 
competent bacteria as described next. 
 
2.2.3  Restriction digestion, ligation and transformation 
 
Plasmid DNA was digested with the relevant restriction enzymes to isolate  a DNA 
fragment to use either as a recipient vector or as an insert to subcloned into another 
vector. Typically, 5 µg of DNA was used to prepare a cut vector and 5-10 µg of DNA 
was used to prepare a cut insert. Digestion was typically carried out in a final volume of 
50 µl containing 1X of the appropriate restriction buffer (New England Biolabs) and 1 
µg/ml  BSA  (New  England  Biolabs)  and  using  20  U  of  each  restriction  enzyme. 
Digestion samples were incubated for 1 h-O/N at 37 °C. Preparations of cut vector were 
generally  dephosphorylated  with  10U  calf  intestine  phophatase  (CIP)  to  reduce  cut 
vector self-ligation. 
Digested DNA samples were resolved by electrophoresis in a 0.5 – 2% agarose 
gel containing 0.5 µg/ml ethidium bromide. After sufficient resolution was achieved, 
the DNA fragments were visualised using a UV transilluminator (UVP BioDoc-IT) and 
the  relevant  pieces  of  DNA  were  excised  and  recovered  using  the  QiaQuick  gel 
extraction kit (Qiagen), according to manufacturer’s instructions. Concentrations of cut 
vector and insert were either estimated by comparison of ethidium bromide staining   56 
internsity, or were more precisely determined by measuring the DNA  concentration 
using  a  NanoDrop  spectrometer  (Thermo  Scientific).  Generally,  ligations  were 
performed using a 3-5:1 ratio of cut vector to cut insert, in a 10 µl reaction containing 
1X T4 ligase buffer and 10U of T4 ligase. A control reaction, using water instead of 
insert,  was  also  performed.  Ligations  were  generally  performed  for  1h  at  room 
temperature (rt) or O/N at 16°C. Ligation of PCR products into either pCR2 or pCR4 
were performed in a similar manner. 
Following ligation, 5µl of the reaction (or the total reaction volume for TOPO 
ligation)  was  used  to  transform  competent  DH5α  bacteria  (provided  by  Marc 
Rodriguez-Niedenführ) or One Shot TOP10 (Invitrogen) chemically competent cells. 
Bacteria were kept on ice for 30 min, heat-shocked for 45 sec at 42 °C and put back on 
ice for 2 min. 100µl of SOC medium was added next and the bacteria were put in a 
shaking incubator at 37 °C for a minimum of 15 min. The bacteria were plated on petri 
dishes containing LB-agar with 100µg/ml ampicilin, and 20 µg/ml X-gal if applicable 
(for  blue-white  selection  of  pCR2/pCR4  clones).  Similarly,  re-transformation  of 
existing plasmids was performed using 1 µl of DNA. 
 
2.2.4  Plasmid DNA preparation 
 
Clones from transformation were grown up as 5 ml cultures in LB containing 100µg/ml 
ampicillin  at  37  °C  O/N.  The  next  day,  an  aliquot  was  taken  for  possible  culture 
expansion, and the remainder of the culture was centrigured to recover the bacterial 
pellet  and  submitted  for  mini-scale  plasmid  preparation  (miniprep)  by  the  LRI 
Equipment Park. Alternatively, the miniprep was performed using the QiaPrep Spin 
Miniprep Kit (Qiagen), according to manufacturer’s guidelines. These minipreps were 
then analysed by restriction enzyme digestion to ascertain whether they contained the 
correct insert. Positive minipreps were then checked by DNA sequencing, as described 
below. A culture of a positive clones was stored in a 1:1 volume of glycerol at -80 °C. 
  To produce a plasmid DNA stock, clones were generally grown in a 100 ml 
culture at 37 °C O/N for a maxi-scale preparation of plasmid DNA (maxiprep). The 
cultures  were  pelleted  by  centrifugation  at  4000rpm  at  4  °C.  The  pellet  was  then 
processed  using  the  HiSpeed  Plasmid  Maxi  Kit  (Qiagen),  according  to  the 
manufacturer’s guidelines. The DNA was eluted in water and the concentration was 
measured by NanoDrop spectrometer. Plasmids were stored at 4 °C.   57 
 
2.2.5  DNA sequencing 
 
Sequencing  of  DNA  was  performed  using  the  ABI  PRISM  Dye  Terminator  Cycle 
sequencing kit (Applied Biosystems). This constitutes a PCR reaction containing a low 
level of labelled ddNTPs, which terminate the extension by the DNA polymerase. This 
produces a series of PCR products of different length from which the position and type 
of labelled base can be derived (performed by the LRI Equipment Park). The PCR 
reaction  consist  of  8  µl  big  dye  terminator  mix  3.1  (BDT),  200-300ng  of  template 
plasmid and 3.2 pmol of a sequencing primer, made up to a final volume of 20 µl with 
water. Commonly used sequencing primers flanking the multiple cloning sites of the 
vectors used are listed in Table 2. The PCR cycling programme used was as follows: 
 
1.  96 °C for 1 min (denaturation) 
2.  96 °C for 10 sec (cyclical denaturation) 
3.  (primers Tm – 4)°C for 5 sec (primer annealing) 
4.  60 °C for 4 min (extension) 
5.  cycle to step 2 for 24 times 
 
PCR reactions were then purified using the DyeEx 2.0 spin kit (Qiagen), according to 
manufacturer’s  instructions  and  vacuum  dried.  Derived  sequences  were  interpreted 
using the MacVector software (Accelrys) and the online BLAST program (NCBI).   58 
 
Primer name  Sequence 
pBABE F1  CGTCTCTCCCCCTTGAACC 
pBABE R2  CTGCCTGCTGGGGAGCC 
pRS F  TACATCGTGACTGGGAAGC 
pRS R  TAAAGCGCATGCTCCAGACT 
T7  AATACGACTCACTATAG 
BGH  TAGAAGGCACAGTCGAGG 
SP6  CATACGATTTAGGTGACACTATAG 
M13F  GTTTTCCCAGTCACGAC 
M13R  CAGGAAACAGCTATGC 
 
Table 2. Commonly used sequencing primers 
 
2.3  Cell culture 
 
All mammalian cell types used were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM)  (Gibco)  supplemented  with  10%  (v/v)  foetal  bovine  serum  (FBS),  which 
together will be referred to as ‘medium’. Cells were grown as monolayers in humified 
air that containing 5% CO2 at 37°C. Before reaching confluency, cells were washed 
once  in  versene  pre-warmed  to  37°C  and  then  incubated  with  a  1:3  trypsin 
(Gibco):versene solution until cells would detach from the plastic surface. Medium was 
then  added  to  neutralise  the  trypsin  and  cells  were  seeded  in  new  culture  dishes, 
generally at in a split ration between 1:2 and 1:6 and the population doubling doublings 
were recorded. 
 
2.3.1  Cell strains/lines 
The cell strains and cell lines used in this work are: 
- BOSC23  Ad5-transformed  human  embryonic  kidney  (HEK)  293  cell  line 
expressing  gag-pol  and  env  genes  for  ecotropic  retrovirus  packaging 
(Pear et al., 1993) 
- 293T  Ad5/SV40 large T-transformed HEK293 (ATCC number CRL-1573) 
- DU-145  Prostate carcinoma (ATCC number HTB-81) 
- MEF  mouse  embryonic  fibroblasts  isolated  from  C57BL/6  embryos 
(performed by LRI Cell Services)   59 
- FDF    Human foetal dermal fibroblasts (Brookes et al., 2004) 
- Hs68  Human neonatal foreskin fibroblast (ATCC number CRL-1635) 
- Q34  Human adult skin fibroblasts (Brookes et al., 2004) 
- Leiden  Human diploid fibroblasts derived from a patient who is homozygous for 
a deletion in exon 2 of INK4A (Brookes et al., 2002) 
- MEF  Mouse embryonic fibroblasts, wildtype derived from C57BL/6 mice by 
LRI Cell services and Mph2
-/- mutant obtained from H. Koseki (Isono et 
al., 2005a) 
 
To allow for infection by ecotropic retroviruses, the various strains of primary human 
diploid fibroblasts (HDFs) were infected with an amphotrophic retrovirus encoding the 
mouse basic amino acid transporter which functions as the cell surface receptor for 
mouse ecotropic retroviruses. Due to the switch to direct amphotrophic viral infection 
of the primary HDFs over the course of this work, the need for the ecotropic receptor 
was alleviated. 
 
2.3.2  Storage, recovery and harvesting of cells 
 
For harvesting and storage, cells were released from the culture dish by trypsinisation as 
previously described and resuspended in PBS. Cells were centrifuged at 1500g for 5 
min. For freezing the cells, the cell pellet was resuspended in freezing medium (50% 
(v/v)  FBS,  10%  (v/v)  DMSO)  and  transferred  into  cryoviles  (Nunc)  and  frozen 
gradually in a freezing container (Nalgene) at -80 °C. Following freezing, cells were 
transferred to liquid nitrogen containers. For harvesting cells, the pellet was washed for 
an additional time in 1ml PBS, transferred to an Eppendorf tube and centrifuged at 
1500g for 5 min. The resulting pellet was either lysed directly or stored at -20°C or 
snapfrozen and stored at -80 °C to optimally preserve protein-protein interactions. To 
recover  frozen  cells,  the  relevant  freezing  vile  was  swiftly  transferred  from  liquid 
nitrogen to a 37 °C. waterbath and incubated until just thawed and then transferred to a 
culture dish containing medium at 4 °C.   60 
2.3.3  Transfection of human cell lines 
 
Approximately 2x10
6 cells were seeded per 10cm dish the day before transfection. The 
next day, 20 µg of plasmid DNA was mixed with 437.5 µl of water and 62.5 µl CaCl2 
was added. The DNA sample was further mixed by pipetting and then transferred to 
500µl of 2x HBS in a drop-wise manner without any mixing. This DNA:HBS mixture 
was then incubated for 30 min at rt, and then added to the cells to be transfected in a 
drop-wise manner without mixing. The cells were then incubated at 37 °C for 14-17 
hours.  The  next  day  the  medium  was  replaced  with  10ml  fresh  medium.  Gene 
expression was assayed 24-48 hours later.  
For  generating  stocks  of  infectious  virus,  BOSC23  (ecotropic)  or  293T 
(amphotrophic) cells were transfected as above. For producing amphotrophic virus, 10 
µg of plasmid DNA was combined with 8 µg of pCG Gag-Pol (retrovirus) or pCMV 
Δ8.2 (lentiviral), and 2 µg of pCG VSV-G and used to transfect 293T cells. 14-17 hours 
after transfection, the medium was changed to half the original volume to concentrate 
the virus being produced. 
For stable transfection, the plasmid DNA was first linearised by cutting at a 
unique  restriction  site.  After  48  hours,  the  cells  were  selected  with  the  respective 
antibiotic drug. Following selection the cells were seeded at a 1:10
4 dilution to allow for 
colonies  to  arise  from  individual  clones.  Selected  clones  were  recovered  by 
trypsinisation of the colony and transferred to a 96-well culture plate. Clones were then 
gradually expanded and screened for expression of the transgene. The best expressing 
clone was used for further expansion. 
 
2.3.4  Viral transduction of human cells 
 
For retroviral or lentiviral transduction of HDFs, the cells were split 1:4 the day before 
infection. To harvest virus, medium collected from the packaging  cells was filtered 
through a 0.45 µm Millix-HV filter (Millipore). The filtered virus-containing medium 
was either added directly to the HDF cultures or frozen at -80 °C, resulting in a 50% 
loss of viral titer upon thawing. After harvesting virus for ecotropic infection, 5 ml of 
fresh medium was added to the BOSC23 cells and a second viral titer was harvested 24 
hours later for a secondary infection. For amphotrophic virus, the medium from the   61 
293T cells was only harvested once. For lentiviral infection the harvested virus was 
diluted 1:2 – 1:5. 
After 32 to 48 hours, the medium was changed to fresh medium containing the 
appropriate antibiotic drug. Puromycin was used at 0.5 µg/ml, hygromycin B at 50µg/ml 
and  blasticidin  at  5  µg/ml.  Selection  efficiency  was  monitored  using  an  uninfected 
control plate of cells. 
 
2.4  Protein biochemistry 
 
2.4.1  Preparation of total cell lysate 
 
Harvested cell pellets were lysed by the addition of 5X v/v ice-cold lysis buffer. Lysis 
was allowed to proceed for 10 min on ice. Lysates were cleared of nuclear derbis by 
centrifugation for 10 min. at 14,000 rpm at 4°C and supernatant was collected on ice. 
Lysis was generally performed with NP40 buffer, but also RIPA buffer was used for 
assessing protein levels by direct immunoblotting. 
The protein concentration of lysates was determined by the Bradford assay using 
Protein Assay Dye Reagent (Bio-Rad). This concentrated solution was diluted 1:5 in 
water and 1 ml of the final  solution was pipetted in a plastic cuvette (Sarstedt). A 
duplicate or triplicate 2µl of each lysate sample to be assayed was added to individual 
cuvettes. Similarly, serial dilutions of BSA standards of known concentrations (20 – 
0.125 mg/ml) were added to individual cuvettes. Cuvettes were then briefly mixed by 
flicking.  Samples  were  incubated  for  15  min.  Consequently  the  absorbance  was 
measured  at  λ=595nm  using  a  Ultrospec-2000  spectrometer  (Pharmacia  Biotech). 
Values were compared to a standard curve obtained from the BSA dilution series. 
 
2.4.2  SDS-PAGE 
 
Polyacrylamide gels (8 x 10 x 0.075 cm) were poured using the Protean system (Bio-
Rad). The running part of the gel was cast from the mix of 375 mM TRIS HCl pH 8.8, 
0.1% (v/v) SDS, 0.1% (v/v) APS and 0.04% TEMED and 8-15% acrylamide depending 
on the molecular weight of the protein of interest. Following casting, the solution was 
covered with water to promote polymerisation of the forming gel. When the running gel   62 
was fully polymerised, the water on top was decanted. Next the stacking part of the gel 
was poured containing 5% acrylamide in 375 mM TRIS HCl pH 6.8, 0.1% (v/v) SDS, 
0.1 (v/v) APS and 0.1% TEMED and a comb was inserted to form wells for sample 
loading. 
  Protein  samples  were  prepared  by  adding  5X  Laemmli  buffer  to  a  1X  final 
concentration and samples were adjusted to an equivalent final volume by using 1X 
Laemli buffer. The samples were then boiled for 10 min. Molecular weight size markers 
(7-175kDa) (New England Biolabs) were used for monitoring fractionation, used for 
size estimation and assisting in gel orientation for immunoblotting. Electrophoresis was 
performed in 1X running buffer in Protean tanks (BioRad) at a constant current of 30 
mA per gel until desired fractionation was achieved. 
  For separating the samples obtained from tandem affinity purification (TAP) the 
NuPAGE system (Invitrogen) was used for higher resolution and better compatibility 
with downstream proteomic analysis. Therefore, the relevant samples were prepared 
using NuPAGE LDS sample buffer (Invitrogen) including 0.01 M DTT. The samples 
were  loaded  onto  a  pre-cast  4-12%  NuPAGE  BIS-Tris  gel  (Invitrogen)  and  run  in 
NuPAGE MOPS running buffer containing 0.1% NuPAGE antioxidant (Invitrogen). 
Gels were run at 200 V for 50 min. 
 
2.4.3  Immunoblotting 
 
After  separation  by  SDS-PAGE,  proteins  were  transferred  to  Protran  nitrocellulose 
membrane (Whatman) using the Protean system (BioRad). The membrane was soaked 
in transfer, placed over the top of the gel and ‘sandwiched’ between 3MM filter paper 
(Whatmann). The closed cassette was then inserted in the Protean transfer module, so 
the proteins would transfer from the negative to the positive electrode. Proteins were 
transferred at a 300 V for 75 min. Following this, the membrane was incubated with 
blocking buffer for 1 hour. 
  The primary antibodies commonly used in this work are listed in Table 3. These 
antibodies will subsequently be referred to by their source/origin. This list does not 
include the antibodies generated over the course of this work, which will be described 
in Chapter 3. Blocked membranes were incubated with primary antibodies against the 
protein/epitope of interest. Antibodies were diluted in blocking buffer, typically at 1 
µg/ml.  Generally  4  ml  of  diluted  antibody  was  used  per  full-size  membrane  and   63 
incubated for 1h at rt or O/N at 4°C. Following incubation with the primary antibody, 
the membrane was washed 3 times for 10 min in washing buffer. Depending on the 
primary  antibody  used,  the  membrane  was  incubated  for  1h  a  1:2000  dilution  in 
blocking  buffer  of  HRP-conjugated  anti-mouse  of  anti-rabbit  IgG  (GE  Healthcare). 
Following  this  incubation,  the  membrane  was  washed  again  3  times  for  10  min  in 
washing  buffer  and  then  incubated  with  a  1:1  mix  of  ECL  reagents  1  and  2  (GE 
Healthcare)  for  1  min  to  intiate  the  chemiluminesence  of  HRP.  Membranes  were 
wrapped in Saran film (Dow Chemical), transferred to a Hypercassette (GE Healthcare) 
and exposed to Hyperfilm MP (GE Healthcare) in the dark for various time periods to 
capture the chemiluminescent signal. 
  For  reprobing  with  another  antibody,  membranes  were  washed  in  PBS-A  to 
remove ECL signals before incubating with a new antibody. For removal of antibody, 
membranes were washed 3 x 10 min in washing buffer and incubated with stripping 
buffer for 30 min at 50 °C. After that, blots were washed 3 x 10 min in washing buffer 
before applying the next antibody. In order to store membranes, they were covered in a 
thin layer of blocking buffer and wrapped in Saran film and stored at -20°C.   64 
 
Epitope/protein  Name  Species and Type  Origin/Source 
Human P16
INK4A  JC8  Mouse monoclonal  Koh & Harlow, LRI 
Mouse p16
Ink4a  M-156  Rabbit polyclonal  Santa Cruz 
CDK4/Cdk4  DCS-35  Mouse monoclonal  Neomarkers 
FLAG  M2 (F3165)  Mouse monoclonal  Sigma 
FLAG affinity gel  M2 (A2220)  Mouse monoclonal  Sigma 
HA (HA.11)  16B12  Mouse monoclonal  Covance 
CBX7  ab21873  Rabbit polyclonal  Abcam 
BMI1  ab14389  Mouse monoclonal  Abcam 
CBX8  LAST+GALD  Rabbit polyclonal  Kristian Helin, BRIC 
Histone H3  ab1791  Rabbit polyclonal  Abcam 
Histone H3K27me3  07-449  Rabbit polyclonal  Millipore 
CBP  07-482  Rabbit polyclonal  Stratagene 
6xHIS  4D11  Mouse monoclonal  CRUK 
MYC  9E10  Mouse monoclonal  CRUK 
 
Table 3. List of commonly used primary antibodies detailing their species, type 
and origin/source 
 
2.4.4  Immunoprecipitation 
 
Immunoprecipitation (IP) was typically performed on 300 µl volumes of cleared NP40 
lysate and 10% of this volume was kept as input sample. For precipitations, generally 5 
µg of purified antibody or 20 µl of unpurified serum and 20µl Protein A or Protein G 
sepharose  beads  (Thermo  Scientific)  were  used.  The  samples  were  incubated  on  a 
rotating wheel at 4 °C for 2 h or O/N. The beads were pelleted at 2,000 rpm for 5 min at 
4 °C and washed 3 times for 10 min in 1 ml of ice-cold NP40 lysis buffer. Immune 
complexes were released from beads by boiling in 2X Laemmli buffer or eluted with 10 
µg of the respective peptide in a 7X bead volume of lysis buffer. Samples were either 
stored at -20°C or directly separated by SDS-PAGE. 
 
2.4.5  Chromatin Immunoprecipitation 
 
Cells to be used for chromatin immunoprecipitation (ChIP) were treated with a cross-
linking reagent before they were harvested. To this end, 37% (w/v) formaldehyde was   65 
added to the medium for a final concentration of 1% (w/v). After incubation at 37 °C 
for 10 min, the cross-linking was then blocked by addition of 125 mM glycine and 
incubation at rt for 5 min. Cells were then washed twice with PBS-A, harvested with a 
cell scraper in PBS-A and centrifuged for 5 min at 1,500 rpm. Cell pellets were lysed in 
ice-cold ChIP lysis buffer and incubated on ice for 10 min and nuclear pellets were 
obtained by centrifugation at 14,000 rpm at 4 °C for 10min. The nuclear pellet was 
washed with 1ml ChIP buffer and resuspended in 300 µl of IP buffer per 10
6 cells. The 
chromosomal  DNA  was  then  sheared  using  a  BioRuptor  waterbath  sonicator 
(Diagenode) at high setting. Samples were sonicated in pulses of 30 sec with 30 sec 
intervals over three 10 min periods, where the ice in the waterbath was replaced after 
each period. Following sonciation, the samples were cleared by centrifugation at 14,000 
rpm  for  10  min  at  4°C.  The  shearing  efficiency  was  checked  by  reversing  the 
crosslinking and RNase treatment (see below) using 5% of the chromatin sample and 
analysing the DNA fragment sizes on a 1% agarose gel. The target DNA fragment size 
range was 0.5 – 1 kb. 
The protein concentration of the resulting chromatin sample was measured by the 
Bradford assay, as described in section 2.4.1. Generally 0.1-0.5 mg of chromatin was 
used per IP, depending on the affinity of the antibody used and a 10% input sample was 
retained. The IP samples were adjusted to 300 µl and 5 µg of antibody was added. As a 
negative control either rabbit unspecific IgG (for rabbit polyclonal antibodies) or mouse 
anti-HA monoclonal (for mouse monoclonal antibodies) was used. Following addition 
of antibody, the samples were incubated on a rotating wheel at 4°C O/N. The next day, 
samples were cleared by centrifugation to remove unspecific complexes and the top 
90% of the sample was transferred to a new Eppendorf tube containing 20µl Protein 
A/G beads (Thermo Scientific) pre-washed in ChIP buffer. Samples were incubated on 
a rotating wheel at 4°C for a minimum of 30 min. The beads were then centrifuged at 
500g for 5 min at 4°C and washed 3 times with 1 ml of ChIP buffer for 10 min at 4°C. 
  The antibody/protein/DNA complexes were eluted from the beads by adding 50 
µl of elution buffer at rt and shaking on a vortexer for 15 min at highest speed. This 
elution step was repeated once more. The input sample(s) were included at this stage 
and adjusted to 100µl with elution buffer. NaCl was added to a final concentration of 
0.2 M and the samples were incubated at 65°C for 4h - O/N to reverse the crosslinking. 
Next, RNase A was added to a final concentration of 0.1 mg/ml and samples were 
incubated for 30 min at 37°C. Finally, the DNA was purified on a QiaQuick purification   66 
column (Qiagen). The relative enrichment for specific DNA sequences was determined 
by quantitative PCR (qPCR), as described in section 2.5.2. 
 
2.4.6  Tandem Affinity Purification 
 
Tandem affinity purification was initially conducted on a relatively small scale (~4 x 
10
7 cells), but was subsequently adjust to much larger cell numbers for sufficient yield 
for downstream analysis. The essential steps are the same and adjustment for small- or 
large scale are indicated as appropriate. 
Cells were lysed in the TAP lysis buffer. After clearing by centrifugation, the 
lysate was incubated  with 30 µl (small scale) or 300 µl (large scale) fast-flow IgG 
sepharose beads (Amersham) at 4°C O/N. The next day, beads were pelleted at 1,000 
rpm and washed 3 times in lysis buffer and a final wash in TEV cleavage buffer for 10 
min at 4°C. Next, the beads were resuspended in 300 µl TEV buffer and 25 U (small 
scale) or 100 U (large scale) of TEV protease was added and incubated on a rocker for 
90  min  at  rt.  The  beads  were  then  pelleted  at  1,000  rpm  and  the  supernatant  was 
collected. Next, the beads were washed 3 times with 300 µl Calmodulin binding buffer 
for 10 min at 4°C and supernatants were combined. The sample was then centrifuged 
briefly at 1,000 rpm and transferred to a new tube to ensure no carry over of IgG 
sepharose  beads  and  30  µl  (small  scale)  or  300  µl  (large  scale)  of  pre-washed 
calmodulin sepharose beads (Strategene) were added and incubated on a rotating wheel 
at 4 °C O/N.  
The following day, beads were washed 3 times for 10 min each with 1 ml ice-cold 
Calmodulin  binding  buffer  at  4°C. The  bound proteins  were  eluted  by  two  10  min 
incubations  with  500µl  EDTA  elution  buffer  at  4  °C.  The  combined  eluate  was 
centrifuged briefly at 1000 rpm at 4 °C and pipetted to another tube to ensure no carry 
over of beads. For protein precipitation, trichloroacetic acid (TCA) was added to a final 
concentration of 10% and briefly mixed by flicking the tube. The samples were then 
incubated  on  ice  1h  –  O/N  at  4  °C.  Next,  precipitated  proteins  were  pelleted  by 
centrifugation at 18,000g for 30 min at 4 °C. The pellet was washed twice with 1 ml of 
ice-cold  acetone  and  finally  air-dried.  The  resulting  pellet  was  resuspended  in  1x 
NuPAGE LDS sample buffer (Invitrogen) and either stored at -20 °C or directly used 
for SDS-PAGE.  
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2.4.7  Protein gel staining 
 
Proteins were fractionated by SDS-PAGE as described in 2.4.2. The gel was then fixed 
for 30 min in fixing solution and Coomassie staining solution as described in section 
2.1. was applied and incubated on a rotating platform for ≥2 h at rt. Next, the gel was 
destained by several washes in fixing solution at rt. For protein samples from small 
scale  TAP,  SDS-PAGE  was  performed  using  the  NuPAGE  system  as  described  in 
section 2.4.6. Following general fixing, the gel was stained using the SilverQuest kit 
(Invitrogen) according to the manufacturer’s protocol. Due to the high sensitivity from 
silver ion reduction, this staining allows detection of down to 0.3 ng of protein, but it is 
not compatible with the downstream mass spectrometry analysis services provided by 
the LRI. For protein samples from large scale TAP, gels were fixed in a solution of 
12.5% (w/v) TCA and 3.5% (w/v) 5-sulfosalicyclic acid (Sigma) for 30 min and stained 
in Colloidal Coomassie Blue (Sigma) O/N at rt. Alternatively for higher sensitivity, gels 
were fixed in a solution of 50% methanol and 7% acetic acid, stained in SYPRO Ruby 
solution (Invitrogen) O/N at rt, and washed once in 10% methanol, 7% acetic acid. 
 
2.4.8  LC/MS/MS Mass spectrometry 
 
The gels stained with either SYPRO Ruby or Colloidal Coomassie Blue were used to 
excise visible bands. Gel slices were added to an Eppendorf tube containing 50 µl of 
Milli-Q-filtered  water.  These  samples  were  snap-frozen  and  transferred  to  the  LRI 
Protein  Analysis  and  Proteomics  service.  The  protein-containing  gel  slices  were 
processed for mass spectrometry using the Janus liquid handling system (PerkinElmer).  
Briefly, the excised protein gel pieces were placed in the wells of a 96-well microtitre 
plate  and  destained  with  50%  v/v  acetonitrile  and  50  mM  ammonium  bicarbonate, 
reduced with 10 mM DTT, and alkylated with 55 mM iodoacetamide. After alkylation, 
the  proteins  were  digested  with  6  ng/µL Trypsin  overnight  at  37  °C.  The resulting 
peptides were extracted in 1% v/v formic acid, 2% v/v acetonitrile. The digest was 
analysed by nano-scale capillary LC/MS/MS using a nanoAcquity UPLC (Waters) to 
deliver a flow of approximately 300 nL/min. A C18 Symmetry 5 µm, 180 µm x 20 mm 
µ-Precolumn (Waters), trapped the peptides prior to separation on a C18 BEH130 1.7 
µm, 75 µm x 100 mm analytical UPLC column (Waters). Peptides were eluted with a 
gradient of acetonitrile.  The analytical column outlet was directly interfaced with a   68 
Triversa nanomate microfluidic chip for mass spectrometric analysis (Advion). Mass 
spectrometric information was obtained using an orthogonal acceleration quadrupole-
Time of Flight mass spectrometer (SYNAPT HDMS, Waters). Data dependent analysis 
was carried out, where automatic MS/MS was acquired on the 8 most intense, multiply 
charged precursor ions in the m/z range 400–1500. MS/MS data were acquired over the 
m/z range 50–1995. LC/MS/MS data were then searched against  a protein database 
(UniProt) using the Mascot search engine programme (Matrix Science). 
 
2.4.9  Recombinant protein expression 
 
2.4.9.1  GST-fusion proteins 
 
E. coli (BL21 rec-A, pLysS) were transformed with the pGEX 6P1 vector containing 
the gene of interest. A set of 6-10 clones were picked and analysed for efficiency of 
induction  following  addition  of  1  mM  IPTG.  Briefly,  bacterial  pellets  were  lysed, 
lysates fractionated by SDS PAGE and  evaluated by Coomassie staining. The best-
expressing clone was used to set up a large culture of 1–5 l and grown in an incubator at 
37 °C. The culture was induced with 1 mM IPTG at an OD at 600nm of 0.8, at which 
the culture is in log phase of growth. Generally the culture was induced for 4h at 37 °C. 
For induction at 16°C, the culture was cooled down for 30 min before addition of IPTG 
and the culture was grown O/N. The bacteria were then harvested by centrifugation at 
4000g for 10 min at 4°C. 
The pellet was resuspended in 5 volumes of lysis buffer with 1 mg/ml lysozyme 
and incubated for 15 min at rt. The lysate was then transferred to a glass centrifuge tube 
(Corex) and sonicated at highest intensity on ice for ≥6 pulses of 45 sec with 15 sec 
intervals  until  the  lysate  was  no  longer  viscous.  Lysate  was  then  cleared  by 
centrifugation at 14,000 rpm for 10 min at 4 °C and the supernatant was then collected. 
A 50% slurry of glutathione sepharose 4B beads (GS4B) (GE Healthcare) was added at 
1 ml/l of bacterial culture, pre-washed in PBS. The lysate and beads were incubated for 
30 min at rt or 2 hour at 4°C, depending on protein stability. Following incubation, 
beads  were  washed  3  times  in  10X  bead  volume  of  ice-cold  PBS  for  10  min  and 
centrifugation at 1000 rpm for 5 min at 4°C. The fusion protein was then eluted 3 times 
with 1ml GST elution buffer per ml of beads, by incubation for 10 min at rt and the   69 
three eluates were combined. The purified protein was then dialysed against 50 mM 
TRIS HCl pH 8.0 to remove glutathione. For use in antibody generation, the fusion 
proteins were dialysed against PBS. 
Alternatively, the protein was recovered from the GS$B beads by proteolytic 
cleavege. To this end, the beads were washed 3 times in 10X bead volume of cleavage 
buffer. Next, the beads were resuspended in 960µl of cleavage buffer/ml of beads and 
40 µl (80 U) per ml of beads of PreScission Protease (GE Healthcare) was added and 
incubated for 4h at 4°C. Following incubation, the cleaved protein was recovered by 
centrifugation at 1000 rpm for 5 min at 4°C, while the GST and protease were retained 
on the beads. 
The purified proteins were analysed by SDS-PAGE in combination with a series 
of BSA standards of known concentration (0.5 – 20 mg/ml). This gel was then stained 
with  Coomassie  and  the  BSA  standards  were  used  to  roughly  determine  the 
concentration of the bands of interest. 
 
2.4.9.2  HIS6-fusion proteins 
 
The  pRSET  A  vector  containing  the  relevant  cDNA  was  used  to  transform  BL21 
bacteria. Colony selection, culture induction and bacterial collection was performed as 
for GST purification. Lysis was performed using 8 ml HIS purification buffer with 1 
mg/ml lysozyme per liter of bacterial culture. Lysis and sonication were performed as 
described above. 1ml of NiNTA agarose beads (Qiagen) were placed in a purification 
column and washed once with 6 volumes of filtered water and twice with 6 volumes of 
HIS purification buffer. The lysate was then transferred to the purification column and 
incubated with gentle shaking for 30 min at rt. The column was then washed 6 times 
with 8ml of wash buffer (HIS purification buffer with HIS imidazole buffer to a final 
concentration of 20 mM imidazole). Protein was eluted by adding elution buffer (HIS 
purification  buffer  with  HIS  imidazole  buffer  to  a  final  concentration  of  250  mM 
imidazole), snapping off the cap and collecting 1 ml fractions. Individual fractions were 
analysed by SDS-PAGE including the BSA standards as described above. 
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2.4.10 In vitro binding assay 
 
1  µg  of  each  cDNA  to  be  evaluated  was  in  vitro  transcribed  and  translated  in  the 
presence  of 
35S-methionine  using  the  TnT  kit  (Promega)  according  to  the 
manufacturer’s instructions. 20 µg of GST-fusion protein or GST alone was added to 20 
µl of 50% GS4B bead slurry and made up to a total of 300 µl with binding buffer. These 
samples were incubated on a rotating wheel O/N at 4°C. Protein-bound beads were then 
placed in binding buffer containing 150 mg/ml BSA, 5% (v/v) FBS and 1 mM DTT on 
a rotating wheel for 10 min at 4 °C. 8 µl of the in vitro translated (IVT) samples were 
then added to the blocked beads and incubated for 1 h at rt with rotation. Beads were 
washed 4 times in ice-cold washing buffer and once in ice-cold 50 mM TRIS HCl pH 
7.4.  Beads  were  then  boiled  in  2X  Laemmli  buffer  and  separated  by  SDS-PAGE 
alongside 0.8 µl (10%) IVT input samples. Gels were fixed as described in section 2.4.7 
and incubated with Amplify (GE Healthcare) according to manufacturer’s instructions. 
Gels were then vacuum dried and the labelled protein were detected by autoradiography 
at -80 °C. 
 
2.5  RNA techniques 
 
2.5.1  RNA isolation 
 
Total cellular RNA was isolated using the RNeasy Mini kit (Qiagen), according to the 
manufacturer’s instructions. The RNA was eluted in 30 µl of RNase-free water. The 
concentration of RNA was determined by Nanodrop spectrometer. For storage, purified 
RNA was snap frozen and stored at -80 °C. 
 
2.5.2  Reverse transcription quantitative PCR (RT-qPCR) 
 
RT was performed using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems), according to the manufacturer’s instructions. Typically 0.25 – 1.0 µg RNA 
was used in a 50 µl reaction primed with oligo dT. The reaction was incubated for 1 h at 
37 °C on a PCR block.   71 
In order to specifically detect the mature mRNAs in the cDNA mixture, primers 
were  designed  to  amplify  across  an  exon-exon  junction.  Further  criteria  for  primer 
design were: size = 20-23mers, Tm ≥ 60°C, GC content = 50-60%, amplicon = 150 bp, 
and  not  more  than  2  consecutive  repeats  of  same  base.  Primers  commonly  used 
throughout this work are listed in Table 4. The qPCR reactions were prepared using the 
EXPRESS qPCR Supermix with Premixed ROX (Invitrogen), which is based on SYBR 
green  incorporation  and  includes  the  ROX  passive  reference  dye.  2  µl  of  the  RT 
reaction and 0.2 µM of both primers were added to the qPCR Supermix at a 1X final 
concentration  of. The  reaction  mixture  was  generally  prepared  per  primer  used  and 
pipetted into a 96-well optical plate. The plate was loaded on the 7500 FAST Real-Time 
PCR System (Applied Biosystems) and the following PCR cycle protocol was executed: 
 
1.  95°C for 15 seconds (hotstart of the polymerase) 
2.  95°C for 3 sec (denaturation) 
3.  60°C for 30 sec (combined annealing and extension) 
4.  read fluorescence 
5.  cycle to step 2 for 39 times 
6.  melting curve  
 
In order to check if the signal observed originated from the specific amplicon produced 
by the primers, rather than possible primer-dimers, the PCR reaction was followed by 
melting curve analysis. The obtained data were analysed using the corresponding SDS 
software (Applied Biosystems). 
The also DNA samples recovered in ChIP were also quantified in a relative 
manner using qPCR. The procedure is largely the same as for cDNA, other than that 4 
µl of purified DNA was used. The primers used for qPCR for ChIP samples are largely 
based on previous published primers (Bracken et al., 2007) and are listed in Table 4 
below.   72 
 
 
Target  Sense Sequence  Antisense sequence 
P16
INK4A  CGGTCGGAGGCCGATCCAG  GCGCCGTGGAGCAGCAGCAGCT 
P15
INK$B  TAGTGGAGAAGGTGCGACAG  GCGCTGCCCATCATCATG 
ARF  CCCTCGTGCTGATGCTACTG  ACCTGGTCTTCTAGGAAGCGG 
HPH1  GCACTCTCTCCAACATCTCCT  ACACCTCCTCTACACTCCAAC 
HPH2  CCACTTACCAAGGATACCAAGA  GAGATGGGTGACAAGGGTTC 
HPH3  GGAGTACTTCCCCTACCTAACG  GACTGACAGGAAGATGACGATG 
CBX7  CGGAAGGGTAAAGTCGAGTATC  TCGGACCTCTCTTCCTATACCC 
GAPDH  TGATGACATCAAGAAGGTGGTGAAG  TCCTTGGAGGCCATGTGGGCCAT 
 
Table 4. List of primers used for amplification of cDNA from mature mRNA 
 
Name  Sense sequence  Antisense sequence 
PS1  GGAACCTAGATCGCCGATGTAG  TGTTTTACGCGTGGAATGCAC 
PS1b  GCCCAACTCCACCAGATAGC  GCTCTGCAGCGTCGTGAT 




PS2  GTGGGTCCCAGTCTGCAGTTA  CCTTTGGCACCAGAGGTGAG 
PS3  GGAGCGATGTGATCCGTTATC  TGAAATCCCAATCGTCTTCCAC 
PS3a  CTTCAAAAACAATTAGGAGGAGCTT  TGAAACATTGAAAACATAAGGATATTG 
PS3b  ATTCAAAAATGAGGGGACTGAA  GAAATTTGGAACTCAAAGACACG 
PS4  GCACTTGCCCTTCCAGGTATA  TGATAGTTCAAGGCCCTATGCC 
PS5  CTCAAAGCGGATAATTCAAGAGC  AAGCCTTAAGAACAGTGCCACAC 
PS6  ACCCCGATTCAATTTGGCAG  AAAAAGAAATCCGCCCCCG 
PS7  AGAGGGTCTGCAGCGG  TCGAAGCGCTACCTGATTCC 
PS8  GCCAAGGAAGAGGAATGAGGAG  CCTTCAGATCTTCTCAGCATTCG 
PS9  CAAGCTTCCTTTCCGTCATGC  GCCAGAGAGAACAGAATGGTCAGAGC
CA 
PS10  ATCGCTGAGCGATGAAGGTAG  ATCACAAAAAGGAAAGGCAAG 
PS11  TAGGAGGCCCCATTAAGCATAC  TGTAGTTGCCAGGAGTTGGAGG 
PS12  TGTCTACCCAACACTTCCCTGC  AAGGCAAAGGTAACTGAAACGC 
 
Table 5. List of primers used for amplification of the INK4/ARF locus. 
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Target  Sense Sequence  Antisense sequence 
HPH1 exon 2  TATGAACGACAAGCAGTGCAG  GTCTGCTGCTGTGTAGTGCTG 
HPH2 exon 5
  CACGCTCTTCCCCAGCCCTGACT  CTGTCAGCTATGCCAGGCTT 
HPH2c end  CAGCCGTTGCTCAGATAACTCA  CTGTATATAGAAGTCTCATGGCCTTT 
HPH3 exon 1  GAAGCGGAATTTAAGGACCAT  CTGTACAGCATGTCGGTCTGA 
 
Table 6. List of primers used for differential PCR of HPH transcripts 
 
2.5.3  Absolute quantification using qPCR 
 
The absolute expression levels of specific transcripts were determined by employing 
corresponding plasmid cDNAs of known copy number. A 10-fold dilution series of the 
plasmid  DNA  was  made,  ranging  from  30  -  30,000  DNA  molecules.  Molecule 
number/µl was calculated using the formula; 
 
(9.1 x 10
11/ length of plasmid (kb)) x (plasmid concentration (ng/ml) / 1 x 10
-6) =  
no of plasmid DNA molecules per µl. 
 
The plasmid dilution series was piptetted in duplicate alongside the cDNA samples. The 
resulting CT
 values were used to make a standard curve, from which a formula was 
derived  in  Excel  (Microsoft)  to  calculate  the  number  of  specific  cDNA  molecules 
present in the cDNA samples 
 
2.5.4  Sense/Antisense-specific RT-qPCR 
 
This procedure largely follows the same steps as in the previous section, but using a 
sequence specific primer rather than oligo dT. By selecting sequence specific primers to 
drive reverse transcription it is possible to dictate whether the reaction is is measuring 
sense or antisense transcription in respect to the gene of interest. For subsequent qPCR, 
both the primer used in the RT reaction and the matching reverse primer were used (as 
listed together in Table 5). 
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2.5.5  RNA ChIP 
 
In  order  to  evaluate  RNA-protein  interactions  within  the  nucleus,  RNA-ChIP  was 
employed.  The  fixing  and  harvesting  of  cells  is  the  same  as  for  ChIP  described  in 
section 2.4.5. The cell pellet was lysed in 5 volumes of ice-cold buffer A with NP40 and 
placed on ice for 10 min. Crude nuclei were pelleted by centrifugation at 5000rpm for 5 
min at 4°C. The pellet was once washed in buffer A without NP40 and resuspended in 
buffer B and placed on ice for 10 min. Next, lysates were sonicated and cleared as 
described in section 2.4.5. The lysate was diluted in IP-buffer to a final volume of 1 ml 
per IP. A 10% aliquot was taken as input sample. 5µg of antibody and appropriate 
unspecific  antibody  control(s)  (as  described  in  section  2.4.5)  were  added  and  the 
samples were incubated on a rotating wheel at 4°C O/N. 
The samples were transferred to washed 50 µl protein A/G agarose beads for 
collection of immune complexes by incubation on a rotating wheel for 2h at 4°C. Beads 
were pelleted by centrifugation at 1000 rpm for 2 min at 4°C. Beads were washed for 5 
min each, once in low-salt wash-, high-salt wash- and LiCl wash buffers and twice in 
TE pH 8.0. Immune complexes were then eluted twice by addition of 250µl elution 
buffer (freshly prepared) and incubation in a rotating wheel for 15 min at 4°C. Eluates 
were combined and NaCl was added to a final concentration of 200mM and placed at 
65°C for a minimum of 2h. Next, 20 µl of 1M TRIS HCl, 10µl 0.5M EDTA and 20µg 
proteinase K were added to each sample and incubated for 45 min at 42°C. Samples 
were then treated with TURBO DNase 1 (Ambion) for 30 min at 37°C. The RNA was 
recovered  using  RNeasy  spin  columns  (Qiagen)  were  then  used  according  to  the 
manufacturer’s  RNA  cleanup  protocol,  including  an  additional  on-column  DNase 
treatment with the RNase-free DNase set (Qiagen). RNA was eluted in 30 µl of RNase-
free water and directly used for antisense specific RT-qPCR as described in section 
2.5.4. 
 
2.5.6  RNA interference 
 
siRNAs targeting the gene of interest were either obtained from the Netherlands Cancer 
Institute (NKI) shRNA library or designed using the siRNA Target Finder (Genescript) 
online  tool.  Additional  sequences  were  copied  from  the  Sigma  Mission  collection 
(evaluated  in  pLKO  only).  The  relevant  sequences  were  then  converted  into  the   75 
following  short  hairpin  template  for  direct  cloning  into  the  pre-cut retroviral  vector 
pRetroSuper; 
 
                  sequence  reverse & complement sequence 
F:                    5’ GATCCCC(…..n19.....)TTCAAGAGA(…..n19....)TTTTTGGAAA 3’ 
R:    5’ AGCTTTTCCAAAAA(......n19.....)TCTCTTGAA(......n19....)GGG 3’ 
BglII  HindIII 
 
Or for cloning into the cut lentiviral vector pLKO.1; 
 
sequence  reverse & complement sequence 
F: 5’         5’  CCGG(……n19……)CTCGAG(……n19……)TTTTTTG 3’ 
R: 5’      5’ AATTCAAAAAA( …...n19……)CTCGAG(……n19……) 3’ 
Age1  EcoR1 
 
The oligonucleotides were annealed by incubating 3 µl of each oligo at 1 mg/ml in 44 µl 
annealing buffer at 95 °C for 4 min and at 70 °C for 10 min. The samples were then 
allowed to cool slowly to allow annealing. Annealed oligos were then ligated into cut 
vector and used to transform competent bacteria, as described in 2.2.3. Positive clones 
were identified by restriction enzyme digestion and sequencing, as described in section 
2.2.3 and 2.2.5. Cloned shRNAs were validated for knockdown of target sequence by 
qPCR or immunoblotting. The validated siRNA sequences used in this work are listed 
in Table 7. 
 
Name  Target sequence  Position in cDNA  Vector 
HPH1-1  CGACAAGCAGTGCAGGCTC  CDS nt100-118  pRS/pLKO 
HPH1-2  GAAGCCAACTATGCTCGCG  CDS nt2539-2557  pRS 
HPH1-3  GAGGAGGTGTACGAGTTTATT  CDS nt2827-2847  pLKO 
HPH2-1  GGAATCTCAAGAAGAAGTA  CDS nt1784-1802  pRS 
HPH2-2  CCAGAATGGTGAGAATAAA  CDS nt1656-1674  pRS/pLKO 
HPH2-3  CTCAAGCTATGAGGAACCCTT  CDS nt2229-2249  pLKO 
HPH3-1  CCAAGTCAGTCTCCTACTA  CDS nt1252-1270  pRS/pLKO 
HPH3-2  AGCCAGAGCTACAGAATAA  CDS nt2279-2297  pRS/pLKO 
CBX7-1
2  GGATGGCCCCCAAAGTAC  CDS nt100-117  pRS 
CBX7-2  GTATAGGAAGAGAGGTCCGAA  CDS nt204-224  pLKO 
 
                                                 
2 Kindly provide by Jesus Gil, Imperial College, London   76 
Table  7  siRNA  sequences  that  were  cloned  into  a  shRNA  format  in  either  a 
retroviral or lentiviral vector or both. 
 
2.6  Cell Biology Techniques 
 
2.6.1  Senescence-associated β-Galactosidase Assay 
 
Cells were plated at equal density the day before the assay was performed. The next 
day, cells were washed twice in PBS and then fixed for 3-5 min at rt with the SA-β-Gal 
fixing solution. Cells were washed in PBS twice and staining solution was added at 2 
ml/35 mm dish. Dishes were incubated at 37 °C O/N. Resulting staining was captured 
by light microscopy. 
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3  The Generation of Antibodies against HPH2 and CBX7 
 
3.1  Introduction 
 
At the onset of this study there were no antibodies available to HPH2 and CBX7 from a 
commercial source. Therefore, an initiative was taken to produce monoclonal antibodies 
to both these proteins. Initially, a recombinant fragment of CBX7 was supplied to the 
internal  CR-UK  Monoclonal  Antibody  Service,  but  due  to  disappointing  results  the 
HuCAL recombinant antibody technology offered by AbD Serotec (Kidlington, UK) 
was employed to successfully create antibodies  against both proteins. In addition, a 
number of polyclonal antibodies were raised in rabbits against CBX7 and all members 
of the HPH family. This chapter outlines the strategies used to generate and evaluate 
reagents that were deployed in the experiments described in later chapters. 
 
3.2  Generation of CBX7 antibodies 
 
3.2.1  Mouse monoclonal antibodies to a CBX7 fragment 
 
Dating from the original demonstration that CBX7 can act as a repressor of INK4A, 
several members of the laboratory had tried to express recombinant CBX7 in E. coli. 
While it was possible to generate and purify a GST-tagged version of mouse Cbx7, 
analogous approaches with human CBX7 were consistently unsuccessful. As discussed 
later, a commercial laboratory (AbD Serotec) also failed to produce recombinant CBX7 
in  their  optimised  bacterial  expression  system.  To  try  to  surpass  the  problems  with 
recovery  of  the  full-length  protein,  the  human  CBX7  cDNA  was  divided  into  five 
separate fragments based on the functional domains of the proteins (Figure 3.1A) and 
each  fragment  was  expressed  as  a  fusion  protein  with  an  N-terminal  GST-tag.  As 
illustrated  in  Figure  3.1B,  only  three  of  the  fragments  were  expressed  at  workable 
levels. Due to the high immunogenicity of GST, an additional obstacle was the need to 
remove  this  tag  prior  to  immunisation  of  mice.  Following  cleavage  of  the  linker 
sequence with Precision Protease, only fragment 1 was recovered in sufficient quantities   78 
to proceed (Figure 3.1C). Although recognising that this fragment was not ideal as it 
contains part of the chromodomain that is highly conserved in other CBX proteins, the 
antigen  was  provided  to  the  CR-UK  Monoclonal  Antibody  Service  for  mouse 
immunisation (see Figure 3.2A). 
After the B-cell fusion stage, 61 hybridomas were found to be positive for the 
CBX7 antigen, as measured by ELISA. The supernatants of the hybridomas were then 
tested  by  immunoblotting,  to  confirm  reactivity  with  fragment  1.  20  out  of  the  61 
hybridomas tested were positive in this assay and based on the strength of signal, 8 were 
selected for single cell cloning and expansion. Unfortunately, upon screening of single 
cell  clones  of  the  positively  identified  hybridomas,  the  only  consistently  observed 
reactivity was to a 73 kDa band in the antigen sample, presumably corresponding to a 
contaminant from the purification. In an attempt to overcome this problem, a HIS6-
tagged  version  of  CBX7  fragment  1  was  produced  in  the  hope  that  the  different 
purification method would eliminate this particular contaminent (see B). Frozen clones 
from positive hybridomas were recovered and the supernatants were re-screened with 
HIS6-CBX7  fragment  1  by  ELISA,  but  no  significant  reactivity  was  found.  It  was 
therefore concluded that the positive clones had been lost at the stage of single cell 
cloning, perhaps by picking too few clones, or that antibody production had switched 
off in the frozen cells. Despite the substantial input of effort, it was decided not to 
further pursue this approach. 
 
3.2.2  Human recombinant antibodies to CBX7 fragments 
 
Instead  of  using  the  CR-UK  monoclonal  service,  it  was  decided  to  commission 
recombinant antibodies from AbD Serotec (Kidlington, UK). The Human Combinatory 
Antibody  Library  (HuCAL)  technology  is  based  on  screening  an  antigen  against  a 
library of over 1.5 x 10
10 antibody specificities in Fab format displayed by phage. This 
allows the identification of candidates that are then further validated by ELISA. Positive 
clones  can  then  be  used  to  generate  recombinant  human  antibodies  in  a  variety  of 
different  formats.  The  standard  format  is  a  bivalent  antibody  with  an  artificial 
dimerization site and carrying the MYC and HIS6 epitopes to facilitate detection. The 
screen could be designed to offer differential ELISA screening with the GST fusion 
protein and GST alone. So, as there was no need to remove the GST-tag, both CBX7 
fragments 1 and 4 (Figure 3.2C+D) were available in sufficient amounts to be screened.   79 
Regrettably, AdB Serotec made a pro-active decision to perform the initial panning with 
fragment  1  and  then  to  check  the  positive  clones  for  reactivity  against  fragment  4, 
whereas  the  reverse  strategy  would  have  reduced  the  aforementioned  problem  of 
chromodomain conservation in CBX7 fragment 1. In fact, CBX7 fragment 4 would 
have offered 58 unique residues of a lower degree of conservation in comparison to the 
47 unique residues of CBX7 fragment 1. As shown in Figure 3.3A, eleven clones were 
obtained in the screen, of which four were also positive against fragment 4, implying 
that they recognise the shared region of amino acids 48 to 81 of full-length CBX7. 
All eleven of the recombinant antibodies were able to IP FLAG-tagged human 
CBX7 in transiently transfected 293T cells (see Figure 3.3B). It is however not yet clear 
whether they will support chromatin immunoprecipitation (ChIP). A complicating issue 
for this application is the use of MYC and HIS6 epitopes in the antibody backbone. As 
endogenous c-MYC is present at the promoters of many genes (Fernandez et al., 2003), 
secondary  precipitation  with  the  9E10  monoclonal  antibody  could  result  in  a  high 
background. Similarly, many endogenous proteins are known to bind to Ni-NTA beads. 
As  illustrated  in  Figure  3.3C,  only  one  of  the  antibodies  tested  by  ChIP  showed 
significant enrichment over beads alone with the anticipated discrimination between the 
INK4A and ARF promoters. This has yet to be confirmed in follow up experiments.  
Enthusiasm  for  pursuing  these  antibodies  was  diminished  by  the  clear  evidence  for 
cross reactivity with other members of the human CBX family (Figure 3.3D, performed 
by Marc Rodriguez-Niedenführ). This is likely to be caused by conservation of the 
epitope, assumed to be located in the chromodomain.  However, while none of the 
antibodies  can  be  regarded  as  monospecific,  several  show  a  strong  preference  for 
CBX7. Moreover, given the size differences between members of the CBX family, it 
should be possible to use the more broadly reactive clones as pan-CBX reagents in 
immunoblotting. 
 
3.2.3  Rabbit polyclonal antibodies to CBX7 peptides 
 
Prior to the start of this project, there had been a number of attempts in the laboratory to 
generate rabbit antibodies against synthetic peptides, based on the primary sequence of 
human  CBX7.    None  of  these  reagents  proved  satisfactory.  There  was  however  a 
commercial source (Abcam) for a polyclonal antibody that was found to work well in 
immunoblotting, IP and ChIP. However, as commercial reagents can suffer from batch-  80 
to-batch  variation  and  significant  quantities  of  such  an  antibody  were  desired,  one 
further attempt was made to obtain a ChIP grade antibody specific for CBX7. Following 
the report of a ChIP grade CBX7 antibody by the Helin lab (Bracken et al., 2007), 
further attempts were made to use the so-called RELF peptide sequence (Table 8) for 
immunization.  Evaluation  of  the  final  bleeds  from  the  two  rabbits  immunised 
(designated #3 and #4) are shown in Figure 3.4.  Although both antisera were able to 
detect FLAG-tagged CBX7 when over-expressed in 293T cells, (Figure 3.4A), they did 
not  work  convincingly  for  immunoprecipitation  of  the  same  protein  (Figure  3.4B).  
Similarly, the C-RELF4 antiserum did not support ChIP under conditions in which a 
commercial CBX7 antibody (Abcam ab21873) showed significant enrichment at the 
INK4A locus using primer sets described in more detail in Chapter 5 (Figure 3.4C). 
 
3.3  Generation of HPH2 Antibodies 
 
3.3.1  Human recombinant antibodies to full length HPH2b 
 
In anticipation of making monoclonal antibodies against HPH2, plasmid vectors were 
generated encoding the short isoform of HPH2, HPH2b (discussed in more detail in 
Chapter 4), as a fusion protein to either GST or HIS6. Upon testing these constructs it 
was  found  that  the  achievable  expression  was  low.  In  order  to  produce  sufficient 
quantities of recombinant protein, the purification was scaled up to 5 liters and the 
induction was at 16º C overnight in order to allow for stable expression of protein. The 
purified  protein  consistently  showed  to  have  degradation  products,  as  confirmed  by 
immunoblotting  for  HPH2  (using  the  1615  antiserum  described  below)  (see  Figure 
3.5A).  It  was  decided  to  use  the  recombinant  protein  for  a  HuCAL  phage  display 
screen. However, the methodology of AbD Serotec required the absence of primary 
amines. This meant that the existing preparations of GST-HPH2b had to be dialysed to 
remove TRIS from the buffer, but this simple step resulted in almost total loss of the 
protein. To circumvent this problem, focus was shifted to HIS6-HPH2b, as the buffers 
used in the purification procedure do not contain primary amines. The final sample 
contained  a  rather  low  concentration  of  fractions  of  the  protein  as  detectable  by 
Coomassie  staining,  but  the  full-length  protein  could  be  detected  in  the  sample  by 
immunoblotting for HIS6 and HPH2 (see Figure 3.5B).   81 
The HuCAL screen yielded eight positive clones (Figure 3.6A), and the derived 
bivalent antibodies were subsequently tested for their ability to detect HIS6-HPH2b by 
immunoblotting. Most antibodies recognised the antigen to a varying degree but the 
best signal was obtained for antibody #74 (Figure 3.6B), which matches to the affinities 
measured  by  ELISA  by  AbD  Serotec.  When  tested  for  their  ability  to 
immunoprecipitate HA-tagged HPH2 from 293T cells, it was found that the procedure 
produced a very high background (Figure 3.6C). This was not resolved by pre-clearing 
with beads. This could possibly be due to the aforementioned limitations of the epitopes 
on these antibodies. Further work will be required to evaluate the full potential of these 
antibodies and it might be possible to reduce the background in IP by re-engineering the 
clones  with  different  epitope  tags,  such  as  HA  or  FLAG  epitope,  which  have  not 
demonstrated any background for the IP of HPH2. 
 
3.3.2  Rabbit polyclonal antibodies to HPH2 peptides 
 
Because of the heavy demand on peptide synthesis and antibody production that ensued 
from the characterization of PRC1 complexes, the laboratory had taken the decision to 
order  custom  made  peptide  antibodies  against  HPH2  from  Eurogentech  (Seraing, 
Belgium).    The  strategy  was  to  inoculate  two  rabbits  with  a  combination  of  two 
synthetic peptides (see Table 8) and to affinity purify an aliquot of serum on the cognate 
peptides (E.85 and E.85) or on protein A sepharose. The evaluation of the resulting 
antibodies (Figure 3.7A) indicated that the 1615 antiserum was the more effective, as 
judged by immunoprecipitation of HA-tagged HPH2 overexpressed in 293T cells, but 
that either peptide-purified (E.84 and E.85) or IgG-purified serum (IS) offered little 
improvement compared to the crude serum (S). As will be discussed in chapter 5, the 
1615 antisera were evaluated for the ability to confirm direct binding of HPH2 to the 
INK4A promoter region by chromatin IP (ChIP), showing a 3-fold enrichment compared 
to the non-specific rabbit IgG control (Figure 3.7). 
Both of the antigenic peptides were from the amino terminal region of HPH2 
that is common to the long and short isoforms of the protein (discussed in more detail in 
Chapter 4). Using the 1615 antisera an endogenous band of approximately 48 kDa could 
be  detected  by  direct  immunoblotting  of  untransfected  293T  cells  (Figure  3.7C). 
However, in parallel immunoblots of three strains of primary human fibroblasts (FDF, 
Hs68  and  Q34),  there  was  no  equivalent  band. Instead,  the  1615  antibody  detected   82 
bands of 60, 55 and 36 kDa, The predicted molecular weight of HPH2b, based on its 
primary amino acid sequence is 35,760Da (as quoted in the Uniprot database), which 
corresponds precisely to the lower band. However, our favoured interpretation at this 
stage is that the three bands detected in primary fibroblasts correspond to degradation 
products from the long isoform, HPH2a. This is based on the appearance of similar 
bands (aligned by blue dotted lines) in 293T cells transiently transfected with an HA-
tagged  version  of  HPH2a  (Figure  3.7D).  Interestingly,  the  48kDa  band  observed  in 
untransfected 293T matches to that observed for ectopically express HA-tagged HPH2b 
(Figure 3.7D, as aligned by a red dotted line). Similar results were obtained using the 
1616 antibody (data not shown). Nevertheless, these experiments need to be repeated, 
preferably  including  a  sample  in  which  HPH2  is  knocked  down,  before  drawing  a 
conclusion. 
  
3.4  Polyclonal antibodies against other HPH proteins 
 
As the project developed, it became increasingly obvious that the other members of the 
HPH  family,  HPH1  and  HPH3,  were  implicated  in  the  regulation  of  INK4A, 
exacerbating the need to have reagents for these proteins as well. To this end, the LRI 
Peptide Synthesis Service was asked to design and synthesize appropriate peptides (see 
Table 8) and rabbits were inoculated with mixtures of these peptides. At the time of 
writing, the resulting antibodies are being evaluated by other members of the laboratory 
(Marc Rodriguez Niedenführ and Julie Stock) and so far the antibodies against HPH1 
and HPH3 are looking promising for use in immunoprecipitation, whereas the anibody 
against HPH3 also shows initial efficacy in the ChIP protocol. 
 
3.5  Discussion 
 
The  original  aim  was  to  obtain  monoclonal  antibodies  against  CBX7  and  HPH2. 
Unfortunately, the project from the LRI’s mouse monoclonal service was unsuccessful. 
Hence the projects were transferred to AbD Serotec (Germany). Although a number of 
high affinity antibodies were derived against CBX7, these were not found to be mono-
specific due to the high conservation of sequence of the antigen used, with respect to 
other PC family members. Therefore these antibodies only have limited application.   83 
Furthermore the antibodies against HPH2 produced overall weaker signals when used 
for  immunoblotting  and  so  far  have  faced  technical  barriers  for  use  in 
immunoprecipitation-based  techniques.  The  polyclonal  antibodies  produced  against 
HPH2,  and  particularly  1615,  were  successful  in  the  evaluation  for 
immunoprecipitation. 
The lack of reliable antibodies against the human CBX and the HPH proteins, 
whether  from  commercial  suppliers  or  other  academic  groups,  and  the  difficulties 
encountered in generating reagents in-house, represented serious barriers to progress in 
the  early  phases  of  this  work.  Although  there  has  been  no  systematic  study,  most 
anecdotal reports imply that PcG proteins are difficult to express as single recombinant 
proteins.  Thus,  despite  taking  advice  from  structural  biologists  accustomed  to 
optimising expression in E. coli, the laboratory still faces a challenge in characterizing 
the human homologue of CBX7. 
Mouse  Cbx7  presents  significantly  increased  stability  over  its  human 
counterpart and can be employed to study PcG regulation of human INK4A (Gil et al., 
2004; Maertens et al., 2009). We have noted that human CBX7 contains a region of 93 
residues that is not present in the mouse homologue (Figure 3.1A). An MRes student in 
the laboratory has subsequently confirmed that these residues are in part responsible for 
the  reduced  stability  of  human  CBX7  compared  to  mouse  Cbx7.  However,  use  of 
mouse Cbx7 is not ideal, as possible interactions with the missing 92 residues may play 
an important role in regulation of human CBX7 in the human system (Nicholls, 2006). 
It is therefore needed to further investigate the underlying cause of instability of human 
CBX7 and to optimise its expression, possibly by the modification of certain residues in 
the unique 93 amino acid domain. The resulting protein could then be used in future 
efforts to develop potent monoclonal antibodies against CBX7. 
As  an  alternative  to  bacterial  expression,  preliminary  efforts  have  been 
undertaken by the laboratory to turn to baculovirus expression systems. Baculovirus has 
been successfully used by other research groups to reconstitute active complexes of 
PRC1  proteins  (Elderkin  et  al.,  2007).  In  our  laboratory,  HPH2b  and  CBX7  were 
recently  cloned  into  the  BaculoDirect  Baculovirus  Expression  System  (Invitrogen) 
using  Gateway  Technology  (performed  by  Tomas  Racek). However,  as  baculovirus 
expression is not currently in routine use by the laboratory, no further progress has been 
made.  It  therefore  remains  to  be  evaluated  whether  the  use  of  baculovirus  would 
enhance expression of these two proteins.   84 
The  phage  display  approach  has  the  potential  to  produce  virtually  unlimited 
quantities of recombinant antibody, rapidly and without problem of clonal instability. In 
principle,  these  engineered  antibodies  can  have  the  same  affinities  as  authentic 
antibodies, but the limited  experience in the laboratory with the HuCAL antibodies 
suggests that epitope tags have problems of producing high background. Alternatively 
to changing the epitopes, it is possible to circumvent these problems by reconstruction 
of the full antibody rather than the artificial bivalent format, but this option has not yet 
been evaluated by our laboratory. These technical issues need to be further assessed, 
especially for the development of ChIP-grade antibodies. The amounts of antibodies 
used  in  large-scale  or  sequential  ChIP  experiments  currently  conducted  by  the 
laboratory would benefit from a more economical and stable source of antibodies. 
In contrast, peptide immunisation of rabbits has succeeded in generating ChIP 
grade antibodies for HPH2 and HPH3, which open up exciting possibilities for future 
research, such as to dissect the co-localisation on chromatin. To much disappointment, 
the validated peptide from CBX7 did not lead to the generation of potent antibodies. It 
should  be  considered  whether  any  difference  in  conjugation  method,  immunisation 
protocol or rabbit species exists, which may account for the difference in antibodies 
generated. 
As  time  has  passed  since  the  start  of  this  project,  the  range  of  commercial 
antibodies available has expanded but it is still far short of supporting a comprehensive 
study of human PRC1 complexes. Reagent generation and evaluation will therefore be a 
continuing challenge to the field.   85 
 
Target  Name  Sequence  Designed by  Rabbit 
HPH2  EP053084  CLPOKTKDTKKQPTGT  Eurogentech 
(Seraing, Belgium) 
1615+1616 
HPH2  EP053085  STSRRRQGQRDLELC  Eurogentech 
(Seraing, Belgium) 
1615+1616 
CBX7  C-RELF  KKEPPRGPNLESHSHRREL
FLQEPPC 
Helin  Group 
(BRIC, Denmark) 
MRO-3/4 
HPH2a  HPH2a 1-18  MENELPVPHTSSAC  O’Reilly  Group 
(LRI) 
MRO-5/6 
HPH2a  HPH2a 450-467  HTSAVILQLQPASPPQQC  O’Reilly  Group 
(LRI) 
MRO-5/6 
HPH2  HPH2a 740-750  CSDNSSYEEP  O’Reilly  Group 
(LRI) 
MRO-7/8 
HPH2  HPH2 841-858  CKLGPALKIYARISMLKDS  O’Reilly  Group 
(LRI) 
MRO-7/8 
HPH1  1-16C  METESEQNSNSTNGSSC  O’Reilly  Group 
(LRI) 
MRO-25/26 
HPH1  304-326  CPRKGTGVVQPLPAAQTV
TVSQG 
O’Reilly  Group 
(LRI) 
MRO-25/26 
HPH3  304-326C  SLIKHQQIPLHSPPSKVSHH
QLIC 
O’Reilly  Group 
(LRI) 
MRO-27/28 
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Figure 3.1 Expression of CBX7 Fragments 
A) Overview of wildtype human CBX7, highlighting the location of the chromodomain 
(CD) and polycomb domain (PC), the 4 CBX7 fragments that were cloned to an N-
terminal GST tag for purification, and the composition of mouse Cbx7 relative to the 
human form in terms of sequence conservation. 
B) The recombinant GST-CBX7 fragments were tested for expression in E. coli. 20 ml 
cultures were induced for 4 h at 37 °C with 1 mM IPTG. The bacteria were lysed, 
lysates  were  fractionated  by  SDS-PAGE  and  resulting  gels  were  stained  with 
Coomassie  staining  solution.  The  presented  induction  for  each  CBX7  fragment 
corresponds  to  either  the  best  (detectable  expression)  or  a  representative  clone 
(undetectable expression) of a set of 5 clones per protein. 
C) Evaluation of stability of CBX7 fragments following TEV cleavage. A 1 l culture of 
the clones for GST-CBX7 fragment 1, as displayed in B) was induced, harvested and 
used  for  GST  purification  and  TEV  cleavage  as  described  in  section  2.4.9.1.  The 
resulting samples were fractionated by SDS-PAGE and the resulting gels were stained 
with Coomassie staining solution.   87 
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Figure 3.2 Overview of the CBX7 antigens 
A) CBX7 fragment 1 as derived from TEV cleavage following purification from 2 l of 
culture  induced  for  4  h  at  37  °C  as  described  in  section  2.4.9.1.  This  protein  was 
submitted as antigen to the CR-UK Monoclonal Production Service. 
B)  HIS6-CBX7  fragment  1.  In  an  attempt  to  resolve  issues  with  cross-reactivity  of 
antibodies to a contaminent in A, CBX7 fragment 1 was cloned with an N-terminal 
HIS6 tag. A set of clones were evaluated for expression levels following 4 h induction at 
37 °C. by 1mM IPTG. 2 l of the best clone were used for purification on NiNTA 
Superflow beads (Qiagen) and eluted using 3 M imidazole as detailed in section 2.4.9.2. 
This antigen was used as a secondary antigen to that described in A, and employed by 
the  CR-UK  Monoclonal  Production  Service  to  re-check  the  clones  of  positively 
identified hybridomas. 
C)  GST-CBX7  fragment  1.  Due  to  higher  stability  in  comparison  to  the  cleaved 
fragment descibed in A, only 1 l culture was induced for 4 h at 37 °C and used for GST 
purification as described in section 2.4.9.1. This sample was supplied as antigen to AbD 
Serotec for screening human recombinant antibodies. 
D) CBX7-CBX7 fragment 4. As the GST tag of CBX7 fragment 4 was found to greatly 
improve stability, this was supplied as an additional antigen to AbD SeroTec. 3 l of 
culture induced, purified and dialysed as described in C. This sample was supplied as 
antigen  to  AbD  Serotec  and  was  used  for  ELISA  screening  of  human  recombinant 
antibodies identified with the antigen in C.   89 
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Figure 3.3 CBX7 Recombinant Human Antibodies Evaluation 
A) ELISA (as performed by AbD Serotec) was used to measure the relative affinity of 
the clones identified from the screen of CBX7 fragment 1 for recognition of both CBX7 
fragments, as well as negative controls GST, N1-CD33-HIS6 and BSA. 
B) 293T cells transfected with pcDNA6 FLAG-CBX7 were lysed with NP40 buffer. 
The lysate was then incubated with 10 µg of all AbD Serotec CBX7 antibodies and 
precipitated using anti-Myc (9E10) and Protein A/G agarose. The immunoprecipitated 
samples and an input of 10% of the orginal lysate (INP) were fractionated by SDS-
PAGE, transferred to nitrocellulose and immunoblotted with anti-FLAG. 
C) ChIP was performed as described in section 2.4.5 with the chromatin of mid-lifespan 
FDF cells (PD29) and the 5 antibodies of AbD Serotec CBX7 displaying the strongest 
IP  capacity  in  B.  An  anti-Myc  secondary  antibody  (9E10)  was  used  to  purify  the 
immunecomplexes on Protein A/G-agarose. The purified DNA was analysed by qPCR 
using primers specific to the INK4A exon 1α (PS7) or to ARF exon 1β (PS2). 
D) 293T cells overexpressing the different human PC proteins in pcDNA6 FLAG were 
lysed with NP40 buffer and used to IP for the FLAG-epitope to purify and concentrate 
the protein. IP samples were fractionated by SDS-PAGE, transferred to nitrocellulose 
and immunoblotted with the AbD Serotec CBX7-13 antibody at a concentration of 5 
mg/ml. Antt-human Fab-HRP was used as a secondary antibody in a 1:2000 dilution.   91 
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Figure 3.4. CBX7 Polyclonal Antibodies Evaluation 
A) 293T cells transfected with pcDNA6 FLAG-CBX7 or pcDNA6 GFP were used to 
evaluate the antisera from rabbit 3 and 4, which were immunised with the C-RELF 
peptide. The cells were lysed in RIPA buffer. Protein was fractionated by SDS-PAGE, 
transferred  to  nitrocellulose  and  immunoblotted  with  the  antisera  from  rabbit  3  or 
rabbit, 4 or with an anti-FLAG as control. 
B) 293T cells transfected with pcDNA6 FLAG-CBX7 were lysed with NP40 buffer. 
The  lysate  was  then  incubated  with  20µl  of  antiserum  from rabbit  4.  The resulting 
immunoprecipitated sample and an input of 10% of the orginal lysate used (INP) were 
fractionated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with anti-
FLAG. 
C) Chromatin Immunoprecipitation (ChIP) was performed as described in section 2.4.5 
using chromatin from mid-life HS68 cells (PD45). The chromatin was incubated with 
20µl of CRELF antiserum from rabbit 4 for with antibodies for CBX7 (Abcam) or 
unspecific rabbit IgG. The purified DNA was analysed by qPCR using primers specific 
to the INK4A promoter region (PS6 and PS7) or the INK4B exon 1 (PS1).   93 
   94 
Figure 3.5 Overview of HPH2 Antigens. 
A) The cDNA of the short isoform of HPH2 (HPH2b) was fused to an N-terminal GST 
tag. Clones were evaluated for expression using 1mM IPTG for induction at 37°C for 4 
hours or overnight at 16°C by 1mM of IPTG. A 5 l culture induced overnight at 16°C of 
the best clone was used for purification on glutathione sepharose 4B  (GE Healthcare) 
and consequent cleavage of the GST tag with prescission protease (GE Healthcare). The 
resulting  product  was  fractionated  by  SDS-PAGE  and  the  gel  was  stained  for  both 
Coomassie  staining  and  immunoblotting  with  a  cross-reacting  anti-Mph2  antibody 
(provided by H. Koseki) 
B) HPH2b was cloned with an N-terminal HIS6 tag. A set of clones were evaluated for 
expression levels following overnight induction at 16 °C by 1 mM IPTG. 2 l of the best 
clone were used for purification on NiNTA Superflow beads (Qiagen) and eluted using 
3M imidazole as detailed in section 2.4.9.2. Although the full length protein (around 
48kDa)  could  not  be  visualised  by  coomassie  staining,  it  was  detectable  by 
immunoblotting for HIS and HPH2 (1615).   95 
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Figure 3.6 HPH2 Recombinant Human Antibodies Evaluation 
A) ELISA (as performed by AbD Serotec) was used to measure the relative affinity of 
identified clones for the antigen HIS6-HPH2b, as well as negative controls GST, N1-
CD33-HIS6 and BSA. 
B) 293T cells overexpressing pcDNA6 HA HPH2a were fractionated by SDS-PAGE, 
transferred  to  nitrocellulose  and  immunoblotted  using  the  8  AbD  Serotec  HPH2 
antibodies or anti-HA. The strongest signal, as obtained with antibody HPH2-74, is 
displayed. 
C) 293T cells transfected with pcDNA6 FLAG-CBX7 were lysed with NP40 buffer. 
The lysate was then incubated with 10 µg of all AbD Serotec HPH2 antibodies and 
precipitated  using  anti-Myc  (9E10)  and  Protein  A/G  agarose.  The  resulting 
immunoprecipitated samples and an input of 10% of the original lysate used (INP) were 
fractionated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with anti-
HA.   97 
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Figure 3.7 HPH2 Polyclonal Antibodies Evaluation. 
A)  293T  cells  overexpressing  pcDNA6  HA-tagged  HPH2b  were  lysed  with  NP40 
buffer. The lysates were incubated with either 5 µg of purified antibody (E.84, E.85, or 
anti-HA) or 20 µl of crude serum (S) or antibodies purified on Protein A (IS) (1615 or 
1616) overnight at 4°C. Immunoprecipitated proteins were fractionated by SDS-PAGE, 
transferred to nitrocellulose and immunoblotted for HA. It is unclear what the additional 
band in the HA control IP is. 
B)  Chromatin  Immunoprecipitation  (ChIP)  was  performed,  as  described  in  section 
2.4.5, using chromatin from mid-life Hs68 cells (PD45). The chromatin was incubated 
with 20 µl of crude serum (S) or antibodies purified on Protein A (IS) or unspecific 
rabbit IgG. The purified DNA was analysed by qPCR using primers specific to the 
INK4A promoter region (PS6), to INK4A exon 1 (PS7) or to INK4B exon 1 (PS1). 
C+D) Wildtype 293T, FDF, Hs68 and Q34 cells were lysed with RIPA buffer. Protein 
lysates were fractionated by SDS-PAGE, transferred to nitrocellulose and immunblotted 
with the HPH2 1615 crude serum in a 1:500 dilution (C). The resulting autoradiographs 
were aligned to one based on immunoblotting the lysate from 293T cells overexpressing 
either pcDNA6 HA-tagged HPH2a  and -HPH2b with anti-HA (D). The blue dotted 
lines align the sizes of bands observed in HDFs to the bands observed after ectopic 
expression of (C-terminal) HA-tagged HPH2a. The red dotted line aligns the size of the 
single band observed in 293T and the main band observed for ectopic expression of 
HA-tagged HPH2b. 
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4  The Characterisation of the Polyhomeotic Family and the 
Interaction with the Human PC Family 
 
4.1  Introduction 
 
Following the identification of CBX7 as a repressor of INK4/ARF transcription, the 
question arose what its partners are in the PRC1 complex and whether these partners 
would potentially constitute a unique complex for the regulation of this particular locus 
(Gil  et  al.,  2004;  Gil  and  Peters,  2006).  For  this  reason,  James  Nicholls,  a  former 
graduate student in our group, purified mouse Cbx7 from 293T cells by tandem affinity 
purification  (TAP)  (Nicholls,  2006).  Three  members  of  the  PSC  family  and  both 
members of the SCE family were found. In contrast, only one PH family member, 
HPH2, was found (Figure 4.1A). In subsequent in vitro binding experiments James also 
found that out of the three HPH proteins, only HPH2 was found to bind to recombinant 
mouse Cbx7  (Figure 4.1B). 
These results collectively  suggested a  specific interaction between Cbx7 and 
only one PH member, HPH2. This was of particular interest due to the fact that Mph2 
has been shown to be involved in the regulation of Ink4a/Arf in MEFs (Isono et al., 
2005a). In this chapter the putative specific interaction between HPH2 and CBX7 was 
further studied by a detailed characterization of the HPH family, further assessment of 
specificity between the HPH and human PC protein families and by investigation of the 
protein domains required for this interaction. 
 
4.2  Characterization of the HPH Family 
 
To establish whether there are preferential interactions between the human PC and PH 
proteins, it was necessary to have a more comprehensive picture of the complete HPH 
family.  At  the  start  of  this  study,  there  was  limited  information  about  the  different 
isoforms of the HPH genes, but at the time of writing the Ensembl, NCBI and UCSC 
databases collectively report several splice variants for all HPH genes (Figure 4.2A). 
However, a number of the variants such as HPH1c and HPH3b, -c, -d and -e do not 
encode  the  highly  conserved  HD1,  FCS  and  SAM  functional  domains  at  their  C-  101 
terminus. As these domains have been demonstrated to be essential for the functions of 
PH in the context of PRC1, these variants were not pursued (Alkema et al., 1997; Kyba 
and Brock, 1998b). In order to confirm the existence of the other reported variants, a set 
of PCR primers was designed to discriminate differential exon usage (performed in 
collaboration with Tomas Racek) and primer locations are indicated in Figure 4.2A. 
RT-PCR was then performed on RNA from various cells types. As shown in Figure 
4.2B the variants HPH1a and -c, HPH2a and -d, and HPH3a were clearly detected, but 
HPH1b and HPH2c were not. 
In contrast to HPH1 and HPH3, HPH2 has been reported to have both a long 
isoform (HPH2a) of 91 kDa, and a short isoform (HPH2b) of 36 kDa that retains all C-
terminal  functional  domains  (Tonkin  et  al.,  2002).  By  analogy  to  the  mouse 
homologues, the shorter isoform is likely to be encoded by a distinct RNA transcript 
(Yamaki et al., 2002). This is consistent with the observation that the start of the 5’ 
UTR of the transcript originates from an intronic region between exons 7 and 8 of the 
HPH2a transcript and thereby may have its own promoter (see Figure 4.2A). Since the 
cDNA of the long isoform was not available at that point, it was constructed using RT-
PCR using template RNA from 293T cells. The resulting sequence corresponds to the 
splice variant a, and is thus missing the 5
th exon found in variant HPH2d. 
In  order  to  study  the  relative  expression  levels  of  the  different  HPH  genes, 
quantitative PCR (qPCR) was used. In order to compensate for differences in primer 
efficiency, a standard curve derived from a titration of respective cDNA plasmid was 
used to determine the absolute number of transcripts for each HPH gene. HPH2b could 
not be specifically detected, as the high GC content of the unique 5’ UTR region limits 
efficient PCR amplification. Upon comparison, it was found that in 293T cells all genes 
are expressed at a similar level, with HPH1 and HPH3 expressed ≥ 2-fold more than 
either HPH2a/d specifically or all HPH2 transcript variants (Figure 4.2C). This result 
also  suggests  that  the  long  transcripts  of  HPH2  represent  the  majority  of  HPH2 
transcripts in 293T cells, which is in contrast to the relative levels observed in murine 
embryonic and adult tissue (Yamaki et al., 2002), as ell as the findings for endogenous 
HPH2 in 293T, as reported in Figure 3.7C.  
Using the cDNA for HPH2a and the cDNA HPH2b previously obtained, it was 
validated that both isoforms bind to CBX7 in a co-expression experiment in 293T cells 
(Figure 4.3). This suggests that, at least in the interaction with CBX7, there is little or 
no difference between the two isoforms. This however does not explain why full-length 
HPH2a or its breakdown products of more than 36 kDa were not identified in the Cbx7   102 
purification (Figure 4.1A). This could also be due to insufficient sensitivity of the mass 
spectrometry analysis, especially since the more sensitive analysis performed on protein 
samples from tandem affinity purifications of both BMI1 and MEL18 did yield several 
identifications of HPH2a and its breakdown products (Maertens et al., 2009). 
In  the  remainder  of  this  work,  HPH2a  will  generally  be  used  as  the 
representative of HPH2, as it contains additional residues with respect to the coding 
region of HPH2b and is more similar in size to HPH1 and HPH3. Thus HPH2 will 
indicate the use of HPH2a, unless specified otherwise. 
 
4.3  Characterization of the interaction of the HPH family with the CBX 
family 
 
4.3.1  All HPH family members bind CBX7 
 
Due to unavailability of the appropriate antibodies at the start of this work, interactions 
were  determined  using  FLAG  epitope-mediated  co-immunoprecipitation  (co-IP) 
following ectopic co-expression in 293T cells. Each HPH family member was initially 
cloned with either an N- or C-terminal HA-tag to verify that the epitope would not 
interfere with possible interactions with the terminal regions of the protein. The epitope 
on  either  terminus  of  HPH2a  or  HPH2b  did  not  interfere  with  the  interaction  with 
CBX7  (data  not  shown)  and  HPH  cDNAs  were  expressed  with  an  N-terminal  HA-
tagged tag in all subsequent experiments. Following expression of all HPH constructs in 
293T cells, it was found that the proteins did not express at equivalent levels. Both 
HPH2 isoforms were expressed at a high level, whereas HPH1 and HPH3 could hardly 
be detected, as determined by immunoblotting for the HA epitope (data not shown). The 
inefficiency of ectopic HPH1 expression is in accordance with the findings of other 
investigators  (Schwermann  et  al.,  2009).  To  circumvent  this  problem,  cells  were 
transfected with increasing amounts of HPH1 and HPH3 and decreasing amounts of 
HPH2a/b in order to obtain equivalent levels of expression. As illustrated in Figure 4.4, 
it was necessary to transfect 30 µg of HPH1 to match the expression level achieved by 1 
µg of HPH2a. Similar results were obtained for HPH3 (data not shown). With similar 
expression levels for all constructs, it was determined that all HPH proteins can co-IP   103 
with FLAG-tagged CBX7 (Figure 4.4B). These data therefore suggest that HPH1, -2 
and -3 are capable of binding to CBX7 under these conditions. 
The subsequent availability of a commercial HPH1 ployclonal antibody and a 
published HPH3 polyclonal antibody (Deshpande et al., 2007), in addition to the 1615 
antibody described in section 3.3.2, made it possible to study the interaction between 
endogenous  HPH  proteins  and  CBX7.  The  prostate  cancer  cell  line  DU-145  was 
employed  for  this  purpose  as  these  cells  express  substantial  levels  of  endogenous 
CBX7. DU-145 cell lysate was used for a batch immunoprecipitation of CBX7, which 
was divided and used for immunoblotting with either the HPH1, -2 or -3 antibody. 
HPH2b could not be studied by this means due to the interference of the anti-CBX7 
rabbit IgG heavy chain proteins in immunoblotting. All HPH proteins were found to 
modestly interact with CBX7 (Figure 4.5A). In a reciprocal setup, HPH2 was able to 
specifically co-immunoprecipitate CBX7 (Figure 4.5B). These data therefore indicate 
that  all  HPH  proteins  can  bind  to  CBX7,  but  that  there  appears  to  be  a  relatively 
stronger interaction between CBX7 and HPH2a, which may indicate a preference of 
interaction. 
To investigate the interaction between HPH2 and CBX7 in more detail, a series 
of deletion mutants were generated of HA-HPH2 to sequentially remove the known C-
terminal functional domains (Figure 4.6A). These mutants were then tested for their 
ability to precipitate with FLAG-tagged CBX7 following ectopic co-expression in 293T 
cells. These co-immunoprecipitations demonstrate that the FCS domain is required for 
the interaction with CBX7 (Figure 4.6B). Since the FCS domain is highly conserved 
between the HPH family proteins, particularly at its key cysteine residues, it can be 
deduced that the FCS domain could be responsible for the interaction of CBX7 with the 
HPH proteins. 
 
4.4  All human PC proteins bind to HPH2 
 
Following the finding that CBX7 interacts with all HPH proteins, it was of interest to 
determine whether there is any inverse specificity in the association of HPH2 with the 
other human PC proteins. To address this question, 293T cells were co-transfected with 
plasmids encoding HA-tagged HPH2a and FLAG-tagged CBX2, CBX4, CBX6, CBX7 
and CBX8 (kindly provided by Marc Rodriguez-Niedenführ). The cell lysates were then 
used  for  immunoprecipitation  of  the  FLAG  epitope  and  precipitates  were   104 
immunoblotted for HA. As shown in Figure 4.7, HPH2 appeared to interact with all 
these CBX proteins under these conditions. An obvious inference is that the interaction 
involves a domain conserved in all CBX proteins. 
Pc/Cbx/CBX proteins contain an amino terminal chromodomain, through which 
they interact with histones and RNA (Bernstein et al., 2006b). A number of key residues 
have been characterised, which, upon mutation, can abrogate these interactions. The 
F11 and W35 residues have been shown to mediate binding of the chromodomain to the 
trimethylated lysine 27 on the tail of histone H3 (Bernstein et al., 2006b), whereas the 
R17  residue  is  believed  to  be  required  for  RNA  binding  (M  Walsh,  personal 
communication).  It  was  therefore  of  interest  to  determine  whether  any  of  these 
mutations would disturb the interaction between CBX7 and HPH2. Versions of FLAG-
tagged  CBX7  carrying  these  mutations  (kindly  provided  by  Marc  Rodriguez-
Niedenführ) were co-expressed with HA-tagged HPH2 in 293T cells and the interaction 
was assessed  as before. Figure 4.8 shows that  none of these mutations affected the 
interaction of CBX7 with HPH2, suggesting that these residues may not be involved in 
the interaction and that the interaction may occur independently of these functions of 
CBX7. 
In order to dissect the domain of CBX7 involved in the interaction with the HPH 
proteins, a series of seven FLAG-tagged CBX7 deletion mutants was made. This series 
was in part based on the CBX7 fragments previously cloned for bacterial expression 
(discussed  in  section  3.2.1).  In  contrast  to  full  length  CBX7,  none  of  the  CBX7 
deletions could be expressed at detectable level following transient transfection of 293T 
cells. In addition, in vitro transcription and translation of these constructs did not yield 
any detectable products, again in contrast to full length CBX7. These results could be 
due to the instability of human CBX7, as previously discussed in Chapter 3. 
As an alternative strategy, a GST pulldown assay was used. The mutants were 
cloned as N-terminal GST-fusion products and  were tested for bacterial expression. 
Three out of the seven deletion mutants constructed could be expressed well, including 
the two CBX7 GST-fusion proteins described in Chapter 3. Of three mutants, only two 
were found to be stably recovered following the GST pulldown procedure; Δ170C (Δ1) 
and Δ47CD-Δ170C (Δ2) (Figure 4.9A). These 2 mutants, GST-Cbx7 and GST were 
subsequently used in GST pulldown experiments with in vitro transcribed and translated 
35S-methionine labelled HPH proteins and luciferase, used as a negative control. As 
shown in Figure 4.9B, Δ1 most efficiently pulled down all HPH proteins. Δ2 did not 
consistently pull down all HPH proteins and overall did so with lower efficiency (with   105 
the exception of HPH1 pulldown). These two mutants both include amino acids 48-81 
(aa48-81) and thereby suggest that these residues are mediating the interaction. The 
aa48-81 region of CBX7 corresponds to the distal portion of the chromodomain and is 
highly conserved in the human CBX proteins, all of which are able to interact with 
HPH2 (see Figure 4.7). 
However, there are a number of unsettling aspects of the GST pulldown data. 
Firstly, the GST negative control produced a signal for both HPH2a and HPH2b. This 
could in part be attributed to apparent GST overloading (HPH2b) and could overall be 
resolved by increased stringency in washing conditions. Secondly, HPH1, HPH2a and 
HPH3  were  not  found  to  bind  mouse  Cbx7.  This  is  consistent  with  previous  GST 
pulldown data (Figure 4.1B), but does not fit with the observations that HPH1, HPH2a 
and HPH3 clearly interact with human CBX7 following co-expression in 293T cells 
(Figure  4.4).  This  may  be  explained  by  the  conformational  constraints  under  these 
artificial  conditions,  which  may  differently  affect  the  interaction  the  smaller-sized 
HPH2b. In order to connect these results to the co-immunoprecipitation of all HPH 
proteins by CBX7 (Figure 4.4), the assay  should ideally have been performed with 
human CBX7, but this cannot be recombinantly expressed as discussed before (Chapter 
3). Noting these reservations, this data suggests that the aa48-81 region of CBX7 is 
responsible for the interaction with HPH proteins and its high degree of conservation 
may explain why all HPH proteins can interact with all CBX proteins.   106 
4.5  Discussion 
 
In summary, the presented data did not demonstrate evidence for binding specificity 
between the CBX and HPH family members. The presented results suggest that there is 
no structural specificity in the interaction of HPH and CBX proteins, that there is a 
direct interaction between these protein families and that this interaction occurs through 
highly  conserved  domains.  Nevertheless,  endogenous  protein  interactions  hint  at 
possible preferential binding between CBX7 and HPH2.  
Practical limitations therefore might best explain the observations from James 
Nicholls,  as  presented  at  the  start  of  this  chapter.  The  low  sensitivity  of  the  mass 
spectrometry analysis of the protein samples obtained from the purification of mouse 
Cbx7 presents an important constraint in evaluating possible specificity of interactions. 
All proteins identified by mass spectrometry were represented by a small number of 
peptides and for HPH2 specifically, not more than two peptides were found in one 
purification experiment. The analysis thus may not have been sufficiently sensitive to 
identify peptides corresponding to HPH2a, or to HPH1 and HPH3. In addition, the HPH 
proteins were detected at similar expression levels in 293T (Figure 4.1C), suggesting 
that the identification of only HPH2b does not correlate to the expression level of the 
individual HPH proteins, although protein instability as demonstrated for these proteins 
may be a concern. Furthermore, the conclusion from the in vitro binding assay of HPH 
proteins to GST-mouse Cbx7 as performed by James Nicholls (Figure 4.1B) does not 
appear to be correct. 
The co-precipitation of all HPH proteins with CBX7 following co-expression in 
cells, and in vitro binding to a specific domain of CBX7 suggests that all HPH proteins 
can directly interact with CBX7 under these  experimental conditions. It is however 
important to recognise the limitations of these techniques. Overexpression of tagged 
proteins and the immunoprecipitation of a foreign epitope can lead to upnspecific or 
high  background  binding.  One  major  drawback  in  the  data  presented  for  these 
experiments  is  the  absence  of  a  control  sample  in  which  the  protein  targeted  for 
precipitation  is  absent  and  hence  will  reveal  whether  the  protein  studied  is  indeed 
unable to bind without it. In addition, the use of recombinant fragments of protein has 
its limitations. Since only a fraction of the protein is used, it is questionable to what 
extent the native structural confirmation is maintained and therefore to what extent a 
native interaction can be reproduced. This concern is strengthened by the observation   107 
that HPH proteins do not precipitate strongly with GST-mCbx7, even though it contains 
highly conserved aa48-81 region. As the GST pulldown experiments were controlled 
for  unspecific  GST  binding,  it  is  unlikely  that  there  were  serious  problems  with 
background  binding.  Considering  these  reservations,  we  can  conclude  that  the  data 
demonstrates a putative direct interaction between the HPH and CBX proteins. It is 
however not straightforward to indisputably validate a direct interaction. 
Furthermore,  a  direct  interaction  between  CBX  and  HPH  proteins  would  go 
against previous findings in Drosophila, where Ph was not found to interact with Pc 
(Kyba and Brock, 1998a). It is interesting to speculate on the role of this interaction in 
the context of the PRC1 complex. The interaction between HPH and PSC has been well 
established,  Ph  was  demonstrated  to  bind  directly  to  the  helix-turn-helix-containing 
(HTH) region of Psc through its HD1 domain (Kyba and Brock, 1998a). Additional 
evidence from studies with mouse constructs found that both the HD1 and SAM domain 
of Mph1 were required for the interaction with Bmi1 and this was confirmed for human 
proteins  using  both  HPH1  and  HPH2  (Alkema  et  al.,  1997;  Gunster  et  al.,  1997). 
Furthermore, our laboratory has been able to co-purify all HPH proteins with BMI1 or 
MEL18. RING1A and Ring1b have also both been demonstrated to interact with HPH1 
and Mph1 respectively (Satijn et al., 1997; Suzuki et al., 2002), but it is not sure if this 
would involve a direct interaction. It may thus be that the HPH proteins have direct 
interactions with all core PRC1 components. 
The putative direct CBX-HPH interaction would suggest that the status of HPH2 
can indeed affect the function of CBX7 in the repression of INK4/ARF. However, since 
these  data  have  ruled  out  the  existence  of  inherent  specificity  between  these  two 
proteins, this role may not only be confined to HPH2 and suggests that HPH1 and 
HPH3  should  also  be  considered  further.  Nevertheless,  it  remains  to  be  determined 
which  of  these  possible  interactions  between  the  CBX  and  HPH  family  (15, 
disregarding the different isoforms or splice forms of HPH2) occur in what context and 
to what degree there is redundancy in function.   108 
Figure  4.1  Potential  specificity  of  the  interaction  between  CBX7  and  HPH2b 
(adapted from (Nicholls, 2006)) 
A) Total cell lysate from 1.2 x 10
9 of 293T cells stably expressing either TAP or mouse 
Cbx7-TAP  was  used  to  carry  out  a  large-scale  TAP-tag  purification.  The  resulting 
protein sample was separated by SDS-PAGE and the gel was stained with Brilliant Blue 
G (Sigma) O/N. Visible bands were excised and subjected to tryptic digestion. Bands 
observed  in  the  control  lane  were  not  submitted  for  mass  spectrometry  analysis. 
Peptides  were  identified  as  described  in  the  Materials  and  Methods  section.  PRC1 
proteins found to co-purify with mouse Cbx7 are labelled with a red asterisk. 
B)  1 µg of plasmid DNA  encoding HPH1, HPH2 or HPH3 was used for coupled in 
vitro transcription and translation in the presence of 
35S-methionine using the TnT kit 
(Promega). 0.5 µl HPH1, 7.5 µl HPH2 and 0.5 µl HPH3 were incubated with 20µg of 
GST or GST-Cbx7 pre-bound to blocked glutathione beads. Proteins bound to the beads 
were  then  fractionated  by  SDS-PAGE  alongside  an  equivalent  volume  of  in  vitro 
translated material (IVT) used in the binding assay. Radiolabelled proteins were then 
detected by autoradiography.    109 
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Figure 4.2 The characterisation of HPH transcripts in human cells 
A) Overview of human polyhomeotic (HPH) members including a simplified cDNA 
structure, highlighting the location of the conserved C-terminal domains, and annotated 
transcripts  as  collectively  listed  in  the  Ensembl,  UCSC  and  NCBI  databases.  PCR 
primer locations for detecting alternative usage of exons of interest are indicated by 
arrowheads aligned with the relevant exons. Sequences are detailed in Table 6. 
B) Discriminative PCRs for the validation of annotated splice variants of HPH1, HPH2 
and HPH3 were performed using the standard conditions (as detailed in the Materials 
and Methods section 2.2.2) with 0.4 µg of cDNA of 293T and U2OS cells (HPH1 and 
HPH3 variants) or cDNA of O2Os and H1299 (HPH2 variants) cells. PCR reactions 
were separated by agarose gel electrophoresis and visualised by exposing the gel to UV 
following ethidium bromide staining. 
C) Quantitative RT-PCR was performed using 0.4 µg of RNA from 293T cells relative 
to  specific  plasmid  standard  curves  to  determine  transcript  copy  number  of  HPH1, 
HPH2,  HPH3  and  the  HPH2a/d  variants  specifically.  Error  bars  indicate  standard 
deviation between biological replicates, with n = 3.   111 
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Figure 4.3. CBX7 interacts with both isoforms of HPH2. 
293T  cells  were  co-transfected  with  pcDNA6  FLAG  CBX7  and  pcDNA6  encoding 
HA–tagged  HPH2a  or  -HPH2b.  Whole  cell  lysates  were  subjected  to 
immunoprecipitation (IP) using the anti-FLAG antibody (as described in section 2.4.4). 
Purified proteins (IP) and 5% input samples (INP) were fractionated by SDS-PAGE, 
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Figure 4.4. CBX7 interacts with all three HPH proteins 
A) 293T cells were transfected with a titrated amount of pcDNA6 HA HPH2a (1-4µg) 
or  HA  HPH1  (10-50  µg).  Whole  cell  lysates  were  fractionated  by  SDS-PAGE, 
transferred to PVDF and immunoblotted with anti-HA or anti-CDK4. 
B) 293T cells were co-transfected with pcDNA6 FLAG CBX7 and 30µg of HPH1, 1 µg 
of HPH2a and 30 µg of HPH3 in a pcDNA6 HA construct. Whole cell lysates were 
subjected  to  immunoprecipitation  (IP)  using  the  anti-FLAG  antibody  (as  described 
section 2.4.4). Purified proteins and 10% of input samples (INP) were fractionated by 
SDS-PAGE,  transferred  to  PVDF  and  immunoblotted  with  anti-HA  (for  horizontal 
lanes  labelled  HPH1,  HPH2,  HPH3)  or  anti-FLAG  (for  lane  labelled  FLAG).  The 
FLAG blot displayed is a representative of all IPs. 
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Figure 4.5 Preferential binding of HPH2 to endogenous CBX7. 
A) DU-145 cells were lysed and subjected to immunoprecipitation (IP) using anti-Cbx7 
(Abcam). Purified proteins (CBX7 IP) and 10% input samples (INP) were fractionated 
by SDS-PAGE, transferred to PVDF and immunoblotted with anti-HPH1 (Abnova), 
anti-HPH2a (1615) and anti-HPH3 (obtained from M.F. Hansen). 
B) DU-145 cells were used for IP as in A), using anti-HPH2 (1615) and an unspecific 
IgG fraction as a mock control. Immunoblotting of precipitates (HPH2 IP) and input 
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Figure 4.6 CBX7 interacts with the FCS domain of HPH2  
A) Overview of the  HA-tagged HPH2a deletion mutants, displaying the cumulative 
deletion of C-terminal functional domains. 
B) 293T cells were co-transfected with pcDNA6 FLAG-CBX7 and pcDNA6 encoding 
HA-HPH2a  wildtype,  -∆SAM,  -∆SAM∆pS  or  -∆SAM∆pS∆FCS,  or  empty  vector 
control. Whole cell lysates were subjected to immunoprecipitation (IP) with the anti-
FLAG antibody (as described in section 2.4.4). Purified proteins (FLAG IP) and 5% 
input  samples  (INP)  were  fractionated  by  SDS-PAGE,  transferred  to  PVDF  and 
immunoblotted with anti-HA or anti-FLAG.  
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Figure 4.7 HPH2 interacts with all five human PC proteins. 
293T cells were co-transfected with pcDNA6-based constructs encoding FLAG-tagged 
CBX2, CBX4, CBX6, CBX7 or CBX8, and HA-tagged HPH2. Whole cell lysates were 
subjected to immunoprecipitation (IP) with the anti-FLAG antibody (as described in 
2.4.4). Purified proteins (FLAG IP) and 5% input samples (INP) were fractionated by 
SDS-PAGE, transferred to PVDF and immunoblotted with anti-HA or anti-FLAG. 
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Figure 4.8 Chromodomain mutations do not affect the interaction of CBX7 with 
HPH2 
293T cells were co-transfected with pcDNA6 plasmids encoding HA-tagged HPH2, and 
FLAG-tagged CBX7 wildtype or F11A, W35A or R17Q mutants. Whole cell lysates 
were  subjected  to  immunoprecipitation  (IP)  for  the  FLAG-epitope  (as  described  in 
section  2.4.4).  Purified  proteins  (FLAG  IP)  and  2%  input  samples  (INP)  were 
fractionated by SDS-PAGE, transferred to PVDF and immunoblotted with anti-HA or 
anti-FLAG. 
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Figure 4.9 HPH proteins interact with a highly conserved domain of CBX7 
A) Overview of the CBX7 deletions produced as GST-fusion proteins (with respect to 
wildtype), which include a combination of N- and C-terminal truncations. The region 
indicated  by  Δ93  is  the  region  that  is  missing  in  the  mouse  relative  to  the  human 
sequence. 
B) 1µg of plasmid DNA encoding HPH1, HPH2a, HPH2b, HPH3 or luciferase was 
used for coupled in vitro transciption and translation in the presence of 
35S-methionine 
using the TnT kit (Promega). 8 µl of the 50 µl reaction was used for incubation with 20 
µg of GST, GST-Cbx7, GST-CBX7Δ170C or GST-CBX7Δ47CD+Δ170C pre-bound to 
blocked glutathione beads. Proteins bound to the beads were then fractionated by SDS-
PAGE alongside 10% input  samples (INP) of in vitro translate. Radiolabelled proteins 
were then detected by autoradiography and the GST pulldown efficiency was checked 
by Coomassie staining 
C) Overview of sequence conservation of aa48-81 of CBX7 relative to all other human 
PC  proteins  and  mouse  Cbx7,  with  the  aa48-81  region  and  corresponding  perfectly 
conserved residues highlighted in yellow.   119 
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5  The Role of the Polyhomeotic Family in the Regulation of 
INK4A 
 
5.1  Introduction 
 
The results in Chapter 2 suggest that all three members of the human polyhomeotic 
(HPH)  family  can  physically  associate  with  CBX7,  but  did  not  address  functional 
interdependence. In mouse knockouts studies, only the murine homolog of HPH2 was 
clearly linked to the regulation of Ink4a (Isono et al., 2005a). It was therefore important 
to  extend  the  analysis  to  all  HPH  proteins  to  define  whether  there  is  a  collective 
involvement of the HPH family in the regulation of the INK4/ARF locus. To this end, 
multiple  shRNAs  were  designed  and  validated  for  depletion  of  HPH1,  -2  and  -3 
expression. Conversely, the respective cDNAs were cloned into retroviral vectors to 
achieve overexpression in primary cells. However, the initial focus was on HPH2, based 
on the findings of the corresponding mouse knockout, the indications of some degree of 
preferential binding by endogenous CBX7 and the availability of reagents at the start of 
this work. 
By definition, all established human cell lines have alterations that allow them to 
bypass senescence. As most of these reflect loss or deregulation of INK4A/ARF, it is 
essential to study the regulation of the locus in primary cells. The system of choice in 
the laboratory is primary human fibroblasts of various origins that have been transduced 
with  the  receptor  for  ecotropic  retroviruses  (Brookes  et  al.,  2004).  Unfortunately, 
primary cells are rather heterogeneous in nature and therefore any effects on INK4A 
expression  are  averaged  out  over  the  population  sampled.  For  instance,  it  has  been 
observed that at mid-age a population of primary fibroblasts will already have a fraction 
of senescent cells with high levels of p16 (Brookes et al., 2004). This heterogeneity can 
therefore obscure the effects that one is aiming to document from an experimentally 
manipulated population. 
Due to the overall increase in the percentage of p16-expressing cells in culture 
over time, it is important to consider the age or the number of population doublings the 
cells have undergone for experimental purposes. As a population of older cells has a 
higher  overall  basal  level  of  p16  protein,  these  cells  were  used  for  documenting 
repression of INK4A. Conversely, a population of younger cells has a lower overall   121 
level of basal p16 protein and was therefore preferred for observing derepression of 
INK4A. For this reason, the number of population doublings for the cells used for each 
experiment  was  chosen  carefully  and  was  stipulated  as  appropriate.  Most  of  the 
experiments were conducted with neonatal foreskin fibroblasts (Hs68) or fetal dermal 
fibroblasts  (FDF),  the  characteristics  of  which  have  been  described (Brookes  et  al., 
2004). 
 
5.2  HPH2 knockdown in HDFs results in derepression of INK4a 
 
Initially, an effort was made to validate whether the effects on Ink4a/Arf derepression as 
reported  for  the  Mph2-/-  knockout  MEFs,  also  apply  to  human  cells  (Isono  et  al., 
2005a). To knockdown the HPH2 transcripts, a set of 6 shRNAs were designed and 
cloned into the retroviral vector pRetroSuper (pRS). Since at that time no antibody 
capable of detecting endogenous HPH2 was available, these constructs were tested for 
their  ability  to  deplete  HA-tagged  HPH2  protein  levels  expressed  in  293T  cells 
(validation of best shRNA shown in Figure 5.1A). The shRNA capable of displaying 
the  best  knockdown,  HPH2-1,  was  consequently  used  to  infect  FDF  cells.  It  was 
observed  that  knockdown  of  HPH2  resulted  in  increased  levels  of  p16  protein, 
suggesting derepression of INK4A (Figure 5.1B). This effect was similar to that seen for 
knockdown of CBX7, which was previously shown to cause an induction of INK4A and 
result in pre-mature senescence of normal human cells (Gil et al., 2004; Maertens et al., 
2009). The induction of INK4A expression by HPH2 and CBX7 was confirmed at the 
RNA  level  (Figure  5.1C).  Interestingly,  it  was  found  that  HPH2  also  induces  the 
expression of INK4B, but not ARF.  
To demonstrate that derepression of INK4A following HPH2 knockdown also 
impacts on proliferation, population doublings were recorded following completion of 
selection. The resulting graph (Figure 5.1D) demonstrates a reduction in proliferation to 
the point where the shRNA-transduced cells stopped dividing (at PD37, 5 population 
doublings after selection), whereas wildtype cells normally continue proliferating up to 
PD80 (Brookes et al., 2004). CBX7 knockdown was used as a positive control and 
reduced  proliferation  to  a  similar  extent.  Additionally,  shRNA  transduced  cells  (at 
PD37) and control cells (PD39) were stained for senescence-associated ß-galactosidase 
(SA ß-gal). It was found that both HPH2 and CBX7 knockdown lead to a significant 
increase in the intensity of SA ß-gal staining (Figure 5.1E), confirming that the arrest   122 
corresponds to premature senescence. With the caveat that only one shRNA was used in 
this experiment, these results clearly demonstrate that that HPH2 is required for INK4A 
repression in human cells. 
 
5.3  HPH2 binds to the promoter and exon 1 region of INK4A 
 
If  HPH2  is  directly  involved  in  PcG-mediated  repression  of  INK4A,  it  would  be 
expected to be associated with the chromatin at the locus. To address this possibility, 
chromatin  immunoprecipitation  (ChIP)  experiments  were  conducted  with  chromatin 
from mid-lifespan FDF cells using the 1615 rabbit polyclonal antibody against HPH2 
(as  validated  in  section  3.3.2).  Other  PRC1  members  BMI1,  CBX7  and  CBX8, 
previously shown to bind to INK4A, were used as positive controls (Dietrich et al., 
2007; Kia et al., 2008; Maertens et al., 2009). A non-specific rabbit IgG or a mouse 
monoclonal against HA were used as negative controls. Using primer pairs spanning the 
INK4B-ARF-INK4A locus (Figure 5.2A), HPH2 was significantly enriched in the region 
from upstream of the promoter region to downstream of the first exon of INK4A (Figure 
5.2B). The distribution of HPH2 is similar to that of CBX7, CBX8 and BMI1 (Figure 
5.2C-E).  H3K27me3,  the  hallmark  of  PRC1  binding,  follows  a  similar,  though 
somewhat  wider  distribution  pattern,  consistent  with  previous  observations  (Figure 
5.2F) (Dietrich et al., 2007; Maertens et al., 2009). These findings correspond to the 
previous study in MEFs that showed Mph2 to be associated with the first and second 
exon of Ink4a (Isono et al., 2005a). These data provide a better definition of INK4B-
ARF-INK4A locus-wide binding and confirm the suspected overlap with other PRC1 
proteins at INK4A. 
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5.4  HPH2 depletion does not affect repression of INK4A by Cbx7 
 
As previously discussed, ectopically expressed mouse Cbx7 is able to downregulate the 
expression of INK4A/ARF (Gil et al., 2004). It is however not clear how the additional 
availability of Cbx7 enhances repression relative to endogenous CBX7 or what PRC1 
partners are involved in this process. It was therefore important to establish whether the 
ability of mouse Cbx7 can down-regulate the expression of INK4A in the face of HPH2 
knockdown.  
As expected, expression of FLAG-tagged mouse Cbx7 in Hs68 cells caused a 
marked reduction in the levels of p16
INK4A protein and RNA at 10 days post-selection 
(Figure 5.3A+B). This was accompanied by increased binding of exogenous FLAG-
tagged Cbx7 at the INK4A promoter (Figure 5.3C). The cells were then infected with 
retroviruses encoding either HPH2 or CBX7 shRNA. Whereas the control cells showed 
significant derepression of INK4A, the cells overexpressing mouse Cbx7 did not display 
such a response to depletion of HPH2 (Figure 5.3D). CBX7 knockdown did have a 
modest effect on relieving INK4A repression. It should be noted that the shRNA against 
CBX7 has a 2 base mismatch (out of the 18 bases) with the sequence of mouse Cbx7 
and it is therefore unclear whether the shRNA will also target the ectopically expressed 
mouse Cbx7, which would be expected to impact on the down-regulation of INK4A. An 
additional approach using lentiviral infection with a different HPH2 shRNA produced 
similar results (Figure 5.3D). This would imply that repression of INK4A by mouse 
Cbx7 in these cells is not sensitive to depletion of HPH2 (nor endogenous CBX7). 
It thus appears that depletion of HPH2 has little effect on the ability of mouse 
Cbx7  to  down-regulate  INK4A  expression.  One  obvious  possibility  is  that  the 
knockdown of HPH2 was incomplete and therefore sufficient HPH2 remains present for 
PcG-mediated  repression.  Alternatively,  it  is  possible  that  ectopic  Cbx7  is  able  to 
produce  INK4A  repression  by  interacting  with  HPH1  and  HPH3.  Another  scenario 
would be that endogenous CBX7 (in the vector control cells) is present at a rate-limiting 
amount  for  PcG  repression,  so  that  its  function  is  very  sensitive  to  knockdown  by 
CBX7-1  or  to  knockdown  of  an  essential  partner,  such  as  HPH2.  In  contrast,  the 
ectopically  expressed  mouse  Cbx7  would  have  greater  potential  to  form  alternative 
partnerships, for example with HPH1 and HPH3, and would therefore be less sensitive 
to HPH2 depletion. 
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5.5  Ink4a repression by Cbx7 is incapacitated in Mph2
-/- MEFs 
 
As mentioned above, the incomplete depletion of HPH2 might obscure any level of 
interdependence with Cbx7. As an alternative, we obtained Mph2 knockout MEFs from 
the  Koseki  laboratory  (Isono  et  al.,  2005a)  to  test  whether  Cbx7  is  able  to  repress 
Ink4/Arf in the complete absence of Mph2. Although these cells are reported to achieve 
7 population doublings (compared to ~15 population doublings for wildtype MEFs), 
cells  as  received  were  unfortunately  found  to  senesce  after  only  2-3  population 
doublings,  allowing  very  little  opportunity  for  experimental  manipulation  and  low 
amounts of material for analysis. 
Because of these limitations, it was first necessary to establish conditions at 
which  the  relevant  retroviral  constructs  delivered  the  expected  effects  in  wildtype 
MEFs. Overexpression of mouse Cbx7 or an shRNA against Cdkn2a, which knocks 
down both the Arf and p16 transcripts, caused a substantial reduction in p16 protein 
levels (Figure 5.4A). Consequently, the same plasmids and a plasmid containing mouse 
Mph2 were used to infect wildtype and Mph2-/- MEFs. Following selection, cells were 
imaged  to  document  both  cell  morphology  and  relative  cell  number  and  their 
proliferation was followed. Whereas Cdkn2a knockdown effectively rescued the Mph2 
knockout cells from senescence, mouse Cbx7 only caused a modest delay in the onset 
of senescence (Figure 5.4B+C). These results are in stark contrast to the proliferation 
seen for the overexpression of mouse Cbx7 in wildtype MEFs and would thus suggest 
that the loss of Mph2 significantly incapacitates the ability of ectopic mouse Cbx7 to 
repress Ink4/Arf. 
In theory ectopic expression of Mph2 should have been rescued senescence in 
Mph2
-/-MEFs. In practice however, although Mph2 expression initially appeared to be 
modestly enhancing proliferation compared to control, this effect was not maintained 
(Figure 5.4B). Surprisingly, ectopic Mph2 severely impaired the proliferation of wild 
type MEFs (Figure 5.4C). This suggests that it might be necessary to optimise the level 
of expression in order to rescue the genetic defect, but this was hindered by the limited 
availability of cells.  
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5.6  Overexpression of HPH2 in HDFs 
 
The  effects  of  Mph2  overexpression  in  wild  type  MEFs  were  surprising  given  that 
ectopic expression of Cbx7 and Bmi1 has been shown to repress Ink4a/Arf and bypass 
senescence in these cells (Gil et al., 2004; Jacobs et al., 1999a). To further investigate 
this  phenomenon,  analogous  experiments  were  performed  by  the  overexpression  of 
HPH2  in  HDFs.  To  this  end,  mid-age  Hs68  cells  were  infected  with  retrovirus 
containing the cDNA of HPH2. Upon analysis of protein and RNA levels, it was found 
that a modest increase (about 8-fold) in HPH2 expression leads to a strong induction of 
INK4A  expression  (Figure  5.5A+B).  Similar  findings  were  drawn  from  FDF  cells, 
suggesting that the effect is not HDF strain specific (data not shown). The induction of 
INK4A  expression  correlates  with  strongly  reduced  proliferation,  but  the  transduced 
cells did not fully arrest or display a senescent phenotype over time (Figure 5.5C). In 
the context of PRC1-mediated repression of INK4A locus, it was relevant to ask whether 
PcG occupancy of the locus was altered in the HPH2-transduced cells. ChIP analyses 
showed  both  CBX7  binding  and  H3K27me3  levels  at  the  INK4A  promoter  were 
significantly reduced, suggesting a loss of PcG repression (Figure 5.5D). 
These findings suggest that even a modest elevation of HPH2 levels can disrupt 
PcG-mediated repression of INK4A, which leads to impaired proliferation.  HPH2 could 
possibly  mediate  this  effect  by  titration  of  other  PRC1  proteins  away  from INK4A, 
although  this  needs  to  be  further  examined.  Although  overexpression  of  PRC1 
members, such as Cbx7 and Bmi1, was generally thought to produce an enhanced effect 
on INK4A repression (Gil and Peters, 2006), this might thus not universally apply to all 
PRC1 proteins. 
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5.6.1  Involvement of HPH1 and HPH3 in INK4A repression 
 
As alluded to before, another important consideration is whether other members of the 
HPH family are also involved in the regulation of INK4a. The phenotype of the Mph1 
knockout mice is similar to that of Mph2 in terms of homeotic transformations, and 
both proteins are proposed to have a synergistic relation in PcG-mediated repression 
(Isono et al., 2005a; Takihara et al., 1997). As ectopic expression of HPH1 and HPH3 
proved difficult and there is an absence of reagents to study binding of the endogenous 
proteins to the INK4A locus, the main strategy employed to answer this question was 
shRNA-mediated knockdown. 
To target HPH1 and HPH3, sets of 5 and 9 shRNAs respectively were designed 
and tested for efficacy by qPCR. Consequently, the best two shRNAs for each gene 
were  used  for  the  infection  of  FDF  cells,  alongside  two  shRNAs  against  HPH2. 
Depletion of both HPH1 and HPH3 resulted in an induction of INK4A expression both 
at the RNA and protein level, and to a similar degree as HPH2 (Figure 5.6). These 
findings  therefore  suggest  that  all  HPH  proteins  are  involved  in  the  repression  of 
INK4A. This would fit with other observations in the laboratory that multiple PRC1 
complexes regulate INK4A and that each constituent core component is required for 
repression (Maertens et al., 2009).. 
To  further  evaluate  the  interrelation  between  the  different  HPH  proteins, 
combined  knockdown  of  different  pairs  of  HPH  transcripts  was  attempted.  For  this 
purpose, mid-lifespan FDF cells were subjected to two rounds of infection, firstly to 
knockdown HPH2 and secondly to knockdown either HPH1, HPH2, HPH3 or CBX7. 
Following  analysis  of  p16  expression  by  RT-qPCR,  it  was  found  that  the  effect  of 
HPH2 knockdown could be enhanced by combination with knockdown of HPH1, HPH3 
or  CBX7  (Figure  5.7).  Interestingly,  double  infection  with  the  same  HPH2  shRNA 
(HPH2-2) only moderately increased INK4A derepression. The fact that infection with 
empty vector control followed by HPH2-2, or vice versa had a similar effect on p16 
transcript level, serves as an internal control to indicate that both plasmids were infected 
with similar efficiency. 
These results further emphasise that repression of INK4A expression is achieved 
by  the  collaboration  of  multiple  HPH  proteins.  With  respect  to  the  concept  of  an 
interdependent multi PRC1-complex system of PcG repression, these results may be 
best explained by the fact that incomplete depletion of HPH2 does not lead to full   127 
derepression of INK4A, but that depletion of two proteins has an enhanced effect. The 
previous observations that Mph1 and Mph2 act in a synergistic manner for Hox gene 
repression in mice further supports this idea (Isono et al., 2005a). Nevertheless, these 
results only represent a single experiment and need to be reproduced to come to any 
firm conclusions. 
 
5.7  Discussion 
 
Following the observations in Chapter 4 that all HPH proteins interact with CBX7, but 
that there might be a preferential interaction with HPH2, it was unclear how the HPH 
proteins are involved in the demonstrated function of endogenous CBX7 or ectopic 
mouse  Cbx7  to  repress  INK4A  expression.  The  functional  studies  reported  in  this 
chapter,  demonstrate  that,  based  on  shRNA-knockdown,  all  three  HPH  proteins 
contribute to the maintenance of INK4A repression. Furthermore, the inability of Cbx7 
to repress Ink4a/Arf in the absence of Mph2 suggests that all PH proteins are required 
for PcG-mediated repression. Double knockdown of two family members suggests that 
indeed  the  individual  contributions  to  PcG-mediated  repression  can  be  targeted 
additively.  It  should  however  be  noted  that  part  of  this  data  set  consists  of  singly 
performed experiments and that therefore the interpretation of the data is limited and no 
firm conclusions can be drawn at this stage. 
So far, only HPH2 has been directly associated with the INK4A locus, but more 
robust ChIP-grade antibodies under current development will allow the binding of all 
three proteins to be investigated. In a preliminary observation, HPH3 was also found to 
bind across the INK4B-ARF-INK4A locus with a similar distribution pattern as all other 
PRC1 proteins (performed by Julie Stock). It should therefore soon be possible to study 
the effect of HPH2 depletion on HPH3 binding to INK4A, or vice versa. Similarly to the 
findings  reported  in  Maertens  et  al.  where  binding  of  CBX7  and  CBX8  could  be 
sequentially  measured  on  INK4A,  binding  of  both  HPH1  and  HPH3  can  also  be 
assessed. It will be of significant interest to determine whether the HPH proteins and 
their  unique  capacity  to  oligomerise  could  play  an  important  part  in  the  structural 
organisation and coordination of such multiple PRC1 complexes. 
The  observations  that  overexpression  of  HPH2  (and  Mph2)  functions  in  a 
dominant-negative manner on INK4A repression demonstrates that the basal level of 
HPH  expression  must  be  strictly  controlled.  The  Drosophila  polyhomeotic  gene  is   128 
known to be tightly regulated, in part through auto-regulation by PcG complexes and by 
TrxG complexes, and it was proposed that the equilibrium between these states ensures 
an accurate level of transcription (Fauvarque et al., 1995). Furthermore, it could be that 
the instability of HPH2 and associated high turnover of the protein contributes to this 
well  controlled  expression  level.  It  remains  rather  speculative  whether  consequent 
dissociation  of  CBX7  and  the  loss  of  H3K27me3  is  a  direct  or  indirect  effect  of 
increased levels of HPH2 protein. It is also important to note that Mel18 expression has 
been  demonstrated  to  negatively  affect  cell  proliferation,  in  part  by downregulating 
Bmi1 expression (Akasaka et al., 1996; Guo et al., 2007a; Guo et al., 2007b; Kajiume et 
al.,  2004),  and  that  there  have  been  observations  in  our  laboratory  that  the 
overexpression  of  CBX8  results  in  an  induction  of  INK4A.  This  suggests  that  this 
finding  is  not  unique  amongst  PcG  proteins  and  might  form  a  basis  for  different 
functions between different family members of the PRC1 core components.  
Another open question is the generalisation of the effects of HPH manipulation 
on  other  PcG  target  genes.  Wider  analysis  of  expression  changes,  for  example  by 
expression microarray, could indicate whether the effect seen for HPH2 overexpression, 
as well as knockdown, result in general activation of PcG target genes. However, more 
within the scope of this  work, preliminary observations from depletion of the HPH 
family  in  the  p16-defective  Leiden  cells  suggest  that  the  effects  observed  on 
proliferation are INK4A-dependent. 
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Figure 5.1 HPH2 is involved in the regulation of human INK4/ARF 
A) In order to validate the knockdown of HPH2 by shRNA HPH2-1, 293T cells were 
co-transfected with pcDNA6 HA HPH2b and pRS HPH2-1. Whole cell lysates were 
fractionated by SDS-PAGE, transferred to nitrocellulose and immunoblotted for HA, 
and CDK4 was used as loading control.  
B) FDF (PD32) cells were infected with pRS HPH2-1 and pRS CBX7-1 or the empty 
vector  control.  Following  2  population  doublings  whole  cell  lysates  were  prepared 
(PD32), fractionated by SDS-PAGE, transferred to nitrocellulose and immunoblotted 
for p16 and CDK4. 
C) FDF cells were infected with pRS HPH2-1 and pRS CBX7-1 or the empty vector 
control. RNA was isolated 10 days after selection (when expiremental cells were at 
PD27  and  control  cells  at  PD35)  and  RT-qPCR  was  used  to  quantify  the  relative 
expression of p15, p16 and ARF, and GAPDH was used as internal standard. Error bars 
indicate standard deviation between unrelated biological replicates, with n=2. 
D) FDF cells as described in B) were cultured and the respective population doublings 
were recorded until cells transduced with HPH2-1 or CBX7-1 were both found to have 
arrested. This result is a representative of two separate biological replicates. 
E) The FDF cells described in B) were cultured for two additional passages of the 
control cells, the cells were fixed and then used for staining of SA β-galactosidase 
activity (as described in the Materials and Methods section). 
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Figure 5.2 HPH2 co-localises with other PRC1 components at the INK4B-ARF-
INK4A locus. 
A) The series of primers used for interrogation of binding along the chromatin of the 
INK4B-ARF-INK4A locus is a combination of published and customly designed primers 
(Dietrich et al., 2007). Primer sequences are shown in section Table 5 in the Materials 
and Methods Chapter.  
B-E)  Chromatin  immunoprecipitation  (ChIP)  was  performed  as  described  in  the 
Materials  and  Methods  section  using  antibodies  for  B)  HPH2  (1615),  C)  CBX7 
(Abcam), D) CBX8 (Dietrich et al., 2007) and E) BMI1 (Abcam) using chromatin of 
mid-life  FDF  cells  (PD34/37).  Rabbit  non-specific  IgG  (Abcam)  was  included  as  a 
negative  control  for  the  rabbit  polyclonal  antibodies  used  in  A,  B  and  C,  whereas, 
mouse  anti-HA  antibody  was  used  as  a  negative  control  for  the  mouse  monoclonal 
antibody  used  in  D. Isolated  DNA  was  interrogated  by  qPCR  using  12  primer  sets 
spanning across the locus as indicated in the diagram of the INK4B-ARF-INK4A locus. 
Error bars indicate variance between technical replicates, with n=2. 
F)  ChIP  of  H3K27me3  (Millipore)  and  H3  (Abcam),  and  qPCR  analysis  were 
performed in the same manner as described above. Due to the high signal/noise ratio of 
both these antibodies the rabbit unspecific IgG control is not included. The resulting 
enrichment of H3K27me3 was normalised to the enrichment of histone H3. A ratio of 
H3K27me3/H3 higher than 1 can be explained by a differential efficacy of the H3 and 
H3K27me3 antibodies.    132 
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Figure 5.3 HPH2 knockdown does not affect INK4A repression by mouse Cbx7 
A) Mid-lifespan  Hs68  (PD39)  were  infected  with  a  pBABE-based  virus  containing 
mCbx7-FLAG or vector control. Cells were harvested 10 days post- selection (PD41). 
Whole cell lysates were fractionated by SDS-PAGE, transferred to nitrocellulose and 
immunoblotted for p16 and CDK4. 
B) Cells as described in A) were used to isolate RNA for RT-qPCR interrogation of the 
expression levels of p16 and GAPDH (used as internal standard). Expression values 
plotted are normalised by the vector control. 
C) The cells described in A) were cultured for an additional 3 population doublings, 
harvested and lysed in ChIP lysis buffer (Materials and Methods). ChIP was performed 
using  either  anti-Cbx7  (Abcam)  or  anti-FLAG  beads  (Sigma).  Amplifications  of 
purified DNA are plotted as fold enrichment over the vector control. 
D) HS68 described in A) were infected with shRNAs against HPH2 (HPH2-1) and 
CBX7 (CBX7-1). Alternatively, cells were infected with lentiviruses either empty or 
containing  shRNA  HPH2-3.  Following  selection,  cells  were  harvested  at  PD47  and 
RNA  was  isolated.  qPCR  was  performed  with  0.02ug  of  cDNA  of  each  sample  to 
measure p16 expression. Expression of GAPDH was used as internal control. Values 
plotted are fold enrichment over the vector control.   134 
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Figure 5.4 Cbx7 repression of Ink4a is impaired in Mph2-/- MEFs 
A) MEFs were infected with a pMARX retrovirus encoding Cbx7-FLAG, Mph2 or 
vector control, or the pMLP retrovirus containing an shRNA against Cdkn2a. After 7 
days,  cells  were  harvested  and  lysed,  extracts  were  fractionated  by  SDS  PAGE, 
transferred to nitrocellulose and immunoblotted with anti-p16 (Santa Cruz) or anti-Cbx7 
(Abcam). 
B) Wildtype and Mph2-/- MEFs were infected with pMARX encoding Mph2 (cDNA), 
Cbx7-FLAG or vector control, or pMLP Cdkn2a shRNA. After selection, and at the 
start  of  population  doubling  measurements,  cells  were  photographed  at  50x 
magnification.  
C) Cells described in B, were cultured and their population doublings were recorded 
over time.   136 
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Figure 5.5 HPH2 overexpression activates INK4A by depletion of PcG-mediated 
repression 
A) Mid-life Hs68 cells were infected with virus containing pBABE FLAG HPH2 or 
vector control. 6 days following infection, cells were harvested and lysed. Whole cell 
lysates  were  fractionated  by  SDS-PAGE,  transferred  to  nitrocellulose  and 
immunoblotted fpr p16, FLAG or GAPDH (Sigma). 
B) RNA was extracted from the same batch of cells as in A) and RT-qPCR was used to 
quantitate the expression of p16, HPH2 and GAPDH (internal standard). Error bars 
indicate standard deviation between independent biological replicates, with n=2. 
C) Hs68 cells as described in A) were cultured and the respective population doublings 
were recorded and plotted over time. This is a representative of results from two distinct 
cell types. 
D) The Hs68 cells described in A) were used for ChIP analysis by precipitating CBX7 
and H3K27 and sampling purified DNA with primers to the INK4A promoter (PS6). 
This  figure  represents  the  combined  results  of  two  independent  biological  replicate 
experiments.    138 
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Figure 5.6 All HPHs are involved in INK4A regulation 
A) Hs68 cells (PD45) were infected with retroviruses encoding shRNAs against HPH1 
(H1-1  and  H1-2),  HPH2  (H2-1  and  H2-2)  and  HPH3  (H3-1  and  H3-2)  and  were 
analysed by qPCR (as described section 2.5.2) for the expression of HPH1, HPH2 and 
HPH3 respectively, and all for p16 and GAPDH (internal standard). 
B) Whole cell lysates of Hs68 cells as described in A) were fractionated by SDS-PAGE, 
transferred to nitrocellulose and immunoblotted for HPH1 (Abnova), HPH2a (Abcam) 
and HPH3 (Marc F. Hansen) for each respective knockdown, and p16 and CDK4. 
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Figure 5.7. Depletion of two HPH proteins suggests synergy in repression 
Mid-age FDF cells were subjected to two rounds of infection and selection with 1) pRS 
hygromycin empty or containing HPH2 shRNA-3 (HPH2-2), and 2) pRS puromycin 
empty  or  containing  HPH2-2,  HPH1-2,  HPH3-1  or  CBX7-1.  Following  the  second 
selection cells were harvested for RNA isolation. 1ug of RNA was used for RT-qPCR 
for p16 and GAPDH (internal standard) expression. Resulting expression levels were 
normalised by the double empty vector infected control. 
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6  The Functional Role of the Human Polyhomeotic Proteins 
in the Regulation of INK4A 
 
6.1  Introduction 
 
As previously discussed, the HPH proteins have a number of properties that could carry 
an  important  role  in  the  mechanism  of  PcG-mediated  repression.  These  properties 
include  RNA-binding,  oligomerisation  and  the  interaction  with  MAPK  and  DDR 
protein kinases, which altogether suggest both regulatory and structural roles for the 
HPH  family.  However,  the  conserved  functional  domains  are  clustered  in  the  C-
terminal  region  of  the  HPH  proteins  and  no  functional  motifs  have  directly  been 
associated  with  the  extensive  amino  terminal  region.  Understanding  how  these  C-
terminal regions confer functionality can lead to new insights into the functionality of 
the different HPH proteins, and also could be instrumental for differentiating between 
the roles of the HPH2a and HPH2b isoforms. 
 
6.2  Identification of novel Interactions of HPH2 
 
As discussed in Chapter 4, the overlap between HPH2a and HPH2b has made it difficult 
to  assess  the  individual  functions  of  each,  as  there  is  no  possibility  of  a  specific 
antibody,  nor  can  the  HPH2b  isoform  be  specifically  amplified  by  PCR.  As  an 
alternative approach, it was decided to try and purify both proteins and compare the 
interacting proteins identified. To this end, the classical TAP tag (Rigaut et al., 1999) 
was cloned on the C-terminus of human HPH2b. This plasmid and TAP-tagged mouse 
Cbx7 (Figure 3.1A) were then transiently transfected in 293T cells and used for a pilot 
scale purification, carried out using IgG sepharose beads followed by TEV cleavage and 
a  second  round  of  purification  on  calmodulin  beads.  Figure  6.2A  shows  that  no 
interacting bands were observed on a silver stained gel for HPH2b, whereas purification 
of Cbx7 was found to produce its characteristic pattern of bands (Figure 4.1A). This 
was observed for small-scale purifications from both transiently transfected 293T and 
DU-145  cells.  One  of  the  possible  explanations  was  that  the  C-terminal  tag  would 
interfere with the functional properties of HPH2b.   142 
  Based on this suspicion, another cloning strategy was employed as to create the 
TAP tag on the amino terminus instead, and constructs were made for both HPH2a and 
HPH2b. Small-scale purifications following transient transfection with these constructs, 
were  separated  by  SDS-PAGE  and  silver  stained.  Following  staining  a  clear  set  of 
bands was visible for both isoforms, which  are both indicated by an  arrow (Figure 
6.2B).  These  include  shared  bands,  but  also  clearly  distinct  ones,  which  were  not 
present in the TAP only control. This therefore suggested that this method may be 
employed to characterize the unique properties of these proteins. 
As HPH2a is likely to boost the most interactions due to its significantly larger 
size, a large scale purification of this protein was pursued. Several attempts to perform 
large scale purifications from transiently transfected cells only produced limited yield 
and no detectable bands following Colloidal Coomassie staining, which has been the 
general criterion in the laboratory for pursuing identification by mass spectometry. As 
scale appeared to be the limiting factor, which may be attributed to low stability of 
HPH2a throughout the purification procedure, it was decided to use a large-scale clonal 
culture. To this end, 293T cells were stably transfected with HPH2a with the N-terminal 
TAP tag. 42 clones were derived and tested for individual expression levels. The best 
expressing  clone  was  consequently  used  for  expansion  (performed  by  LRI  Cell 
Services)  and  50  ml  of  cells  were  used  to  achieve  sufficient  purification  yield  for 
downstream analysis. The purified proteins were then separated by SDS-PAGE, stained 
by  either  SYPRO  Ruby  (purification  1)  or  Coomassie  Colloidal  Brilliant  Blue 
(purification 2) (Figure 6.3). Protein gel bands were manually excised, and samples 
were  consequently  trypsinised  and  analysed  by  LC-MS/MS  (performed  by  the  LRI 
Protein Analysis and Proteomics laboratory). 
The two purifications yielded 169 and 68 identified proteins, respectively, and 
had a reasonable amount of overlap (39 proteins) ( 
Table 9 and Table 10). Although the same amount of starting material was used 
for both purifications, the difference in the number of identifications and the number of 
peptides for mutual identifications suggests that the second purifications was overall 
less efficient or that the analysis performed was less sensitive. The fact that the purified 
proteins were visualised by different stains does not allow for direct comparison of 
yield. The large total number of different proteins identified is a reason for concern, 
especially since no TAP alone clone was available to use as a negative control for this 
scale  of  purifications,  and  therefore  no  background  identifications  can  be  reliably   143 
discounted.  However,  the  reasonable  number  of  reproducible  indentifications, 
especially of other PcG proteins, is reassuring.  
  The resulting list of proteins co-purifying with HPH2a includes both PRC1 and 
non-Polycomb proteins. It is confirmatory to find that at least one representative of each 
PRC1  core  component  was  found  to  co-purify,  which  suggests  that  intact  PRC1 
complexes were purified. In addition to RING1B, RING1A was also found in the first, 
possibly more sensitive purification, with 2 peptides in contrast to 13 for RING1B. The 
possible co-purification of both RING1 and RING2 as well as both CBX2 and CBX8 
suggests that HPH2 is indeed involved in multiple PRC1 complexes. This would fit 
with  the  findings  in  Chapter  4  that  suggest  that  HPH2a  has  no  specificity  for  any 
particular member of the CBX family. In this context, it is important to consider that the 
composition of PRC1 is likely to be influenced by the expression levels of individual 
proteins in 293T cells. CBX7 is only expressed at low level in 293T cells and therefore 
may not have been identified (Bernard et al., 2005). The same may possibly apply to 
CBX4 and CBX6. 
  The non-PRC1 proteins identified represent a diverse range of proteins. Some 
are likely contaminents, such as keratin and immunoglobulin chains. Others are known 
to frequently co-purify unspecifically, including a large number of ribosomal proteins, 
heat shock proteins (HSPs) and histone proteins. The purifications also yielded many 
proteins which fall within the ‘sepharose proteome’, which refers to proteins which 
commonly  interact  directly  with  the  sepharose  beads  used  in  many  purification 
protocols,  includes  numerous  RNA  binding  proteins,  such  as  heterogeneous  nuclear 
ribonucleoproteins  (hnRNPs),  ATP-dependent  RNA  helicases  and  splicing  factors 
(Trinkle-Mulcahy  et  al.,  2008).  The  identified  proteins  suspected  to  bind  sepharose 
according to this resource  are highlighted in light yellow in Table 9 and Table 10. 
However, as HPH proteins are expected to bind RNA via the conserved FCS domain, it 
would be premature to fully dismiss these proteins as contaminents (Zhang et al., 2004). 
An interesting example of this would be the identification of RNA helicase A (RHA), 
which  has  been  shown  to  specifically  bind  to  the  promoter  of INK4A  and  mediate 
activation of the locus (Myohanen and Baylin, 2001). This would thus suggest that there 
is possible co-localisation of RHA and HPH2 at the INK4A, an interesting hypothesis 
that  remains  to  be  tested.  Furthermore,  the  following  proteins  were  reproducibly 
identified to bind to HPH2 and are not described to be general contaminents; 
Nucleolar  protein  6  and  UT14A  are  both  involved  in  the  processing  of  pre-
rRNA primary transcripts (Rohozinski and Bishop, 2004; Utama et al., 2002). RNA   144 
binding motif protein 14 (RBM14/CoAA) is involved in the regulation of alternative 
splicing  and  is  overexpressed  in  a  subset  of  human  tumours  (Sui  et  al.,  2007). 
Interestingly, RBM14 is also reported to be a substrate of ATM/ATR phosphorylation, 
in  conjunction  with  HPH2  (Matsuoka  et  al.,  2007).  Splicing  factor  3B  subunit  4 
(SF3B4)  is  also  involved  in  splicing  as  SF3B  is  part  of  the  U2  small  nuclear 
ribonucleoprotein particle, a subcomponent of the splicosome. SF3B subunit 2 was also 
identified in the second purification (4 peptides). The co-purification of these subunits 
is particularly interesting since subunit 1 of Sf3b has been reported to be essential for 
mammalian PcG repression of Hox genes and to interact with a number of PcG proteins, 
including mouse Mph1, Mel18 and Ring2 (Isono et al., 2005b). This report also found 
the interaction of Sf3b4 with all PRC1 proteins tested (Mel18 and Ring2). Altogether 
this strongly suggests an interaction between the SF3B and PRC1 complexes. 
Furthermore, the YLP-motif containing protein 1 (YLMP1/ZAP3) is a putative 
nucleoside kinase that targets protein phosphatase-1 (PP1) and interacts with a number 
of RNA binding proteins, including a member of the hnRNP family (Ulke-Lemee et al., 
2007). Interestingly, PP1 was shown to dephosphorylate SF3B1 through the action of 
the nuclear inhibitor of PP1 (NIPP1) protein, which leads to the activation of splicing 
(Tanuma et al., 2008). Strikingly, NIPP1 has been reported to interact directly with 
EZH2 and SUZ12 and to be regulated by the associated methylation activity of these 
proteins (Roy et al., 2007). 
The co-purification of histone H1.2 is also intriguing. Although histone proteins 
are regarded as possible contaminents, histone H1.2 is involved in mediating higher-
order chromatin structures and depletion of this specific H1 variant results in a G1-
phase  arrest,  correlated  with  expression  changes  of  cell  cycle  genes,  including 
downregulation  of  CDKN2A  and  CDKN2B  expression  (Sancho  et  al.,  2008). 
Furthermore,  loss  of  histone  H1  has  an  important  role  in  cellular  senescence  by 
allowing the formation of SAHFs. These findings suggest that H1.2 could have a role in 
PcG repression of INK4A and warrants further investigation.  
The Thyroid hormone receptor-associated protein 3 (THRAP3/TRAP150) is a 
component  of  the  human  mediator  coactivator  complex  that  interacts  with 
transcriptional activator TFIID (Johnson et al., 2002). This is particularly relevant, as 
Drosophila PRC1 proteins, including polyhomeotic, were found to robustly associate 
with TFIID (Saurin et al., 2001; Wang and Brock, 2003). Furthermore, amongst the 
three best individual hits from the second purification were Polymerase delta-interacting 
protein 3 (3 peptides) and Transcription elongation factor A protein-like 4 (2 peptides).   145 
Altogether  this  would  suggest  a  possible  link  between  HPH2  and  the  transcription 
machinery. 
7,8-dihydro-8-oxoguanine triphosphatase (8ODP/NUDT1/MTH1) is an enzyme 
that hydrolyzes oxidized purine nucleoside triphosphates, to monophosphates, thereby 
preventing misincorporation into DNA/RNA during replication and transcription (Mo et 
al.,  1992;  Nakabeppu  et  al.,  2006).  It  is  overexpressed  in  a  number  of  cancers, 
potentially  as  a  result  of  increased  reactive  oxygen  species  (ROS) (Kennedy  et  al., 
2003).  Interestingly,  MTH1  depletion  was  reported  to  lead  to  premature-senescence 
with  elevation  of  p21
cip1,  p53  and  p16
INK4A  (Rai  et  al.,  2009).  Although  the 
identification  of  both  these  proteins  are  not  intuitive  based  on  conventional  PcG 
literature,  recent  studies  have  reported  mitochondria-  and  ROS-related  genes  to  be 
regulated  by  PcG  and  that  Bmi1
-/-
  mice  have  impaired  mitochondrial  function  and 
elevated levels of intracellular ROS, suggesting that PRC1 could be involved in the 
regulation of mitochondrial function and ROS generation (Bracken et al., 2006; Liu et 
al., 2009). 
Although heat shock proteins (HSPs) are commonly regarded as contaminents in 
protein purification (Trinkle-Mulcahy et al., 2008), the identification of several HSPs in 
the  HPH2  purifications  may  be  connected  to  a  number  reported  findings.  Firstly, 
HSP70, was previously identified as a component of PRC1 (Levine et al., 2002; Saurin 
et al., 2001). Furthermore, PcG might also be involved in the regulation of HSP70, as in 
Drosophila  Pho  was  shown  to  be  required  for  transcriptional  repression  of  Hsp70 
following heat shock (Beisel et al., 2007). In addition to HSP70, heat shock cognate 4 
(Hsc4) has shown a genetic interaction with PcG genes and Hsc4 stably associates with 
polyhomeotic in Drosophila (Mollaaghababa et al., 2001; Wang and Brock, 2003). Also 
known interacting proteins of polyhomeotic are associated with HSPs; MK2 was found 
to phosphorylate stress-dependent small HSPs (Vertii et al, 2006). 
In  summary,  the  purification  of  HPH2  has  provided  insight  into  possible 
preferential PRC1 interactions and a number of putative novel interactions. There is a 
prominence of proteins involved in RNA processing, which could directly be connected 
to the RNA binding capacity of HPH2. Furthermore, the possible connection of HPH2 
to linker histones, basal transcription factors and mitochondrial function would suggest 
novel additional roles for the protein.   146 
HPH2 interactions with RNA 
 
As  discussed  in  Chapter  4,  the  RNA  binding  domain  of  HPH  proteins  is  highly 
conserved  and  is  thought  to  mediate  the  interaction  between  the  HPH  and  CBX 
families. Several studies have implicated non-coding RNA (ncRNA) in the regulation of 
the PcG target genes (Khalil et al., 2009; Pandey et al., 2008; Rinn et al., 2007; Zhao et 
al., 2008). It was therefore investigated whether ncRNA is involved in the repression of 
INK4A and whether this would involve the RNA binding properties of HPH2. 
 
6.2.1  Profiling  of  antisense  transcription  along  the  INK4B-ARF-INK4A 
locus 
 
Several antisense ncRNAs have been identified to originate from or read through the 
INK4B-ARF-INK4A locus (Gonzalez et al., 2008; Guttman et al., 2009; Yu et al., 2008), 
but little is known about their likely structure or regulation. Since a comprehensive 
assessment of INK4B-ARF-INK4A non-coding transcripts was lacking, a low-resolution 
profile was made of sense and antisense transcription of the INK4B-ARF-INK4A locus 
using  a  ‘sense/antisense  specific  RT-qPCR’  method  (Figure  6.4).  The  previously 
mentioned INK4B-ARF-INK4A genomic primer sets, providing coverage of the locus at 
low  resolution,  were  employed.  By  performing reverse  transcription  (RT)  using  the 
forward primer of one of these primer pairs, any RNA transcript antisense with respect 
to the locus is specifically reverse transcribed from total RNA. Conversely, using the 
reverse primer of a pair in the RT reaction, any transcript sense with respect to the locus 
is reverse transcribed. The resulting cDNA was then purified on a PCR purification 
column (Qiagen) to ensure no carry-over of RNA and RT reaction components. In the 
next step the cDNA is amplified by qPCR using both the forward and the reverse primer 
(one of which was originally used for the RT reaction). Using qPCR to amplify the 
series of RT reactions corresponding to the different target regions along the INK4/ARF 
locus, a relative expression pattern across the locus is produced. Differences in primer 
amplification  efficiency  were  accounted  for  by  normalisation  to  the  signal  from 
amplification of genomic DNA.  
This procedure was performed to map sense- and antisense transcripts of the 
INK4B-ARF-INK4A locus with total RNA from Hs68 and IMR90 (female fetal lung)   147 
HDFs.  Both  cell  types  produced  a  very  similar  profile.  High  levels  of  sense 
transcription could be found at the promoter of INK4A and smaller peaks were observed 
along the rest of the gene. A relative abundance of antisense transcription relative to the 
promoter and exon 1 region of INK4A was found (Figure 6.5). Interestingly, these peaks 
overlap with the enrichment of PcG proteins on the locus (as demonstrated in Figure 
5.2). 
 
6.2.2  HPH2 binds transcripts antisense to the INK4A promoter 
 
As the antisense transcription and binding of the PRC1 proteins appear to co-localise, 
the  possible  RNA  binding  to  PRC1  was  studied.  For  this  purpose,  RNA  chromatin 
immunoprecipitation (RNA ChIP) was employed. Since the HPH and CBX proteins are 
the candidate RNA binding proteins in the PRC1 complex and antibodies for CBX7 and 
HPH2 were available, these 2 proteins were specifically evaluated. Briefly, the RNA 
ChIP  technique  employs  the  same  principles  as  conventional  ChIP,  but  focus  is  on 
ensuring  the  stability  and  recovery  of  RNA  molecules  rather  than  DNA  molecules 
throughout  the  procedure.  Since  the  protocol  involves  a  formaldehyde  cross-linking 
step, the possible contamination of genomic DNA was minimised by two independent 
RNase-free  DNase  treatments.  In  addition,  RT  control  reactions,  lacking  the  RT 
enzyme, were performed for each sample, and consistently did not render any detectable 
amplifications  in  qPCR  analysis.  Following  precipitation  of  the  RNA,  it  was 
investigated  whether  any  antisense  RNA  transcripts  corresponding  to  the  INK4A 
promoter region (primer set 6) could be amplified. This was based on the overlap of 
HPH2 or CBX7 binding and the high level of transcription at this site. In contrast to 
CBX7, HPH2 was found to reproducibly co-purify RNA transcripts antisense to the 
INK4A  promoter  (Figure  6.6).  Due  to  the  low  yield  of  RNA  obtained  from  this 
procedure, the binding at other locations could not be examined. 
Following the observation that HPH2 interacts with RNA antisense to the INK4A 
promoter, it was questioned whether mutation of the RNA binding capacity of HPH2 
affects the induction of INK4A following HPH2 overexpression. To this end, mutants of 
the conserved cysteine residues of the FCS domain, cysteine 1 and 2 (C1C2) or all 4 
cysteines  (C1-4)  were  constructed  as  previously  characterised  (Zhang  et  al.,  2004) 
(kindly  provided  by  Marc  Rodriguez-Niedenführ).  These  mutants  were  then 
overexpressed in Hs68 alongside wildtype HPH2. Evaluation of INK4A induction by   148 
qPCR  demonstrates  that  the  induction  of  INK4A  expression  was  not  found  to  be 
affected by the loss of RNA binding capacity of HPH2 (Figure 6.7). Furthermore, no 
differential effect on proliferation was observed for these mutants in comparison to 
wildtype (empirical observations). At this stage, the experiment was only conducted 
once  and  therefore  no  conclusions  can  be  drawn  based  on  these  initial  findings. 
However, this data would  suggest that RNA binding is not required for the, as yet 
uncharacterised,  mechanism  of  INK4A  induction  by  ectopic  expression  HPH2. 
Therefore,  the  question  remains  open  on  what  the  mechanistic  importance  of  the 
interaction between HPH2 and INK4A antisense transcripts is. 
 
6.3  Discussion 
 
As the polyhomeotic component remains the most elusive of the PRC1 complex, it was 
aimed that investigation of the properties of HPH2, preferably in the direct context of 
INK4A repression, would shed more light on HPH functions in regulating a particular 
target gene. 
Purification of HPH2 from 293T cells has provided a general list of putative 
interactions that might eventually contribute to the mechanism of INK4A repression. 
This  set  of  interacting  proteins  strongly  suggests  a  connection  to  the  RNA  binding 
function  of  the  FCS  domain  of  HPH2  and  it  will  be  of  much  interest  to  further 
understand any underlying mechanisms. In addition, the putative interactions between 
HPH2 and the SF3B subunits, as well as YLPM1/ZAP3, provide a hypothesis on how 
HPH2 and other PcG proteins may be involved in the regulation of splicing. The SF3B 
complex is an important component of the splicosome. SF3B subunit 4 reproducibly co-
purified with HPH2, whereas SF3B subunit 2 co-purified with HPH2 once. In addition, 
the interaction between PRC1 proteins and SF3B subunit 1 has previously been reported 
(Isono  et  al.,  2005b). ZAP3,  a  co-factor  of  PP1,  also  reproducibly  co-purified  with 
HPH2 (Ulke-Lemee et al., 2007). ZAP3 has been reported to interact with hnRNP G, 
which co-purified once with HPH2 (Ulke-Lemee et al., 2007). Furthermore, NIPP1 has 
been reported to interact with PRC2 (Roy et al., 2007), whereas the PRC2-associated 
protein NURF55 was co-purified once with HPH2 as well. Altogether these published 
and novel findings can be structured as displayed in Figure 6.1. 
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Figure 6.1 Putative hypothesis for the regulation of splicing in the context of PcG 
complexes 
NIPP1-mediated dephosphorylation by PP1 of SF3B subunit 1 (Tanuma et al., 2008) 
may occur in the context of PRC1 and PRC2 proteins based on previously reported 
findings and the data presented in this work. An unfilled shape represents a protein not 
co-purified with HPH2, a shape with shaded fill indicates a protein co-purified with 
HPH2 once, and a filled shape indicates a protein co-purified twice with HPH2.  
 
Although the novel interactions identified by tandem affinity purification have 
interesting  implications,  a  number  of  known  HPH2-interacting  proteins  were  not 
identified  through  this  approach.  Examples  of  these  include  MK2/3,  SP1  and 
ATM/ATR. Nevertheless, these interactions have either been found in vitro and/or are 
likely to be of a transient nature and may therefore not have sustained throughout the 
purification procedure. Additionally, it is important to consider the artefacts that may 
have arisen from the supraphysiological levels of HPH2. Stably transfected 293T cells 
with a more modest level of expression would have been preferred in this regard, but 
would have further compromised the yield of the purification. 
Furthermore,  investigation  of  RNA  binding  and  transcription  sense  and 
antisense to the INK4B-ARF-INK4B locus has led to several interesting observations. 
First of all it was found that there is clearly a strong level of transcripts antisense to the   150 
INK4A promoter and exon 1 region, which is not affected at senescence when the locus 
is strongly expressed. It is furthermore striking that these transcripts correspond to the 
peaks of PRC1 protein binding, which would suggest that the two events might be 
linked.  The  fact  that  HPH2,  but  not  CBX7,  was  found  to  co-immunoprecipitate 
transcripts antisense to the INK4A promoter is therefore compelling and needs to be 
further investigated in order to define a possible mechanism. 
  Given  the  time  restraint  to  complete  this  work,  only  the  surface  of  HPH 
functionality in the context of INK4A regulation has been scratched. It will be important 
to dissect the role that the identified interactions have in the regulation of INK4A and 
possibly extend this to the known related mechanisms, especially with respect to RNA 
processing.  As  it  is  becoming  increasingly  evident  that  RNA  is  linked  to  PcG 
repression,  it  will  be  important  to  understand  the  nature  of  antisense  (and  sense) 
transcripts that match to INK4A and understand their role, origin and regulation. As it 
appears that transcripts of RNA detected are of a relatively short length, it is difficult to 
target them by RNA interference without disturbing the coding transcripts originating 
from the locus. Therefore, the aim should be to characterise these transcripts by full 
transcriptome sequencing and consequently be able to ectopically express the transcripts 
to determine the effect on INK4A repression.   151 
Figure 6.2 Evaluation of HPH2 Tandem Affinity Purification 
A)  DU-145  cells  were  transiently  transfected  with  pcDNA3  encoding  Cbx7-TAP, 
HPH2b-TAP or TAP alone. The cells were lysed in NP40 lysis buffer and a small scale 
TAP purification was carried out as described in section 2.4.6. The purified proteins 
samples were fractionated by SDS-PAGE and the gel was stained using SilverQuest 
Silver Staining kit (Invitrogen). Similar results were obtained using 293T cells (data not 
shown). 
B)  293T  were  transiently  transfected  with  pcDNA6  encoding  TAP-HPH2a,  TAP- 
HPH2b or TAP alone. Purification was performed as described in A).  
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Figure 6.3. Identifcation of HPH2a interacting proteins 
Large scale tandem affinity purification was carried out two consecutive times using 
50ml of 293T cells stably expressing HPH2a with an N-terminal TAP-tag. The resulting 
proteins  were  fractionated  by  SDS  PAGE  on  a  Novex®  4-20%  Tris-Glycine  gel 
(Invitrogen) and stained with SYPRO ruby (first purification) or Coomassie Briliiant 
Blue (Sigma) (second purification). Visible bands were excised for analysis by mass 
spectrometry. Reproducibly identified proteins not suspected to be likely contaminants 
are indicated by name, with PRC1 proteins in red and CBP-HPH2a in bold. 
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Identified Proteins  MW  P1  Prob1  P2  Prob2 
Polyhomeotic-like protein 2 - Homo sapiens (Human)  91 kDa  14  100%  6  100% 
E3 ubiquitin-protein ligase RING2 - Homo sapiens (Human)  38 kDa  13  100%  1  95% 
Histone H1.2 - Homo sapiens (Human)  21 kDa  6  100%  2  91% 
Chromobox protein homolog 8 - Homo sapiens (Human)  43 kDa  5  100%  5  100% 
Nucleolar protein 6 - Homo sapiens (Human)  128 kDa  5  100%  5  100% 
YLP motif-containing protein 1 - Homo sapiens (Human)  220 kDa  4  100%  1  75% 
RNA-binding protein 14 - Homo sapiens (Human)  69 kDa  3  85%  3  99% 
Thyroid hormone receptor-associated protein 3 - Homo sapiens (Human)  109 kDa  3  80%  2  98% 
Chromobox protein homolog 2 - Homo sapiens (Human)  56 kDa  2  92%  3  100% 
Polycomb complex protein BMI-1 - Homo sapiens (Human)  37 kDa  2  100%  1  94% 
U3 small nucleolar RNA-associated protein 14 homolog A - Homo sapiens 
(Human)  88 kDa  1  53%  3  100% 
7,8-dihydro-8-oxoguanine triphosphatase - Homo sapiens (Human)  23 kDa  1  87%  1  90% 
Splicing factor 3B subunit 4 - Homo sapiens (Human)  44 kDa  1  84%  1  100% 
Heat shock 70 kDa protein 1 - Homo sapiens (Human)  70 kDa  12  100%  3  100% 
Heterogeneous nuclear ribonucleoprotein M - Homo sapiens (Human)  78 kDa  10  100%  2  100% 
Heat shock cognate 71 kDa protein - Homo sapiens (Human)  71 kDa  9  100%  7  100% 
Heterogeneous nuclear ribonucleoprotein U - Homo sapiens (Human)  91 kDa  9  100%  5  100% 
Matrin-3 - Homo sapiens (Human)  95 kDa  6  89%  2  95% 
Probable ATP-dependent RNA helicase DDX41 - Homo sapiens (Human)  70 kDa  5  100%  2  94% 
Stomatin-like protein 2 - Homo sapiens (Human)  39 kDa  4  100%  1  95% 
60S ribosomal protein L23a - Homo sapiens (Human)  18 kDa  4  100%  1  91% 
Electron transfer flavoprotein subunit beta - Homo sapiens (Human)  28 kDa  2  99%  3  100% 
60S ribosomal protein L22 - Homo sapiens (Human)  15 kDa  2  100%  2  97% 
60S ribosomal protein L11 - Homo sapiens (Human)  20 kDa  2  99%  1  77% 
60S ribosomal protein L13 - Homo sapiens (Human)  24 kDa  2  97%  1  93% 
40S ribosomal protein S19 - Homo sapiens (Human)  16 kDa  1  49%  2  85% 
60S ribosomal protein L27a - Homo sapiens (Human)  17 kDa  1  96%  2  92% 
40S ribosomal protein S8 - Homo sapiens (Human)  24 kDa  1  91%  1  87% 
40S ribosomal protein S23 - Homo sapiens (Human)  16 kDa  1  94%  1  91% 
ATP synthase subunit O, mitochondrial precursor - Homo sapiens (Human)  23 kDa  1  97%  1  91% 
60S ribosomal protein L24 - Homo sapiens (Human)  18 kDa  1  88%  1  92% 
Keratin, type I cytoskeletal 10 - Homo sapiens (Human)  60 kDa  10  100%  7  100% 
Keratin, type I cytoskeletal 9 - Homo sapiens (Human)  62 kDa  7  100%  5  100% 
Alpha-S2-casein precursor [Contains: Casocidin-1 - Bos taurus (Bovine)  26 kDa  5  100%  2  98% 
Ig gamma-2 chain C region - Homo sapiens (Human)  36 kDa  3  99%  1  95% 
Ig alpha-1 chain C region - Homo sapiens (Human)  38 kDa  1  64%  5  100% 
Immunoblobulin light chain - Homo sapiens (Human)  24 kDa  1  100%  2  100% 
Calcium/calmodulin-dependent  protein  kinase  type  II  delta  chain  -  Homo 
sapiens (Human)  56 kDa  1  91%  1  94% 
Serum albumin precursor - Bos taurus (Bovine)  69 kDa  1  89%  1  70% 
 
Table 9 Reproducible identifications of proteins co-purifying with TAP-HPH2a 
This  table  includes  LC/MS/MS  identifications  that  were  obtained  from  both  TAP-
HPH2a purifications (P1 and P2) conducted. The identifications were categorised as 
putative  specific  interaction  (no  highlighting),  possible  sepharose  contaminant  (light 
yellow highlighting) or contaminant (yellow highlighting), and sorted by purification   154 
and number of identified peptides. In addition, the probabilities of correct identification 
are indicated per purification. Proteins in blue font indicate manual identification.   155 
 
Identified Proteins  MW  P1  P2 
E3 ubiquitin-protein ligase UBR5 - Homo sapiens (Human)  309 kDa  13    
Transferrin receptor - Homo sapiens (Human)  85 kDa  5    
Histone H2A - Nematostella vectensis (Starlet sea anemone)  20 kDa  4    
RNA binding motif protein 28 - Homo sapiens (Human)  86 kDa  4    
Dedicator of cytokinesis protein 7 - Homo sapiens (Human)  243 kDa  3    
Spectrin beta chain, brain 1 - Homo sapiens (Human)  275 kDa  3    
Uncharacterized protein C17orf85 - Homo sapiens (Human)  71 kDa  3    
ADP-ribosylation factor-like protein 6-interacting protein 4 - Homo sapiens (Human)  38 kDa  2    
Carboxypeptidase, vitellogenic-like - Homo sapiens (Human)  54 kDa  2    
E3 ubiquitin-protein ligase RING1 - Homo sapiens (Human)  42 kDa  2    
Heterochromatin protein 1-binding protein 3 - Homo sapiens (Human)  61 kDa  2    
NF-kappa-B-activating protein - Homo sapiens (Human)  47 kDa  2    
Pyruvate dehydrogenase - Homo sapiens (Human)  43 kDa  2    
RRP7A ribosomal RNA processing 7 homolog A - Homo sapiens (Human)  32 kDa  2    
Spectrin alpha chain, brain - Homo sapiens (Human)  285 kDa  2    
Spectrin beta chain, brain 2 - Homo sapiens (Human)  271 kDa  2    
60 kDa SS-A/Ro ribonucleoprotein - Homo sapiens (Human)  61 kDa  1    
Caspase 14 - Homo sapiens (Human)  28 kDa  1    
CDW4/GRWD1 - Homo sapiens (Human)  49 kDa  1    
Cell division protein kinase 10 - Homo sapiens (Human)  41 kDa  1    
CIR protein - Homo sapiens (Human)  50 kDa  1    
Coiled-coil-helix-coiled-coil-helix domain-containing protein 1 - Homo sapiens (Human)  13 kDa  1    
Cyclin-related protein FAM58A - Homo sapiens (Human)  28 kDa  1    
Far upstream element-binding protein 2 - Homo sapiens (Human)  73 kDa  1    
F-box only protein 22 - Homo sapiens (Human)  45 kDa  1    
Histone-binding protein RBBP4 - Homo sapiens (Human)  48 kDa  1    
Lipocalin-1 precursor - Homo sapiens (Human)  19 kDa  1    
Neuroguidin - Homo sapiens (Human)  36 kDa  1    
Nuclear protein NP60 - Homo sapiens (Human)  61 kDa  1    
Nuclease-sensitive element-binding protein 1 - Homo sapiens (Human)  36 kDa  1    
Nucleolar protein 10 - Homo sapiens (Human)  80 kDa  1    
P40 - Homo sapiens (Human)  40 kDa  1    
Pinin - Homo sapiens (Human)  82 kDa  1    
Probable rRNA-processing protein EBP2 - Homo sapiens (Human)  35 kDa  1    
Probable UPF0334 kinase-like protein C1orf57 - Homo sapiens (Human)  21 kDa  1    
Protein FAM133A - Homo sapiens (Human)  29 kDa  1    
Protein phosphatase from PCR H32 protein - Homo sapiens (Human)  3 kDa  1    
Protein S100-A8 - Homo sapiens (Human)  11 kDa  1    
Pumilio domain-containing protein KIAA0020 - Homo sapiens (Human)  74 kDa  1    
Putative helicase MOV-10 - Homo sapiens (Human)  114 kDa  1    
RPS9 protein - Homo sapiens (Human)  13 kDa  1    
SAFB2 protein - Homo sapiens (Human)  57 kDa  1    
Serine/arginine repetitive matrix 2 - Homo sapiens (Human)  191 kDa  1    
SMAD family member 9 - Homo sapiens (Human)  49 kDa  1    
TCOF1 protein - Homo sapiens (Human)  144 kDa  1    
Tetratricopeptide repeat protein 14 - Homo sapiens (Human)  88 kDa  1    
Transferrin - Homo sapiens (Human)  77 kDa  1    
Transformer-2 protein homolog - Homo sapiens (Human)  33 kDa  1    
U3 small nucleolar ribonucleoprotein protein IMP3 - Homo sapiens (Human)  22 kDa  1    
Uncharacterized protein C21orf70 - Homo sapiens (Human)  25 kDa  1      156 
Zinc finger protein 346 - Homo sapiens (Human)  33 kDa  1    
Splicing factor 3B subunit 2 - Homo sapiens (Human)  98 kDa     4 
Polymerase delta-interacting protein 3 - Homo sapiens (Human)  46 kDa     3 
Transcription elongation factor A protein-like 4 - Homo sapiens (Human)  25 kDa     2 
DIS3 - Homo sapiens (Human)  109 kDa     2 
Multiple myeloma tumor-associated protein 2 - Homo sapiens (Human)  29 kDa     1 
Probable serine carboxypeptidase CPVL precursor - Homo sapiens (Human)  54 kDa     1 
Numb-like protein - Homo sapiens (Human)  65 kDa     1 
SNW domain-containing protein 1 - Homo sapiens (Human)  61 kDa     1 
UPF0399 protein C6orf153 - Homo sapiens (Human)  30 kDa     1 
Peroxisome biogenesis factor 1 - Homo sapiens (Human)  143 kDa     1 
Centrosomal protein of 170 kDa - Homo sapiens (Human)  175 kDa     1 
Putative splicing factor, arginine/serine-rich 14 - Homo sapiens (Human)  120 kDa     1 
Mitochondrial fission regulator 1 - Homo sapiens (Human)  37 kDa     1 
Liprin-beta-1 - Homo sapiens (Human)  114 kDa     1 
MAP7 domain-containing protein 3 - Homo sapiens (Human)  98 kDa     1 
Tubulin, beta polypeptide - Homo sapiens (Human)  48 kDa  8    
Matrin 3 - Homo Sapiens (Human)  100 kDa  6    
Heterogeneous nuclear ribonucleoproteins C1/C2 - Homo sapiens (Human)  34 kDa  5    
40S ribosomal protein S4, X isoform - Homo sapiens (Human)  30 kDa  5    
Heterogeneous nuclear ribonucleoproteins A2/B1 - Homo sapiens (Human)  37 kDa  4    
Nucleolar RNA helicase 2 - Homo sapiens (Human)  87 kDa  4    
Probable ATP-dependent RNA helicase DDX5 - Homo sapiens (Human)  69 kDa  4    
Protein-L-isoaspartate(D-aspartate) O-methyltransferase - Homo sapiens (Human)  25 kDa  4    
Tubulin alpha-1B chain - Homo sapiens (Human)  50 kDa  4    
Vimentin - Homo sapiens (Human)  54 kDa  4    
Ribosomal protein S3A - Homo sapiens (Human)  30 kDa  4    
RPL14 protein - Homo sapiens (Human)  24 kDa  4    
ATP synthase subunit O, mitochondrial precursor - Homo sapiens (Human)  23 kDa  3    
DEAH - Homo sapiens (Human)  141 kDa  3    
Peroxiredoxin-1 - Homo sapiens (Human)  22 kDa  3    
40S ribosomal protein S25 - Homo sapiens (Human)  14 kDa  3    
60S acidic ribosomal protein P0 - Homo sapiens (Human)  34 kDa  3    
60S ribosomal protein L26 - Homo sapiens (Human)  17 kDa  3    
60S ribosomal protein L4 - Homo sapiens (Human)  48 kDa  3    
Ribosomal protein L18 - Homo sapiens (Human)  19 kDa  3    
Ribosomal protein L7a - Homo sapiens (Human)  22 kDa  3    
Heterogeneous nuclear ribonucleoprotein AB isoform a variant - Homo sapiens (Human)  36 kDa  2    
Heterogeneous nuclear ribonucleoprotein K - Homo sapiens (Human)  51 kDa  2    
Myosin light chain kinase 2, skeletal/cardiac muscle - Homo sapiens (Human)  65 kDa  2    
Probable ATP-dependent RNA helicase DDX27 - Homo sapiens (Human)  90 kDa  2    
DnaJ - Homo sapiens (Human)  254 kDa  2    
Heat shock 70kDa protein 9B - Homo sapiens (Human)  74 kDa  2    
Heat shock protein HSP 90-beta - Homo sapiens (Human)  83 kDa  2    
28S ribosomal protein S31, mitochondrial precursor - Homo sapiens (Human)  45 kDa  2    
40S ribosomal protein S11 - Homo sapiens (Human)  18 kDa  2    
40S ribosomal protein S14 - Homo sapiens (Human)  16 kDa  2    
40S ribosomal protein S18 - Homo sapiens (Human)  18 kDa  2    
40S ribosomal protein S20 - Homo sapiens (Human)  13 kDa  2    
60S ribosomal protein L38 - Homo sapiens (Human)  8 kDa  2    
Ribosomal protein L12 variant - Homo sapiens (Human)  21 kDa  2    
RPL3 protein - Homo sapiens (Human)  34 kDa  2      157 
Small nuclear ribonucleoprotein Sm D3 - Homo sapiens (Human)  14 kDa  1    
Actin, alpha skeletal muscle - Homo sapiens (Human)  42 kDa  1    
ELAV-like protein 1 - Homo sapiens (Human)  36 kDa  1    
Elongation factor 1-alpha 2 - Homo sapiens (Human)  50 kDa  1    
Heterogeneous nuclear ribonucleoprotein A1 - Homo sapiens (Human)  39 kDa  1    
Heterogeneous nuclear ribonucleoprotein U-like protein 2 – Homo sapiens (Human)  85 kDa  1    
MCM7 minichromosome maintenance deficient 7 - Homo sapiens (Human)  81 kDa  1    
RNA-binding motif protein, X-linked-like-2 - Homo sapiens (Human)  43 kDa  1    
Small nuclear ribonucleoprotein Sm D3 - Homo sapiens (Human)  14 kDa  1    
Thioredoxin - Homo sapiens (Human)  9 kDa  1    
Short heat shock protein 60 Hsp60s2 - Homo sapiens (Human)  27 kDa  1    
40S ribosomal protein S10 - Homo sapiens (Human)  19 kDa  1    
40S ribosomal protein S17 - Homo sapiens (Human)  16 kDa  1    
40S ribosomal protein S2 - Homo sapiens (Human)  31 kDa  1    
40S ribosomal protein S6 - Homo sapiens (Human)  29 kDa  1    
60S acidic ribosomal protein P2 - Homo sapiens (Human)  12 kDa  1    
60S ribosomal protein L10 - Homo sapiens (Human)  25 kDa  1    
60S ribosomal protein L19 - Homo sapiens (Human)  23 kDa  1    
60S ribosomal protein L29 - Homo sapiens (Human)  18 kDa  1    
60S ribosomal protein L30 - Homo sapiens (Human)  13 kDa  1    
60S ribosomal protein L31 - Homo sapiens (Human)  14 kDa  1    
60S ribosomal protein L7 - Homo sapiens (Human)  29 kDa  1    
Peroxiredoxin 6 - Homo sapiens (Human)  9 kDa  1    
Ribosomal protein S19 binding protein 1 - Homo sapiens (Human)  15 kDa  1    
Stress-70 protein, mitochondrial precursor - Homo sapiens (Human)  74 kDa     4 
Tubulin beta chain - Homo sapiens (Human)  50 kDa     3 
60S ribosomal protein L3 - Homo sapiens (Human)  46 kDa     2 
HEJ1 - Homo sapiens (Human)  7 kDa     1 
LIM domain and actin-binding protein 1 - Homo sapiens (Human)  85 kDa     1 
Immunoblobulin G1 Fab heavy chain variable region - Homo sapiens (Human)  25 kDa     1 
60S ribosomal protein L12 - Homo sapiens (Human)  18 kDa     1 
40S ribosomal protein S19-binding protein 1 - Homo sapiens (Human)  15 kDa     1 
28S ribosomal protein S7, mitochondrial precursor - Homo sapiens (Human)  28 kDa     1 
Keratin 1 - Pan troglodytes verus  65 kDa  14    
Alpha-S1-casein precursor [Contains: Antioxidant peptide] - Bos taurus (Bovine)  25 kDa  5    
IGHG1 protein - Homo sapiens (Human)  51 kDa  5    
Keratin, type II cytoskeletal 2 epidermal - Homo sapiens (Human)  66 kDa  5    
Genome polyprotein [Contains: P1 proteinase - Tobacco etch virus (TEV)  346 kDa  4    
Immunoglobulin lambda protein - Homo sapiens (Human)  25 kDa  4    
Hair acidic keratin 1 - Capra hircus (Goat)  47 kDa  3    
Poly(rC)-binding protein 1 - Bos taurus (Bovine)  37 kDa  2    
Ig kappa chain V-I region EU - Homo sapiens (Human)  13 kDa  2    
KRT5 protein - Bos taurus (Bovine)  63 kDa  2    
Lysozyme C precursor - Gallus gallus (Chicken)  16 kDa  2    
MGC139925 protein - Bos taurus (Bovine)  54 kDa  2    
LOC733345 protein - Xenopus laevis (African clawed frog)  27 kDa  1    
Lysozyme C precursor - Homo sapiens (Human)  17 kDa  1    
Putative ATP-dependent RNA helicase DHX30 - Bos taurus (Bovine)  136 kDa  1    
RPS4Y1 - Pongo pygmaeus (Bornean orangutan)  2 kDa  1    
Beta-casein - Capra hircus (Goat)  21 kDa  1    
Keratin associated protein 11-1 - Homo sapiens (Human)  17 kDa  1    
Serum albumin precursor - Bos taurus (Bovine)  69 kDa  1      158 
Keratin, type II cytoskeletal 1 - Homo sapiens (Human)  66 kDa     7 
Beta-lactoglobulin precursor - Bos taurus (Bovine)  20 kDa     1 
Trypsinogen 10 - Mus musculus (Mouse)  26 kDa     1 
Ig lambda chain C regions - Homo sapiens (Human)  11 kDa     1 
Calmodulin - Homo sapiens (Human)  17 kDa     1 
 
Table 10 Single identifications of proteins co-purifying with TAP-HPH2a 
This list includes LC/MS/MS identifications that were obtained from only one of the 
two  TAP-HPH2a  purifications  (P1  and  P2)  conducted.  The  identifications  were 
categorised  as  putative  specific  interaction  (no  highlighting),  possible  sepharose 
contaminent  (light  yellow  highlighting)  or  contaminent  (yellow  highlighting),  and 
sorted by purification and number of identified peptides. Proteins in blue font indicate 
manual identification.   159 
Figure 6.4 Sense/antisense-specific RT-qPCR Methodology 
For a given primer pair that is used to specifically amplify genomic DNA, such as the 
INK4A promoter, the individual primers also provide complementary binding to the 
transcripts sense or antisense to this region (step 1). Therefore such such an individual 
primer  can  be  used  to  specifically  reverse  transcribe  the  transcripts  either  sense  or 
antisense to this region (step 2). Consequently the cDNA is purified and now both 
primers of the pair are used to amplify the cDNA in a qPCR reaction (step 3). 
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Figure 6.5 Profile of INK4B-ARF-INK4A sense and antisense transcription 
A)  Sense  and  antisense-specific  RT  reactions  were  performed  with  specific  primers 
along the locus and using 0.125µg of total RNA from IMR-90 (PD18) (as described in 
section 2.5.4). cDNA was purified and interrogated by qPCR with the matching forward 
and reverse primer set. Resulting amplification Ct values were normalised for relative 
primer efficiency and divided by a constant c=0.05 to provided simplified comparison 
and plotted. 
B) Sense and antisense-specific RT-qPCR as described under A) using 0.100µg of total 
RNA from mid-lifespan Hs68 cells. 
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Figure 6.6. HPH2 co-immunoprecipitates RNA transcripts antisense to the INK4A 
promoter region 
RNA ChIP was performed with unspecific IgG (Abcam), CBX7 (Abcam) and HPH2 
(1615)  (as  described  in  section  2.5.5).  Purified  RNA  was  reverse  transcribed  using 
primer  6-F  and  PCR  was  performed  using  the  PS6  primer  pair  (described  in  the 
Materials  and  Methods  section).  A  control  RT  reaction  was  performed  for  each IP 
without the reverse transcriptase, but no amplification was observed for these samples 
in qPCR and thus these have not been plotted. Error bars indicate standard deviation 
between unrelated biological replicates, with n=2. 
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Figure 6.7  Mutation of the FCS RNA binding domain of HPH2 does not affect its 
induction of INK4A 
Hs68 cells (PD33) were infected with pBABE pu encoding wildtype HPH2 or the C1C2 
or C1-C4 mutants, or vector control. 5 days following selection cells were harvested 
and RNA was extracted (as described in section 2.5.1). RT-qPCR was performed to 
measure the transcript levels of p16, HPH2 and GAPDH (internal standard). Resulting 
transcript levels were normalised to the pBABE vector control. 
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7  Discussion 
 
This  thesis  set  out  to  define  the  involvement  of  the  HPH  family  proteins  in  the 
repression of INK4A and a number of achievements to this end have been described. 
Firstly,  a  series  of  antibodies  against  human  CBX7  and  the  HPH  proteins  were 
generated  and  evaluated.  Secondly,  it  was  shown  that  contrary  to  the  preliminary 
indications, there is no in vitro evidence for specific interactions between individual 
members of the HPH and CBX families although the possibility remains open for a 
preferential  interaction  between  CBX7  and  HPH2  in  vivo.  Thirdly,  all  three  HPH 
proteins  were  shown  to  be  involved  in  the  repression  of INK4A  in  primary  human 
fibroblasts and for HPH2 (and HPH3, data not shown) it was confirmed that they are 
directly associated with the locus. Curiously, overexpression of HPH2 was found to 
activate expression of INK4A, typically associated with loss of PcG-mediated repression 
by an as yet uncharacterised mechanism. Fourthly, to gain a better understanding of the 
contribution of the HPH family to PcG-mediated repression, the proteins interacting 
with HPH2 were identified by affinity purification and mass spectrometry, revealing a 
large number of proteins implicated in RNA processing. Lastly, HPH2 was shown to 
interact with an RNA antisense to the INK4A promoter. 
 
7.1  Lessons about PRC1 composition 
 
The fact that mammalian cells express multiple paralogues of each of the Drosophila 
PRC1 components presents a considerable challenge as well as a fascinating topic for 
research.  A  comprehensive  study  of  the  individual  core  proteins  would  in  principle 
require a minimum of 16 antibodies, notwithstanding possible splice variants and post-
translational modifications, and obtaining suitable reagents for immunodetection and 
chromatin immunoprecipitations continues to be a major obstacle for progress in the 
field. Difficulties in expressing the recombinant proteins and cross-reactivity against 
conserved domains, as discussed in Chapter 3, add to this challenge.  
In considering why there are so many PcG paralogues in mammalian cells, a 
central question is whether there are any preferential interactions between individual 
members of each family. In the literature, the PRC1 complex is often described as a 
single entity. Purifications of PRC1 complexes rather have provided mixed messages   164 
about stoichiometry and composition. Parallel work in our laboratory has demonstrated 
convincingly  that  each  PRC1  complex  in  human  cells  interacts  with  only  a  single 
representative  of  the  Pc,  Psc,  Ph  or  Sce  families  (Maertens  et  al.,  2009).  The 
characterization of HPH2 interactions described in Chapter 6 supports this contention in 
that there was no evidence for co-purification of HPH1 or HPH3. It is nevertheless clear 
that all three HPH proteins can be co-purified with BMI1, MEL18 and CBX8 (Dietrich 
et al., 2007; Maertens et al., 2009) and that CBX2 and CBX8, and both RING proteins 
co-purify with HPH2. This argues against specificity between particular members of the 
PRC1 subfamilies and in direct comparisons, all five human Pc proteins were shown to 
interact with HPH2 when transiently co-expressed (Chapter 4). Although the data by no 
means  exclude  the  possibility  of  preferential  associations in  vivo,  perhaps  based  on 
relative expression levels in different cell types, collectively they suggest that there are 
multiple permutations of PRC1 complexes. 
Based on their common ancestry, it might be expected that the several paralogues 
of each PRC1 core component have the same or similar functions. This could mean that 
depending on their relative abundance, they are used interchangeably in the assembly of 
a functional PRC1 complex without any particular logic. However, a number of reports 
ascribe specific functions to particular PRC1 proteins or implicate these proteins in 
unique mechanisms that most likely cannot be generalised. Examples of such unqiue 
mechanisms  include  the  SUMO  E3  ligase  activity  of  CBX4  or  unique  putative 
ATM/ATR phosphorylation sites in HPH2 and  HPH3. While it seems unlikely that 
every homologue provides unique functionality or levels of regulation, differences in 
the expression of PcG proteins in different cell types may be explained by some degree 
of functional diversity tailored to specific needs. 
Another way to rationalise the multiplicity of PRC1 complexes would be if they 
had preferred target genes, perhaps dictated by specific elements that are not part of the 
core PRC1 complex. However, one of the more remarkable findings in this work was 
that all three human HPH proteins appear to contribute to the regulation of the INK4a 
gene  in  human  fibroblasts,  as  judged  by  shRNA-mediated  knockdown.  Recently 
published work from our laboratory and others (Cales et al., 2008; Dietrich et al., 2007; 
Gil  et  al.,  2005;  Jacobs  et  al.,  1999a;  Maertens  et  al.,  2009)  has  drawn  similar 
conclusions for two Pc orthologues (CBX7 and CBX8), two Psc proteins (BMI1 and 
MEL18)  and  at  least  one  of  the  Sce  proteins  (RING1B).  These  findings  are  also 
supported by genetic ablation of PcG genes in mice, which in several cases has been 
reported to cause derepression of Ink4a/Arf and premature senescence in the derived   165 
MEFs (Cales et al., 2008; Isono et al., 2005a; Jacobs et al., 1999a). It thus appears that 
so far no PRC1 component has been characterised that does definitely not link to the 
regulation of INK4a. 
After  having  argued  that  each  PRC1  complex  comprises  of  only  a  single 
representative from the Pc, Psc, Ph and Sce families, the involvement of HPH1, HPH2 
and HPH3 effectively triples the number of PRC1 complexes that are implicated in the 
regulation  of  INK4a.  In  fact,  these  results  are  the  first  demonstration  that  all 
homologues of a particular PRC1 core component are implicated in the regulation of 
INK4A (if not any PcG target gene). Simplistically, this number of PRC1 complexes 
regulating INK4A currently stands at 12 (2Pc x 2Psc x 3Ph) and if both RING proteins 
are involved it will rise to 24. The rationale is very puzzling and suggests that the 
simple  paradigm  of  a  single  generic  PRC1  complex  binding  to  a  target  gene  is 
untenable.  Importantly,  each  of  the  tested  proteins  shows  the  same  binding  profile 
across the promoter and first exon of INK4A, and ChIP-reChIP analyses with CBX7 and 
CBX8 indicated that they are bound to the same piece of DNA (Maertens et al., 2009), 
although the data does not exclude the possibility of cross-linking between separate 
alleles of INK4A. The generation and validation of ChIP grade antibodies against HPH2 
(and HPH3) as described in this thesis now open up the possibility to do a similar 
assessment of the binding of two different HPH proteins to a single copy of INK4A. 
 
7.2  Interactions between PcG complexes 
 
The fact that depletion of either HPH1, HPH2 or HPH3, or the different Pc and Psc 
homologues, leads to loss of repression of INK4A implies that they are not functionally 
redundant. However, it is difficult to come up with an explanation based on current 
understanding  of  the  mechanism.  One  important  observation  is  that  the  shRNA-
mediated knockdown of CBX7 results in the depletion of both CBX7 and CBX8 at the 
INK4A locus as judged by ChIP, and vice versa (Maertens  et al., 2009). The same 
conclusions apply to the two PSC proteins, BMI1 and MEL18, leading to the idea that 
the PRC1 proteins bind to INK4A as a complex of complexes. In this scenario, very 
much like a ‘house of cards’, loss of one component can lead to the collapse of the 
entire system and it will be interesting to extend the observations to the HPH proteins. 
The  demonstrated  oligomerisation  potential  of  the  HPH  proteins  could  play  a 
fundamental role in the formation of these higher order structures (Kim et al., 2002).   166 
Hence the HPH proteins could present particular weak spots in maintaining the overall 
structure of the complex and this could be further characterised by the effect of recently 
generated SAM oligomerisation mutants in. It thus remains to be determined what the 
structure would be of a PRC1 multicomplex and how polyhomeotic may structurally 
contribute to it. 
Another unknown in the context of PcG-mediated repression is the extent to 
which the PRC1 and PRC2 complexes co-operate. The two complexes are often co-
localised  at  repressed  genes  and  it  has  been  proposed  that  a  transient  interaction  is 
required  for  setting  up  PcG-mediated  repression  (van  Lohuizen  et  al.,  1998).  The 
identification  of  RBBP4/NURF55  as  a  putative  binding  partner  of  HPH2  would  be 
consistent with this idea but needs to be confirmed. Another element that might link the 
two  complexes  is  the  interaction  with  RNA.  As  the  results  in  Chapter  6  provide  a 
preliminary basis for the interaction of HPH2 with RNA antisense to INK4A, the use of 
ncRNAs might be shared by both PRC2 and PRC1 and may add directionality to PcG 
repression. 
 
7.3  The HPH proteins and cell proliferation 
 
Although the complex-of-complexes model serves to fit the discussed observations, it is 
difficult to reconcile with the effects observed upon over-expression of particular PRC1 
components. For example, it is well documented that ectopic expression of Bmi1 and 
Cbx7 can delay replicative senescence in human fibroblasts through the repression of 
INK4A (Bracken et al., 2007; Gil et al., 2004). This fits well with the evidence that both 
Bmi1 and Cbx7 function as oncogenes in transgenic mice (Jacobs et al., 1999b; Scott et 
al., 2007a). Indeed, Bmi1 was initially identified by its ability to collaborate with Myc 
in retrovirally induced lymphomas in mice (Haupt et al., 1991; van Lohuizen et al., 
1991). The oncogenic effects can largely be explained in terms of suppression of mouse 
Ink4a/Arf. Conversely, ablation of Bmi1 leads to loss of proliferative potential due to 
derepression of Ink4a/Arf. A similar line of reasoning would implicate the mouse HPH2 
homologue (Mph2) as a potential oncogene (Isono et al., 2005a). 
The question that arises is whether the  ability of BMI1 or CBX7 to repress 
INK4A  is  dependent  on  HPH2  or  other  HPH  proteins.  The  ‘house  of  cards’  model 
implies that the PRC1 complexes are interdependent but knockdown of HPH2 did not 
prevent mCbx7-mediated repression of INK4a (Chapter 5). This could both imply that   167 
HPH2 is not rate limiting or that its functions can be substituted by HPH1 or HPH3. 
Similarly, it was reported that the ability of mouse Cbx7 to repress mouse Ink4a/Arf 
was not dependent on Bmi1 (Gil et al 2004), again contradicting the model. However, in 
the MEF experiments conducted in this work, Mph2 did appear to be important for 
mCbx7-mediated  effects.  Clearly,  further  work  will  be  required  to  resolve  these 
inconsistencies and the tools for including HPH3 in the analyses are now in place. 
Further work will also be required to address the apparent anachronism that 
over-expression  of  HPH2  activates  rather  than  represses  INK4a.  This  cannot  be 
dismissed as an oddity, as similar findings have been reported for MEL18 ((Guo et al., 
2007a; Guo et al., 2007b; Tetsu et al., 1998)) and with CBX8 (Julie Stock, personal 
communication).  It  is  conceivable  that  the  over-expressed  proteins  are  acting  in  a 
dominant-negative  fashion  by  sequestering  or  titrating  out  a  rate  limiting  factor  or 
activity, but this would have to be a specific mechanism for some, but not all PRC1 
proteins,  as  BMI1  or  CBX7  overexpression  has  a  diametrically  opposite  effect. 
Alternatively,  over-expressed  HPH2  might  be  acting  indirectly  by  suppressing  the 
expression of a protein or several proteins that are essential for repression of INK4a. 
Obvious candidates would be the PcG genes themselves. Also, given the precedents for 
autoregulation of the Drosophila polyhomeotic genes, it is important to consider the 
potential intra-regulation of polyhomeotic genes (Bloyer et al., 2003; Fauvarque et al., 
1995). It has also been reported that CBX4, CBX7, CBX8 and BMI1 may be subject to 
PcG repression (Bracken et al., 2006), and recently our laboratory found through ChIP-
Seq that CBX7 and CBX8 co-localise on the CBX7 promoter. For this to be a tenable 
explanation the extent to which PcG genes are regulated by PRC1 complexes would 
have to be explored in more depth and a distinction would have to be drawn between 
the PcG genes that are subject to feedback regulation and those that are not. 
As well as cross-regulation of PcG genes, the effects of HPH overexpression both 
on INK4A expression and cell proliferation could involve a wide array of other PcG 
target genes. For example, a recent report demonstrated that polyhomeotic has a role in 
mediating  control  of  proliferation  by  regulating  Notch  signalling  in  Drosophila, 
therefore  ascribing  it  a  ‘tumour  suppressor’  role  (Martinez  et  al.,  2009).  A  tumour 
suppressive  function  is  also  supported  by  the  observed  loss  of  expression  of  HPH 
homologues in human cancer (Deshpande et al., 2007; Tokimasa et al., 2001). It will 
therefore be important to study the overexpression of each HPH protein in order to 
better understand their effects. In this context, it might be informative to compare gene   168 
expression profiles in human fibroblasts in which each HPH protein has been either 
knocked down or over-expressed. 
 
7.4  Novel interacting partners for HPH2 
 
Whereas  PC  proteins  have  chromodomains  that  are  implicated  in  binding  to  the 
H3K27me3 mark and the PSC-SCE dimers have RING finger domains that catalyse 
ubiquitination of H2AK119, little is known about the functional contribution of PH to 
the  PRC1  complex.  It  was  hoped  that  the  tandem  affinity  purification  of  HPH2 
complexes would shed light on non-PcG proteins that are recruited by binding to HPH2, 
as  well  as  extract  possible  differences  between  the  HPH2a  and  HPH2b  isoforms. 
Although the preliminary findings looked very promising, it proved difficult to scale up 
the purification to a level that was amenable to mass spectrometry. This prevented a 
proper comparison between HPH2a and HPH2b within the span of this work, but in 
principle,  the  longer  isoform  demonstrated  a  greater  potential  for  identifying  novel 
partners. It is debatable whether efforts should be made to improve the purification 
protocol for improved yield, for example by altering the expression vector or seeking 
transient rather than stable expression, or rather to focus on the validation of the current 
list of candidate proteins. Repeating the purification with the short isoform or one of the 
other HPH proteins has the potential to uncover common interactions shared by all HPH 
proteins and simplify the follow up.   
It will be important to assess whether any of the novel interacting proteins are 
associating with the PRC1 complex.  Previous reports suggest that PRC1 proteins can 
act outside of the context of the classical PRC1 complex, often associated with specific 
functions (reviewed in (Simon and Kingston, 2009)). An example of this is the RING-
associated factor (dRAF) complex in Drosophila or the BCL6 co-repressor (BCOR) 
complex in mammals, which is capable of performing efficient ubiquitylation of H2A 
without the full complement of PRC1 components (Gearhart et al., 2006; Lagarou et al., 
2008).  No  HPH  proteins  were  present  in  these  complexes  and  in  reconstitution 
experiments it has proved possible to generate active complexes without a HPH protein 
(Levine et al., 2002). Such unconventional functionality is not restricted to PRC1, as the 
PRC2 complex was shown to have a distinct cytosolic function in the regulation of actin 
polymerisation  (Su  et  al.,  2005).  These  findings  suggest  that  PcG  complexes  or 
derivatives thereof can be involved in distinct functions.   169 
HPH proteins therefore could also carry out independent of conventional PRC1 
functions.  As  such,  it  was  reported  that  HPH1  is  distinct  from  other  PRC1  core 
components in timing of recruitment to the inactive X-chromosome (Plath et al., 2004). 
Furthermore, apart from known PRC1 proteins, none of the potential HPH2-associated 
proteins identified by mass spectrometry featured in the affinity purified CBX7, BMI1 
and  MEL18  complexes  characterized  previously  in  our  laboratory,  although  these 
complexes did contain HPH2. This opens up the possibility that some of the functions 
attributed  to  HPH2  in  this  thesis  may  reflect  its  participation  in  separate  non-
conventional PRC1 or even independent complexes.  
 
7.4.1  Splicing and RNA binding 
 
The finding that HPH2 is associated with multiple RNA processing proteins, many of 
them involved in splicing, suggests that HPH2 is closely associated with RNA. It is 
becoming increasingly evident that the processes of chromatin regulation, transcription 
and splicing are tightly integrated and there is a clear precedent for the recruitment and 
regulation of splicing factors by chromatin modifiers (reviewed in (Allemand et al., 
2008)). Recent literature suggests that splicing occurs directly at the level of the nascent 
transcripts  and  thereby  mediates  the  production  of  transcript  variants  for  nearly  all 
mammalian genes (Listerman et al., 2006; Pandya-Jones and Black, 2009; Wang et al., 
2008). The involvement of chromatin and its modifiers in this process has recently 
gained further support as it was found that nucleosomes are preferentially localised at 
exonic regions and may play an important role in exon recognition (Schwartz et al., 
2009; Tilgner et al., 2009). This would suggest that processes involved in PcG-mediated 
repression that either modify the nucleosomes or alter their compaction may potentially 
influence the effectiveness of splicing. 
Previous  findings  have  mainly  been  centred  around  a  connection  between 
splicing and the chromatin remodelling activity of SWI/SNF in the context of active 
transcription,  but  a  link  between  PcG-mediated  repression  and  splicing  has  also 
previously been established (Isono et al., 2005b). It will be interesting to define how 
these  opposing  systems  modulate  splicing  and  if  the  PcG  proteins  have  indeed  a 
negative  effect  on  splicing.  The  potentially  negative  involvement  of  HPH2  in  this 
process  could  produce  an  instant  effect  on  the  transcription  of  target  genes  before 
promoter silencing is achieved. Furthermore, alternative splicing is influenced by the   170 
modification of nucleosomes, which can create a barrier for transcriptional elongation 
(de la Mata et al., 2003; Hodges et al., 2009). This would provide a putative mechanism 
for  the  PRC1  complex  to  block  transcriptional  elongation  or  by  preventing  the 
processing  of  primary  transcripts,  and  may  possibly  collaborate  with  the  effects  of 
histone H2A ubiquitination. 
Another possibility would be that HPH2 is closely involved in the processing of 
ncRNAs employed by the PcG system for targeting specific genes (reviewed in (Simon 
and Kingston, 2009)). Rather than being an exclusive property of PRC2 complexes, as 
previously  implied,  the  RNA  binding  capacity  of  HPH2  and  the  RNA  processing 
activities of its interaction partners might function in handling transcripts that will guide 
the PRC complexes to their targets. Alternatively, the ncRNA might have a direct role 
in gene silencing and will have to be processed at the chromatin of the target gene. 
There is previous evidence suggesting that ncRNA contributes to gene silencing by 
infiltrating  the  DNA  double  strand,  leading  to  the  formation  of  a  triplex  structure 
(Martianov et al., 2007). Although these observations have not been connected to PcG-
mediated repression, this might be a general mechanism by which ncRNA contributes 
to sequence specific gene silencing. 
It is therefore encouraging to find HPH2 binding to RNA that is antisense with 
respect to the INK4A promoter. Although these preliminary findings need to be further 
investigated, there is precedence for antisense transcription through the INK4B-ARF-
INK4A  locus  (Gonzalez  et  al.,  2008;  Pasmant  et  al.,  2007).  In  addition,  the  low 
resolution  transcriptional  profiling  of  the  INK4B-ARF-INK4A  locus  performed 
highlights some interesting transcriptional activity that appears to localise  with PcG 
binding.  The  laboratory  is  currently  undertaking  efforts  to  map  the  strand-specific 
transcription of the locus at a much higher resolution. Nevertheless, a common principle 
about how ncRNA is involved in PcG repression is still lacking, which limits any such 
strategies.  In  this  regard  the  finding  that  a  substantial  number  of  conserved  long 
ncRNAs interact with PRC2 is encouraging (Khalil et al., 2009), but it is not yet clear 
whether these RNA molecules consistently work in trans to recruit PRC2, or work in 
cis analogous to the PcG recruitment by XIST (Rinn et al., 2007; Zhao et al., 2008). The 
list  of  ncRNAs  reported  by  Khalil  and  colleagues  did  not  include  any  transcripts 
spanning the INK4A-ARF-INK4B locus. 
These highly speculative ideas will need to be addressed carefully. The current 
priority lies in the identification of the RNA molecules bound by HPH2. This would be 
best addressed by employing high-throughput sequencing of reverse transcribed RNAs   171 
using technology that produces long reads (such as the 454 sequencer from Roche). 
This  is  imperative  as  there  is  no  reference  sequence  for  the  full  transcriptome  and 
substantial variability in transcripts would hamper RNA sequence reconstruction based 
on short sequence reads. The identified RNA molecules could then be matched back to 
the sequence of INK4/ARF to find sense/antisense sequence alignments. The matching 
transcripts could then be further investigated through modulation of their expression 
levels and studying the regulation of their endogenous expression.  
 
7.4.2  Higher-order chromatin regulation 
 
The  involvement  of  PRC1  complexes  in  a  higher  order  chromatin  structure  has 
previously been demonstrated for the regulation of the homeotic bithorax gene cluster in 
Drosophila (Lanzuolo et al., 2007). This concept might not be restricted to repression of 
gene clusters, but could extend to single target genes. It has been proposed that intra-
locus chromatin looping may be a general feature of PcG repression that is mediated by 
the H3K27me3 mark (Schwartz and Pirrotta, 2007; Simon and Kingston, 2009). Intra- 
and interchromosomal contacts between such loops could establish nuclear domains that 
impose repression on large collections of target genes (Tiwari et al., 2008). 
The H1 linker histone is involved in the compaction of the chromatin fiber and 
therefore is involved in the establishment of higher order structures. The co-purification 
of histone H1.2 (H1d) with HPH2a thus provides an interesting prospect, although it 
will first be necessary to determine whether this represents a direct interaction between 
the two proteins. As previously mentioned, one of the isoforms of EED enables the 
PRC2 complex to trimethylate histone H1 on K26, which is conserved in most variants 
of H1 (Kuzmichev et al., 2004). In fact, the sequence surrounding H1K26 is highly 
similar to that of H3K27, but only in isoform H1.4 (H1b) (reviewed in (Schwartz and 
Pirrotta,  2007)).  It  thus  remains  to  be  determined  if  H1.2  is  also  a  target  of  PRC2 
methylation in the context of INK4A repression and whether this modification has any 
impact on the putative interaction with HPH2. 
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7.4.3  DNA damage response 
 
Another  fascinating  angle  that  deserves  further  investigation  is  the  possible  role  of 
HPH2 in the DNA damage response (DDR). This is of particular interest, following the 
recent identification of a role for Bmi1 in regulating the DDR, as most of the Bmi1
-/- 
phenotype could be rescued by knockout of Chk2 (Liu et al., 2009). Furthermore, it has 
been  reported  that  the  strength  of  the  DDR  is  determined  by  overall  chromatin 
compaction, which is limiting access to the double strand breaks (Fernandez-Capetillo 
and Murga, 2008). Removal of PRC1 from repressed loci could allow de-compaction of 
the chromatin fiber and access to the sites of DNA damage. The putative interaction 
between HPH2 and histone H1.2 could further contribute to this process, as a 50% 
reduction of H1 levels has been shown to increase the magnitude of the DDR (Murga et 
al., 2007). This study reports that a similar increase could also be obtained by inhibition 
of HDAC activity by trichostatin A, which would be in line with a reduction of PcG 
activity. 
Although the functional relevance has not been explored, HPH2 and HPH3 both 
have potential target sites for phosphorylation by ATM or ATR.  This also applies to a 
number  of  the  proteins  that  co-purify  with  HPH2,  including  RBM14/CoAA, 
heterochromatin protein 1-binding protein 3 (HP1BP3/H1BP74) and others (Matsuoka 
et  al.,  2007).  It  will  therefore  be  interesting  to develop  phospho-specific  antibodies 
against  HPH2  and  HPH3  to  study  whether  it  indeed  becomes  modified  upon  DNA 
damage and how this affects its binding to INK4A. The identification of the ubiquitin 
ligase EDD in the HPH2 complex further strengthens the case for a link with the DDR. 
EDD is known to interact with the damage-specific DNA binding protein 1 (DDB1).  
Interestingly,  DDB1  is  also  implicated,  along  with  CUL4,  as  a  component  of  a 
Trithorax like complex that is required for RAS-induced activation of INK4A (Kotake et 
al., 2009; Maddika and Chen, 2009). A high priority for the future will be to determine 
whether EDD directly interacts with HPH2 and if so through which domains. 
 
7.5  Conclusions 
 
This thesis has addressed the suspected role of the HPH proteins in the regulation of 
INK4A and has sparked a number of different avenues to pursue in order to understand   173 
the impact of the HPH proteins on INK4A-related complex composition, the interaction 
between  these  complexes,  a  putative  role  for  an  RNA  component,  and  additional 
functions  that  might  illuminate  novel  aspects  of  the  PcG-mediated  repression 
mechanism. It is hoped that this work will stimulate further interest in the HPH proteins 
and can serve as a foundation for exploring these exciting new avenues.   174 
References 
•  Acosta, J.C., A. O'Loghlen, A. Banito, M.V. Guijarro, A. Augert, S. Raguz, M. 
Fumagalli,  M.  Da  Costa,  C.  Brown,  N.  Popov,  Y.  Takatsu,  J.  Melamed,  F. 
d'Adda  di  Fagagna,  D.  Bernard,  E.  Hernando,  and  J.  Gil.  2008.  Chemokine 
signaling via the CXCR2 receptor reinforces senescence. Cell. 133:1006-18. 
•  Agger, K., P.A. Cloos, L. Rudkjaer, K. Williams, G. Andersen, J. Christensen, 
and  K.  Helin.  2009.  The  H3K27me3  demethylase  JMJD3  contributes  to  the 
activation of the INK4A-ARF locus in response to oncogene- and stress-induced 
senescence. Genes Dev. 23:1171-6. 
•  Akasaka, T., M. Kanno, R. Balling, M.A. Mieza, M. Taniguchi, and H. Koseki. 
1996.  A  role  for  mel-18,  a  Polycomb  group-related  vertebrate  gene,  during 
theanteroposterior specification of the axial skeleton. Development. 122:1513-
22. 
•  Akasaka, T., K. Tsuji, H. Kawahira, M. Kanno, K. Harigaya, L. Hu, Y. Ebihara, 
T. Nakahata, O. Tetsu, M. Taniguchi, and H. Koseki. 1997. The role of mel-18, 
a  mammalian  Polycomb  group  gene,  during  IL-7-dependent  proliferation  of 
lymphocyte precursors. Immunity. 7:135-46. 
•  Akhtar, A., D. Zink, and P.B. Becker. 2000. Chromodomains are protein-RNA 
interaction modules. Nature. 407:405-9. 
•  Al-Hajj, M., M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke. 
2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl 
Acad Sci U S A. 100:3983-8. 
•  Alkema, M.J., M. Bronk, E. Verhoeven, A. Otte, L.J. van 't Veer, A. Berns, and 
M.  van  Lohuizen.  1997.  Identification  of  Bmi1-interacting  proteins  as 
constituents  of  a  multimeric  mammalian  polycomb  complex.  Genes  Dev. 
11:226-40. 
•  Allemand, E., E. Batsche, and C. Muchardt. 2008. Splicing, transcription, and 
chromatin: a menage a trois. Curr Opin Genet Dev. 18:145-51. 
•  Ballestar, E., and M. Esteller. 2008. Epigenetic gene regulation in cancer. Adv 
Genet. 61:247-67. 
•  Banito, A., S.T. Rashid, J.C. Acosta, S. Li, C.F. Pereira, I. Geti, S. Pinho, J.C. 
Silva, V. Azuara, M. Walsh, L. Vallier, and J. Gil. 2009. Senescence impairs 
successful reprogramming to pluripotent stem cells. Genes Dev. 23:2134-9.   175 
•  Bannister, A.J., P. Zegerman, J.F. Partridge, E.A. Miska, J.O. Thomas, R.C. 
Allshire, and T. Kouzarides. 2001. Selective recognition of methylated lysine 9 
on histone H3 by the HP1 chromo domain. Nature. 410:120-4. 
•  Barradas,  M.,  E.  Anderton,  J.C.  Acosta,  S.  Li,  A.  Banito,  M.  Rodriguez-
Niedenfuhr, G. Maertens, M. Banck, M.M. Zhou, M.J. Walsh, G. Peters, and J. 
Gil.  2009.  Histone  demethylase  JMJD3  contributes  to  epigenetic  control  of 
INK4a/ARF by oncogenic RAS. Genes Dev. 23:1177-82. 
•  Barski, A., S. Cuddapah, K. Cui, T.Y. Roh, D.E. Schones, Z. Wang, G. Wei, I. 
Chepelev, and K. Zhao. 2007. High-resolution profiling of histone methylations 
in the human genome. Cell. 129:823-37. 
•  Bartkova, J., N. Rezaei, M. Liontos, P. Karakaidos, D. Kletsas, N. Issaeva, L.V. 
Vassiliou,  E.  Kolettas,  K.  Niforou,  V.C.  Zoumpourlis,  M.  Takaoka,  H. 
Nakagawa, F. Tort, K. Fugger, F. Johansson, M. Sehested, C.L. Andersen, L. 
Dyrskjot,  T.  Orntoft,  J.  Lukas,  C.  Kittas,  T.  Helleday,  T.D.  Halazonetis,  J. 
Bartek, and V.G. Gorgoulis. 2006. Oncogene-induced senescence is part of the 
tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 444:633-7. 
•  Bates, S., A.C. Phillips, P.A. Clark, F. Stott, G. Peters, R.L. Ludwig, and K.H. 
Vousden.  1998.  p14ARF  links  the  tumour  suppressors  RB  and  p53.  Nature. 
395:124-5. 
•  Bea,  S.,  F.  Tort,  M.  Pinyol,  X.  Puig,  L.  Hernandez,  S.  Hernandez,  P.L. 
Fernandez, M. van Lohuizen, D. Colomer, and E. Campo. 2001. BMI-1 gene 
amplification and overexpression in hematological malignancies occur mainly in 
mantle cell lymphomas. Cancer Res. 61:2409-12. 
•  Beisel, C., A. Buness, I.M. Roustan-Espinosa, B. Koch, S. Schmitt, S.A. Haas, 
M. Hild, T. Katsuyama, and R. Paro. 2007. Comparing active and repressed 
expression states of genes controlled by the Polycomb/Trithorax group proteins. 
Proc Natl Acad Sci U S A. 104:16615-20. 
•  Bernard,  D.,  J.F.  Martinez-Leal,  S.  Rizzo,  D.  Martinez,  D.  Hudson,  T. 
Visakorpi, G. Peters, A. Carnero, D. Beach, and J. Gil. 2005. CBX7 controls the 
growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf 
locus. Oncogene. 24:5543-51. 
•  Bernstein, B.E., T.S. Mikkelsen, X. Xie, M. Kamal, D.J. Huebert, J. Cuff, B. 
Fry, A. Meissner, M. Wernig, K. Plath, R. Jaenisch, A. Wagschal, R. Feil, S.L. 
Schreiber, and E.S. Lander. 2006a. A bivalent chromatin structure marks key 
developmental genes in embryonic stem cells. Cell. 125:315-26.   176 
•  Bernstein, E., E.M. Duncan, O. Masui, J. Gil, E. Heard, and C.D. Allis. 2006b. 
Mouse polycomb proteins bind differentially to methylated histone H3 and RNA 
and are enriched in facultative heterochromatin. Mol Cell Biol. 26:2560-9. 
•  Besson, A., S.F. Dowdy, and J.M. Roberts. 2008. CDK inhibitors: cell cycle 
regulators and beyond. Dev Cell. 14:159-69. 
•  Blasco,  M.A.,  H.W.  Lee,  M.P.  Hande,  E.  Samper,  P.M.  Lansdorp,  R.A. 
DePinho, and C.W. Greider. 1997. Telomere shortening and tumor formation by 
mouse cells lacking telomerase RNA. Cell. 91:25-34. 
•  Bloyer, S., G. Cavalli, H.W. Brock, and J.M. Dura. 2003. Identification and 
characterization of polyhomeotic PREs and TREs. Dev Biol. 261:426-42. 
•  Bodnar, A.G., M. Ouellette, M. Frolkis, S.E. Holt, C.P. Chiu, G.B. Morin, C.B. 
Harley, J.W. Shay, S. Lichtsteiner, and W.E. Wright. 1998. Extension of life-
span by introduction of telomerase into normal human cells. Science. 279:349-
52. 
•  Boyer, L.A., K. Plath, J. Zeitlinger, T. Brambrink, L.A. Medeiros, T.I. Lee, S.S. 
Levine, M. Wernig, A. Tajonar, M.K. Ray, G.W. Bell, A.P. Otte, M. Vidal, D.K. 
Gifford,  R.A.  Young,  and  R.  Jaenisch.  2006.  Polycomb  complexes  repress 
developmental regulators in murine embryonic stem cells. Nature. 441:349-53. 
•  Bracken,  A.P.,  N.  Dietrich,  D.  Pasini,  K.H.  Hansen,  and  K.  Helin.  2006. 
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate 
transitions. Genes Dev. 20:1123-36. 
•  Bracken, A.P., D. Kleine-Kohlbrecher, N. Dietrich, D. Pasini, G. Gargiulo, C. 
Beekman,  K.  Theilgaard-Monch,  S.  Minucci,  B.T.  Porse,  J.C.  Marine,  K.H. 
Hansen, and K. Helin. 2007. The Polycomb group proteins bind throughout the 
INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21:525-
30. 
•  Bracken, A.P., D. Pasini, M. Capra, E. Prosperini, E. Colli, and K. Helin. 2003. 
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and 
amplified in cancer. Embo J. 22:5323-35. 
•  Braig,  M.,  S.  Lee,  C.  Loddenkemper,  C.  Rudolph,  A.H.  Peters,  B. 
Schlegelberger,  H.  Stein,  B.  Dorken,  T.  Jenuwein,  and  C.A.  Schmitt.  2005. 
Oncogene-induced senescence as an initial barrier in lymphoma development. 
Nature. 436:660-5.   177 
•  Breiling,  A.,  B.M.  Turner,  M.E.  Bianchi,  and  V.  Orlando.  2001.  General 
transcription  factors  bind  promoters  repressed  by  Polycomb  group  proteins. 
Nature. 412:651-5. 
•  Brookes, S., J. Rowe, A. Gutierrez Del Arroyo, J. Bond, and G. Peters. 2004. 
Contribution of p16(INK4a) to replicative senescence of human fibroblasts. Exp 
Cell Res. 298:549-59. 
•  Brookes, S., J. Rowe, M. Ruas, S. Llanos, P.A. Clark, M. Lomax, M.C. James, 
R. Vatcheva, S. Bates, K.H. Vousden, D. Parry, N. Gruis, N. Smit, W. Bergman, 
and G. Peters. 2002. INK4a-deficient human diploid fibroblasts are resistant to 
RAS-induced senescence. Embo J. 21:2936-45. 
•  Brown,  C.J.,  A.  Ballabio,  J.L.  Rupert,  R.G.  Lafreniere,  M.  Grompe,  R. 
Tonlorenzi, and H.F. Willard. 1991. A gene from the region of the human X 
inactivation centre is expressed exclusively from the inactive X chromosome. 
Nature. 349:38-44. 
•  Brown,  J.L.,  D.J.  Grau,  S.K.  DeVido,  and  J.A.  Kassis.  2005.  An  Sp1/KLF 
binding site is important for the activity of a Polycomb group response element 
from the Drosophila engrailed gene. Nucleic Acids Res. 33:5181-9. 
•  Brown,  J.P.,  W.  Wei,  and  J.M.  Sedivy.  1997.  Bypass  of  senescence  after 
disruption  of  p21CIP1/WAF1  gene  in  normal  diploid  human  fibroblasts. 
Science. 277:831-4. 
•  Bruggeman, S.W., D. Hulsman, E. Tanger, T. Buckle, M. Blom, J. Zevenhoven, 
O.  van  Tellingen,  and  M.  van  Lohuizen.  2007.  Bmi1  controls  tumor 
development in an Ink4a/Arf-independent manner in a mouse model for glioma. 
Cancer Cell. 12:328-41. 
•  Buchwald,  G.,  P.  van  der  Stoop,  O.  Weichenrieder,  A.  Perrakis,  M.  van 
Lohuizen, and T.K. Sixma. 2006. Structure and E3-ligase activity of the Ring-
Ring complex of polycomb proteins Bmi1 and Ring1b. Embo J. 25:2465-74. 
•  Cairns,  B.R.  2009.  The  logic  of  chromatin  architecture  and  remodelling  at 
promoters. Nature. 461:193-8. 
•  Cales, C., M. Roman-Trufero, L. Pavon, I. Serrano, T. Melgar, M. Endoh, C. 
Perez,  H.  Koseki,  and  M.  Vidal.  2008.  Inactivation  of  the  polycomb  group 
protein Ring1B unveils an antiproliferative role in hematopoietic cell expansion 
and cooperation with tumorigenesis associated  with Ink4a deletion. Mol Cell 
Biol. 28:1018-28.   178 
•  Campisi, J., and F. d'Adda di Fagagna. 2007. Cellular senescence: when bad 
things happen to good cells. Nat Rev Mol Cell Biol. 8:729-40. 
•  Cao, R., Y. Tsukada, and Y. Zhang. 2005. Role of Bmi-1 and Ring1A in H2A 
ubiquitylation and Hox gene silencing. Mol Cell. 20:845-54. 
•  Cao, R., L. Wang, H. Wang, L. Xia, H. Erdjument-Bromage, P. Tempst, R.S. 
Jones,  and  Y.  Zhang.  2002.  Role  of  histone  H3  lysine  27  methylation  in 
Polycomb-group silencing. Science. 298:1039-43. 
•  Chamberlain,  S.J.,  D.  Yee,  and  T.  Magnuson.  2008.  Polycomb  repressive 
complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. 
Stem Cells. 26:1496-505. 
•  Chen,  Z.,  L.C.  Trotman,  D.  Shaffer,  H.K.  Lin,  Z.A.  Dotan,  M.  Niki,  J.A. 
Koutcher,  H.I.  Scher,  T.  Ludwig,  W.  Gerald,  C.  Cordon-Cardo,  and  P.P. 
Pandolfi. 2005. Crucial role of p53-dependent cellular senescence in suppression 
of Pten-deficient tumorigenesis. Nature. 436:725-30. 
•  Cho, Y.W., T. Hong, S. Hong, H. Guo, H. Yu, D. Kim, T. Guszczynski, G.R. 
Dressler, T.D. Copeland, M. Kalkum, and K. Ge. 2007. PTIP associates with 
MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J 
Biol Chem. 282:20395-406. 
•  Classon, M., and E. Harlow. 2002. The retinoblastoma tumour suppressor in 
development and cancer. Nat Rev Cancer. 2:910-7. 
•  Collado, M., J. Gil, A. Efeyan, C. Guerra, A.J. Schuhmacher, M. Barradas, A. 
Benguria, A. Zaballos, J.M. Flores, M. Barbacid, D. Beach, and M. Serrano. 
2005. Tumour biology: senescence in premalignant tumours. Nature. 436:642. 
•  Core,  L.J.,  and  J.T.  Lis.  2008.  Transcription  regulation  through  promoter-
proximal pausing of RNA polymerase II. Science. 319:1791-2. 
•  Core, N., S. Bel, S.J. Gaunt, M. Aurrand-Lions, J. Pearce, A. Fisher, and M. 
Djabali.  1997.  Altered  cellular  proliferation  and  mesoderm  patterning  in 
Polycomb-M33-deficient mice. Development. 124:721-9. 
•  Czermin, B., R. Melfi, D. McCabe, V. Seitz, A. Imhof, and V. Pirrotta. 2002. 
Drosophila  enhancer  of  Zeste/ESC  complexes  have  a  histone  H3 
methyltransferase  activity  that  marks  chromosomal  Polycomb  sites.  Cell. 
111:185-96. 
•  d'Adda di Fagagna, F., P.M. Reaper, L. Clay-Farrace, H. Fiegler, P. Carr, T. Von 
Zglinicki, G. Saretzki, N.P. Carter, and S.P. Jackson. 2003. A DNA damage 
checkpoint response in telomere-initiated senescence. Nature. 426:194-8.   179 
•  D'Alessio, J.A., K.J. Wright, and R. Tjian. 2009. Shifting players and paradigms 
in cell-specific transcription. Mol Cell. 36:924-31. 
•  Daujat, S., U. Zeissler, T. Waldmann, N. Happel, and R. Schneider. 2005. HP1 
binds  specifically  to  Lys26-methylated  histone  H1.4,  whereas  simultaneous 
Ser27 phosphorylation blocks HP1 binding. J Biol Chem. 280:38090-5. 
•  de la Mata, M., C.R. Alonso, S. Kadener, J.P. Fededa, M. Blaustein, F. Pelisch, 
P. Cramer, D. Bentley, and A.R. Kornblihtt. 2003. A slow RNA polymerase II 
affects alternative splicing in vivo. Mol Cell. 12:525-32. 
•  de Napoles, M., J.E. Mermoud, R. Wakao, Y.A. Tang, M. Endoh, R. Appanah, 
T.B. Nesterova, J. Silva, A.P. Otte, M. Vidal, H. Koseki, and N. Brockdorff. 
2004. Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to 
heritable gene silencing and X inactivation. Dev Cell. 7:663-76. 
•  Deatrick, J., M. Daly, N.B. Randsholt, and H.W. Brock. 1991. The complex 
genetic locus polyhomeotic in Drosophila melanogaster potentially encodes two 
homologous zinc-finger proteins. Gene. 105:185-95. 
•  Dellino, G.I., Y.B. Schwartz, G. Farkas, D. McCabe, S.C. Elgin, and V. Pirrotta. 
2004. Polycomb silencing blocks transcription initiation. Mol Cell. 13:887-93. 
•  Deng, Y., S.S. Chan, and S. Chang. 2008. Telomere dysfunction and tumour 
suppression: the senescence connection. Nat Rev Cancer. 8:450-8. 
•  Deshpande, A.M., J.D. Akunowicz, X.T. Reveles, B.B. Patel, E.A. Saria, R.G. 
Gorlick, S.L. Naylor, R.J. Leach, and M.F. Hansen. 2007. PHC3, a component 
of  the  hPRC-H  complex,  associates  with  E2F6  during  G0  and  is  lost  in 
osteosarcoma tumors. Oncogene. 26:1714-22. 
•  Dhawan, S., S.I. Tschen, and A. Bhushan. 2009. Bmi-1 regulates the Ink4a/Arf 
locus to control pancreatic beta-cell proliferation. Genes Dev. 23:906-11. 
•  Di Micco, R., M. Fumagalli, A. Cicalese, S. Piccinin, P. Gasparini, C. Luise, C. 
Schurra, M. Garre, P.G. Nuciforo, A. Bensimon, R. Maestro, P.G. Pelicci, and F. 
d'Adda  di  Fagagna.  2006.  Oncogene-induced  senescence  is  a  DNA  damage 
response triggered by DNA hyper-replication. Nature. 444:638-42. 
•  Dietrich, N., A.P. Bracken, E. Trinh, C.K. Schjerling, H. Koseki, J. Rappsilber, 
K. Helin, and K.H. Hansen. 2007. Bypass of senescence by the polycomb group 
protein  CBX8  through  direct  binding  to  the  INK4A-ARF  locus.  Embo  J. 
26:1637-48. 
•  Dimri,  G.P.,  X.  Lee,  G.  Basile,  M.  Acosta,  G.  Scott,  C.  Roskelley,  E.E. 
Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith, and et al. 1995. A biomarker   180 
that identifies senescent human cells in culture and in aging skin in vivo. Proc 
Natl Acad Sci U S A. 92:9363-7. 
•  Dimri,  G.P.,  J.L.  Martinez,  J.J.  Jacobs,  P.  Keblusek,  K.  Itahana,  M.  Van 
Lohuizen, J. Campisi, D.E. Wazer, and V. Band. 2002. The Bmi-1 oncogene 
induces telomerase activity and immortalizes human mammary epithelial cells. 
Cancer Res. 62:4736-45. 
•  Dura,  J.M.,  H.W.  Brock,  and  P.  Santamaria.  1985.  Polyhomeotic:  a  gene  of 
Drosophila melanogaster required for correct expression of segmental identity. 
Mol Gen Genet. 198:213-20. 
•  Dura, J.M., N.B. Randsholt, J. Deatrick, I. Erk, P. Santamaria, J.D. Freeman, 
S.J. Freeman, D. Weddell, and H.W. Brock. 1987. A complex genetic locus, 
polyhomeotic,  is  required  for  segmental  specification  and  epidermal 
development in D. melanogaster. Cell. 51:829-39. 
•  Dyson, N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev. 
12:2245-62. 
•  Ebert,  A.,  G. Schotta,  S. Lein, S.  Kubicek,  V. Krauss,  T.  Jenuwein,  and  G. 
Reuter.  2004.  Su(var)  genes  regulate  the  balance  between  euchromatin  and 
heterochromatin in Drosophila. Genes Dev. 18:2973-83. 
•  Elderkin, S., G.N. Maertens, M. Endoh, D.L. Mallery, N. Morrice, H. Koseki, G. 
Peters, N. Brockdorff, and K. Hiom. 2007. A phosphorylated form of Mel-18 
targets the Ring1B histone H2A ubiquitin ligase to chromatin. Mol Cell. 28:107-
20. 
•  Endoh, M., T.A. Endo, T. Endoh, Y. Fujimura, O. Ohara, T. Toyoda, A.P. Otte, 
M. Okano, N. Brockdorff, M. Vidal, and H. Koseki. 2008. Polycomb group 
proteins Ring1A/B are functionally linked to the core transcriptional regulatory 
circuitry to maintain ES cell identity. Development. 135:1513-24. 
•  Ezhkova,  E.,  H.A.  Pasolli,  J.S.  Parker,  N.  Stokes,  I.H.  Su,  G.  Hannon,  A. 
Tarakhovsky, and E. Fuchs. 2009. Ezh2 orchestrates gene expression for the 
stepwise differentiation of tissue-specific stem cells. Cell. 136:1122-35. 
•  Faast, R., J. White, P. Cartwright, L. Crocker, B. Sarcevic, and S. Dalton. 2004. 
Cdk6-cyclin  D3  activity  in  murine  ES  cells  is  resistant  to  inhibition  by 
p16(INK4a). Oncogene. 23:491-502. 
•  Fauvarque, M.O., V. Zuber, and J.M. Dura. 1995. Regulation of polyhomeotic 
transcription  may  involve  local  changes  in  chromatin  activity  in  Drosophila. 
Mech Dev. 52:343-55.   181 
•  Fernandez,  P.C.,  S.R.  Frank,  L.  Wang,  M.  Schroeder,  S.  Liu,  J.  Greene,  A. 
Cocito,  and  B.  Amati.  2003.  Genomic  targets  of  the  human  c-Myc  protein. 
Genes Dev. 17:1115-29. 
•  Fernandez-Capetillo, O., and M. Murga. 2008. Why cells respond differently to 
DNA damage: a chromatin perspective. Cell Cycle. 7:980-3. 
•  Fischle, W., Y. Wang, S.A. Jacobs, Y. Kim, C.D. Allis, and S. Khorasanizadeh. 
2003. Molecular basis for the discrimination of repressive methyl-lysine marks 
in histone H3 by Polycomb and HP1 chromodomains. Genes Dev. 17:1870-81. 
•  Francis, N.J., R.E. Kingston, and C.L. Woodcock. 2004. Chromatin compaction 
by a polycomb group protein complex. Science. 306:1574-7. 
•  Francis, N.J., A.J. Saurin, Z. Shao, and R.E. Kingston. 2001. Reconstitution of a 
functional core polycomb repressive complex. Mol Cell. 8:545-56. 
•  Gaestel, M. 2006. MAPKAP kinases - MKs - two's company, three's a crowd. 
Nat Rev Mol Cell Biol. 7:120-30. 
•  Gearhart,  M.D.,  C.M.  Corcoran,  J.A.  Wamstad,  and  V.J.  Bardwell.  2006. 
Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex 
that is recruited to BCL6 targets. Mol Cell Biol. 26:6880-9. 
•  Gil, J., D. Bernard, D. Martinez, and D. Beach. 2004. Polycomb CBX7 has a 
unifying role in cellular lifespan. Nat Cell Biol. 6:67-72. 
•  Gil, J., D. Bernard, and G. Peters. 2005. Role of polycomb group proteins in 
stem cell self-renewal and cancer. DNA Cell Biol. 24:117-25. 
•  Gil,  J.,  and  G.  Peters.  2006.  Regulation  of  the  INK4b-ARF-INK4a  tumour 
suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol. 7:667-77. 
•  Goldberg, A.D., C.D. Allis, and E. Bernstein. 2007. Epigenetics: a landscape 
takes shape. Cell. 128:635-8. 
•  Gonzalez,  S.,  D.G.  Pisano,  and  M.  Serrano.  2008.  Mechanistic  principles  of 
chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle. 7:2601-8. 
•  Grimaud,  C.,  F.  Bantignies,  M.  Pal-Bhadra,  P.  Ghana,  U.  Bhadra,  and  G. 
Cavalli.  2006.  RNAi  components  are  required  for  nuclear  clustering  of 
Polycomb group response elements. Cell. 124:957-71. 
•  Gunster, M.J., D.P. Satijn, K.M. Hamer, J.L. den Blaauwen, D. de Bruijn, M.J. 
Alkema, M. van Lohuizen, R. van Driel, and A.P. Otte. 1997. Identification and 
characterization of interactions between the vertebrate polycomb-group protein 
BMI1 and human homologs of polyhomeotic. Mol Cell Biol. 17:2326-35.   182 
•  Gunther, M., M. Laithier, and O. Brison. 2000. A set of proteins interacting with 
transcription factor Sp1 identified in a two-hybrid screening. Mol Cell Biochem. 
210:131-42. 
•  Guo, W.J., S. Datta, V. Band, and G.P. Dimri. 2007a. Mel-18, a polycomb group 
protein, regulates cell proliferation and senescence via transcriptional repression 
of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell. 18:536-46. 
•  Guo, W.J., M.S. Zeng, A. Yadav, L.B. Song, B.H. Guo, V. Band, and G.P. 
Dimri.  2007b.  Mel-18  acts  as  a  tumor  suppressor  by  repressing  Bmi-1 
expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 
67:5083-9. 
•  Gupta, P.B., C.L. Chaffer, and R.A. Weinberg. 2009. Cancer stem cells: mirage 
or reality? Nat Med. 15:1010-2. 
•  Guttman, M., I. Amit, M. Garber, C. French, M.F. Lin, D. Feldser, M. Huarte, 
O. Zuk, B.W. Carey, J.P. Cassady, M.N. Cabili, R. Jaenisch, T.S. Mikkelsen, T. 
Jacks, N. Hacohen, B.E. Bernstein, M. Kellis, A. Regev, J.L. Rinn, and E.S. 
Lander. 2009. Chromatin signature reveals over a thousand highly conserved 
large non-coding RNAs in mammals. Nature. 458:223-7. 
•  Hager, G.L., J.G. McNally, and T. Misteli. 2009. Transcription dynamics. Mol 
Cell. 35:741-53. 
•  Haupt,  Y.,  W.S.  Alexander,  G.  Barri,  S.P.  Klinken,  and  J.M.  Adams.  1991. 
Novel  zinc  finger  gene  implicated  as  myc  collaborator  by  retrovirally 
accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 65:753-63. 
•  Hayflick, L., and P.S. Moorhead. 1961. The serial cultivation of human diploid 
cell strains. Exp Cell Res. 25:585-621. 
•  He,  S.,  T.  Iwashita,  J.  Buchstaller,  A.V.  Molofsky,  D.  Thomas,  and  S.J. 
Morrison. 2009. Bmi-1 over-expression in neural stem/progenitor cells increases 
proliferation and neurogenesis in culture but has little effect on these functions 
in vivo. Dev Biol. 328:257-72. 
•  Helgadottir, A., G. Thorleifsson, A. Manolescu, S. Gretarsdottir, T. Blondal, A. 
Jonasdottir, A. Jonasdottir, A. Sigurdsson, A. Baker, A. Palsson, G. Masson, 
D.F. Gudbjartsson, K.P. Magnusson, K. Andersen, A.I. Levey, V.M. Backman, 
S. Matthiasdottir, T. Jonsdottir, S. Palsson, H. Einarsdottir, S. Gunnarsdottir, A. 
Gylfason, V. Vaccarino, W.C. Hooper, M.P. Reilly, C.B. Granger, H. Austin, 
D.J.  Rader,  S.H.  Shah,  A.A.  Quyyumi,  J.R.  Gulcher,  G.  Thorgeirsson,  U. 
Thorsteinsdottir,  A.  Kong,  and  K.  Stefansson.  2007.  A  common  variant  on   183 
chromosome 9p21 affects the risk of myocardial infarction. Science. 316:1491-
3. 
•  Hernandez-Munoz, I., P. Taghavi, C. Kuijl, J. Neefjes, and M. van Lohuizen. 
2005.  Association  of  BMI1  with  polycomb  bodies  is  dynamic  and  requires 
PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell 
Biol. 25:11047-58. 
•  Hodges, C., L. Bintu, L. Lubkowska, M. Kashlev, and C. Bustamante. 2009. 
Nucleosomal  fluctuations  govern  the  transcription  dynamics  of  RNA 
polymerase II. Science. 325:626-8. 
•  Isono,  K.,  Y.  Fujimura,  J.  Shinga,  M.  Yamaki,  O.W.  J,  Y.  Takihara,  Y. 
Murahashi, Y. Takada, Y. Mizutani-Koseki, and H. Koseki. 2005a. Mammalian 
polyhomeotic homologues Phc2 and Phc1 act in synergy to mediate polycomb 
repression of Hox genes. Mol Cell Biol. 25:6694-706. 
•  Isono, K., Y. Mizutani-Koseki, T. Komori, M.S. Schmidt-Zachmann, and H. 
Koseki.  2005b.  Mammalian  polycomb-mediated  repression  of  Hox  genes 
requires the essential spliceosomal protein Sf3b1. Genes Dev. 19:536-41. 
•  Issaeva, I., Y. Zonis, T. Rozovskaia, K. Orlovsky, C.M. Croce, T. Nakamura, A. 
Mazo,  L.  Eisenbach,  and  E.  Canaani.  2007.  Knockdown  of  ALR  (MLL2) 
reveals ALR target genes and leads to alterations in cell adhesion and growth. 
Mol Cell Biol. 27:1889-903. 
•  Iwama, A., H. Oguro, M. Negishi, Y. Kato, Y. Morita, H. Tsukui, H. Ema, T. 
Kamijo, Y. Katoh-Fukui, H. Koseki, M. van Lohuizen, and H. Nakauchi. 2004. 
Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb 
gene product Bmi-1. Immunity. 21:843-51. 
•  Jacobs,  J.J.,  K.  Kieboom,  S.  Marino,  R.A.  DePinho,  and  M.  van  Lohuizen. 
1999a.  The  oncogene  and  Polycomb-group  gene  bmi-1  regulates  cell 
proliferation and senescence through the ink4a locus. Nature. 397:164-8. 
•  Jacobs, J.J., B. Scheijen, J.W. Voncken, K. Kieboom, A. Berns, and M. van 
Lohuizen. 1999b. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting 
c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13:2678-90. 
•  Jaenisch,  R.,  and  R.  Young.  2008.  Stem  cells,  the  molecular  circuitry  of 
pluripotency and nuclear reprogramming. Cell. 132:567-82. 
•  Janzen,  V.,  R.  Forkert,  H.E.  Fleming,  Y.  Saito,  M.T.  Waring,  D.M. 
Dombkowski,  T.  Cheng,  R.A.  DePinho,  N.E.  Sharpless,  and  D.T.  Scadden.   184 
2006.  Stem-cell  ageing  modified  by  the  cyclin-dependent  kinase  inhibitor 
p16INK4a. Nature. 443:421-6. 
•  Johnson, K.M., J. Wang, A. Smallwood, C. Arayata, and M. Carey. 2002. TFIID 
and human mediator coactivator complexes assemble cooperatively on promoter 
DNA. Genes Dev. 16:1852-63. 
•  Kajiume,  T.,  Y.  Ninomiya,  H.  Ishihara,  R.  Kanno,  and  M.  Kanno.  2004. 
Polycomb group gene mel-18 modulates the self-renewal activity and cell cycle 
status of hematopoietic stem cells. Exp Hematol. 32:571-8. 
•  Kalantry,  S.,  S.  Purushothaman,  R.B.  Bowen,  J.  Starmer,  and  T.  Magnuson. 
2009.  Evidence  of  Xist  RNA-independent  initiation  of  mouse  imprinted  X-
chromosome inactivation. Nature. 460:647-51. 
•  Kamb,  A.,  N.A.  Gruis,  J.  Weaver-Feldhaus,  Q.  Liu,  K.  Harshman,  S.V. 
Tavtigian, E. Stockert, R.S. Day, 3rd, B.E. Johnson, and M.H. Skolnick. 1994. A 
cell  cycle  regulator  potentially  involved  in  genesis  of  many  tumor  types. 
Science. 264:436-40. 
•  Kamijo, T., F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, 
G. Grosveld, and C.J. Sherr. 1997. Tumor suppression at the mouse INK4a locus 
mediated by the alternative reading frame product p19ARF. Cell. 91:649-59. 
•  Kang,  M.K.,  R.H.  Kim,  S.J.  Kim,  F.K.  Yip,  K.H.  Shin,  G.P.  Dimri,  R. 
Christensen,  T.  Han,  and  N.H.  Park.  2007.  Elevated  Bmi-1  expression  is 
associated with dysplastic cell transformation during oral carcinogenesis and is 
required for cancer cell replication and survival. Br J Cancer. 96:126-33. 
•  Kennedy, C.H., H.I. Pass, and J.B. Mitchell. 2003. Expression of human MutT 
homologue  (hMTH1)  protein  in  primary  non-small-cell  lung  carcinomas  and 
histologically normal surrounding tissue. Free Radic Biol Med. 34:1447-57. 
•  Kennison,  J.A.,  and  J.W.  Tamkun.  1988.  Dosage-dependent  modifiers  of 
polycomb and antennapedia mutations in Drosophila. Proc Natl Acad Sci U S A. 
85:8136-40. 
•  Khalil, A.M., M. Guttman, M. Huarte, M. Garber, A. Raj, D. Rivea Morales, K. 
Thomas,  A.  Presser,  B.E.  Bernstein,  A.  van  Oudenaarden,  A.  Regev,  E.S. 
Lander, and J.L. Rinn. 2009. Many human large intergenic noncoding RNAs 
associate with chromatin-modifying complexes and affect gene expression. Proc 
Natl Acad Sci U S A.   185 
•  Kia, S.K., M.M. Gorski, S. Giannakopoulos, and C.P. Verrijzer. 2008. SWI/SNF 
mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-
INK4a locus. Mol Cell Biol. 28:3457-64. 
•  Kim, C.A., M. Gingery, R.M. Pilpa, and J.U. Bowie. 2002. The SAM domain of 
polyhomeotic forms a helical polymer. Nat Struct Biol. 9:453-7. 
•  Kim, C.A., M.R. Sawaya, D. Cascio, W. Kim, and J.U. Bowie. 2005. Structural 
organization of a Sex-comb-on-midleg/polyhomeotic copolymer. J Biol Chem. 
280:27769-75. 
•  Kim, D.H., L.M. Villeneuve, K.V. Morris, and J.J. Rossi. 2006. Argonaute-1 
directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct 
Mol Biol. 13:793-7. 
•  Kim, W.Y., and N.E. Sharpless. 2006. The regulation of INK4/ARF in cancer 
and aging. Cell. 127:265-75. 
•  Kirmizis,  A.,  S.M.  Bartley,  and  P.J.  Farnham.  2003.  Identification  of  the 
polycomb  group  protein  SU(Z)12  as  a  potential  molecular  target  for  human 
cancer therapy. Mol Cancer Ther. 2:113-21. 
•  Kleer, C.G., Q. Cao, S. Varambally, R. Shen, I. Ota, S.A. Tomlins, D. Ghosh, 
R.G. Sewalt, A.P. Otte, D.F. Hayes, M.S. Sabel, D. Livant, S.J. Weiss, M.A. 
Rubin,  and  A.M.  Chinnaiyan.  2003.  EZH2  is  a  marker  of  aggressive  breast 
cancer and promotes neoplastic transformation of breast epithelial cells. Proc 
Natl Acad Sci U S A. 100:11606-11. 
•  Kotake, Y., Y. Zeng, and Y. Xiong. 2009. DDB1-CUL4 and MLL1 mediate 
oncogene-induced p16INK4a activation. Cancer Res. 69:1809-14. 
•  Krimpenfort,  P.,  A.  Ijpenberg,  J.Y.  Song,  M.  van  der  Valk,  M.  Nawijn,  J. 
Zevenhoven, and A. Berns. 2007. p15Ink4b is a critical tumour suppressor in the 
absence of p16Ink4a. Nature. 448:943-6. 
•  Krimpenfort, P., K.C. Quon, W.J. Mooi, A. Loonstra, and A. Berns. 2001. Loss 
of  p16Ink4a  confers  susceptibility  to  metastatic  melanoma  in  mice.  Nature. 
413:83-6. 
•  Krishnamurthy, J., M.R. Ramsey, K.L. Ligon, C. Torrice, A. Koh, S. Bonner-
Weir, and N.E. Sharpless. 2006. p16INK4a induces an age-dependent decline in 
islet regenerative potential. Nature. 443:453-7. 
•  Krishnamurthy, J., C. Torrice, M.R. Ramsey, G.I. Kovalev, K. Al-Regaiey, L. 
Su, and N.E. Sharpless. 2004. Ink4a/Arf expression is a biomarker of aging. J 
Clin Invest. 114:1299-307.   186 
•  Krumlauf, R. 1994. Hox genes in vertebrate development. Cell. 78:191-201. 
•  Kuilman, T., C. Michaloglou, L.C. Vredeveld, S. Douma, R. van Doorn, C.J. 
Desmet, L.A. Aarden, W.J. Mooi, and D.S. Peeper. 2008. Oncogene-induced 
senescence  relayed  by  an  interleukin-dependent  inflammatory  network.  Cell. 
133:1019-31. 
•  Kuilman, T., and D.S. Peeper. 2009. Senescence-messaging secretome: SMS-
ing cellular stress. Nat Rev Cancer. 9:81-94. 
•  Kuzmichev,  A.,  T.  Jenuwein,  P.  Tempst,  and  D.  Reinberg.  2004.  Different 
EZH2-containing complexes target methylation of histone H1 or nucleosomal 
histone H3. Mol Cell. 14:183-93. 
•  Kuzmichev,  A.,  R.  Margueron,  A.  Vaquero,  T.S.  Preissner,  M.  Scher,  A. 
Kirmizis,  X.  Ouyang,  N.  Brockdorff,  C.  Abate-Shen,  P.  Farnham,  and  D. 
Reinberg.  2005.  Composition  and  histone  substrates  of  polycomb  repressive 
group complexes change during cellular differentiation. Proc Natl Acad Sci U S 
A. 102:1859-64. 
•  Kuzmichev,  A.,  K.  Nishioka,  H.  Erdjument-Bromage,  P.  Tempst,  and  D. 
Reinberg.  2002.  Histone  methyltransferase  activity  associated  with  a  human 
multiprotein  complex  containing  the  Enhancer  of  Zeste  protein.  Genes  Dev. 
16:2893-905. 
•  Kyba, M., and H.W. Brock. 1998a. The Drosophila polycomb group protein Psc 
contacts ph and Pc through specific conserved domains. Mol Cell Biol. 18:2712-
20. 
•  Kyba, M., and H.W. Brock. 1998b. The SAM domain of polyhomeotic, RAE28, 
and scm mediates specific interactions through conserved residues. Dev Genet. 
22:74-84. 
•  Lachner,  M.,  D.  O'Carroll,  S.  Rea,  K.  Mechtler,  and  T.  Jenuwein.  2001. 
Methylation  of  histone  H3  lysine  9  creates  a  binding  site  for  HP1  proteins. 
Nature. 410:116-20. 
•  Lagarou, A., A. Mohd-Sarip, Y.M. Moshkin, G.E. Chalkley, K. Bezstarosti, J.A. 
Demmers,  and  C.P.  Verrijzer.  2008.  dKDM2  couples  histone  H2A 
ubiquitylation to histone H3 demethylation during Polycomb group silencing. 
Genes Dev. 22:2799-810. 
•  Lan, F., P.E. Bayliss, J.L. Rinn, J.R. Whetstine, J.K. Wang, S. Chen, S. Iwase, 
R. Alpatov, I. Issaeva, E. Canaani, T.M. Roberts, H.Y. Chang, and Y. Shi. 2007.   187 
A histone H3 lysine 27 demethylase regulates animal posterior development. 
Nature. 449:689-94. 
•  Lanzuolo,  C.,  V.  Roure,  J.  Dekker,  F.  Bantignies,  and  V.  Orlando.  2007. 
Polycomb  response  elements  mediate  the  formation  of  chromosome  higher-
order structures in the bithorax complex. Nat Cell Biol. 9:1167-74. 
•  Lapidot, T., C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. 
Minden,  B.  Paterson,  M.A.  Caligiuri,  and  J.E.  Dick.  1994.  A  cell  initiating 
human acute myeloid leukaemia after transplantation into SCID mice. Nature. 
367:645-8. 
•  Lechtenberg, B.C., M.D. Allen, T.J. Rutherford, S.M. Freund, and M. Bycroft. 
2009. Solution structure of the FCS zinc finger domain of the human polycomb 
group protein L(3)mbt-like 2. Protein Sci. 18:657-61. 
•  Lee, M.G., R. Villa, P. Trojer, J. Norman, K.P. Yan, D. Reinberg, L. Di Croce, 
and  R.  Shiekhattar.  2007.  Demethylation  of  H3K27  regulates  polycomb 
recruitment and H2A ubiquitination. Science. 318:447-50. 
•  Lee, T.I., R.G. Jenner, L.A. Boyer, M.G. Guenther, S.S. Levine, R.M. Kumar, 
B. Chevalier, S.E. Johnstone, M.F. Cole, K. Isono, H. Koseki, T. Fuchikami, K. 
Abe, H.L. Murray, J.P. Zucker, B. Yuan, G.W. Bell, E. Herbolsheimer, N.M. 
Hannett, K. Sun, D.T. Odom, A.P. Otte, T.L. Volkert, D.P. Bartel, D.A. Melton, 
D.K. Gifford, R. Jaenisch, and R.A. Young. 2006. Control of developmental 
regulators by Polycomb in human embryonic stem cells. Cell. 125:301-13. 
•  Leeb,  M.,  and  A.  Wutz.  2007.  Ring1B  is  crucial  for  the  regulation  of 
developmental  control  genes  and  PRC1  proteins  but  not  X  inactivation  in 
embryonic cells. J Cell Biol. 178:219-29. 
•  Lessard,  J.,  and  G.  Sauvageau.  2003.  Bmi-1  determines  the  proliferative 
capacity of normal and leukaemic stem cells. Nature. 423:255-60. 
•  Lessard,  J.,  A.  Schumacher,  U.  Thorsteinsdottir,  M.  van  Lohuizen,  T. 
Magnuson, and G. Sauvageau. 1999. Functional antagonism of the Polycomb-
Group  genes  eed  and  Bmi1  in  hemopoietic  cell  proliferation.  Genes  Dev. 
13:2691-703. 
•  Leung, C., M. Lingbeek, O. Shakhova, J. Liu, E. Tanger, P. Saremaslani, M. 
Van  Lohuizen,  and  S.  Marino.  2004.  Bmi1  is  essential  for  cerebellar 
development  and  is  overexpressed  in  human  medulloblastomas.  Nature. 
428:337-41.   188 
•  Levine, S.S., A. Weiss, H. Erdjument-Bromage, Z. Shao, P. Tempst, and R.E. 
Kingston.  2002.  The  core  of  the  polycomb  repressive  complex  is 
compositionally and functionally conserved in flies and humans. Mol Cell Biol. 
22:6070-8. 
•  Lewis,  E.B.  1978.  A  gene  complex  controlling  segmentation  in  Drosophila. 
Nature. 276:565-70. 
•  Lewis, J.L., W. Chinswangwatanakul, B. Zheng, S.B. Marley, D.X. Nguyen, 
N.C. Cross, L. Banerji, J. Glassford, N.S. Thomas, J.M. Goldman, E.W. Lam, 
and M.Y. Gordon. 2001. The influence of INK4 proteins on growth and self-
renewal kinetics of hematopoietic progenitor cells. Blood. 97:2604-10. 
•  Li, B., J. Zhou, P. Liu, J. Hu, H. Jin, Y. Shimono, M. Takahashi, and G. Xu. 
2007. Polycomb protein Cbx4 promotes SUMO modification of de novo DNA 
methyltransferase Dnmt3a. Biochem J. 405:369-78. 
•  Li,  H.,  M.  Collado,  A.  Villasante,  K. Strati,  S. Ortega,  M.  Canamero,  M.A. 
Blasco,  and  M.  Serrano.  2009.  The  Ink4/Arf  locus  is  a  barrier  for  iPS  cell 
reprogramming. Nature. 460:1136-9. 
•  Li, T., J.F. Hu, X. Qiu, J. Ling, H. Chen, S. Wang, A. Hou, T.H. Vu, and A.R. 
Hoffman. 2008. CTCF regulates allelic expression of Igf2 by orchestrating a 
promoter-polycomb  repressive  complex  2  intrachromosomal  loop.  Mol  Cell 
Biol. 28:6473-82. 
•  Li, Z., R. Cao, M. Wang, M.P. Myers, Y. Zhang, and R.M. Xu. 2006. Structure 
of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex. J Biol Chem. 
281:20643-9. 
•  Lin, A.W., M. Barradas, J.C. Stone, L. van Aelst, M. Serrano, and S.W. Lowe. 
1998. Premature senescence involving p53 and p16 is activated in response to 
constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12:3008-19. 
•  Listerman,  I.,  A.K.  Sapra,  and  K.M.  Neugebauer.  2006.  Cotranscriptional 
coupling of splicing factor recruitment and precursor messenger RNA splicing 
in mammalian cells. Nat Struct Mol Biol. 13:815-22. 
•  Liu, J., L. Cao, J. Chen, S. Song, I.H. Lee, C. Quijano, H. Liu, K. Keyvanfar, H. 
Chen, L.Y. Cao, B.H. Ahn, N.G. Kumar, Rovira, II, X.L. Xu, M. van Lohuizen, 
N. Motoyama, C.X. Deng, and T. Finkel. 2009. Bmi1 regulates mitochondrial 
function and the DNA damage response pathway. Nature. 459:387-92. 
•  Liu, L., L.G. Andrews, and T.O. Tollefsbol. 2006. Loss of the human polycomb 
group protein BMI1 promotes cancer-specific cell death. Oncogene. 25:4370-5.   189 
•  Lu,  T.,  and  T.  Finkel.  2008.  Free  radicals  and  senescence.  Exp  Cell  Res. 
314:1918-22. 
•  Maddika,  S.,  and  J.  Chen.  2009.  Protein  kinase  DYRK2  is  a  scaffold  that 
facilitates assembly of an E3 ligase. Nat Cell Biol. 11:409-19. 
•  Maertens, G.N., S. El Messaoudi-Aubert, T. Racek, J.K. Stock, J. Nicholls, M. 
Rodriguez-Niedenfuhr, J. Gil, and G. Peters. 2009. Several distinct polycomb 
complexes regulate and co-localize on the INK4a tumor suppressor locus. PLoS 
One. 4:e6380. 
•  Margueron, R., G. Li, K. Sarma, A. Blais, J. Zavadil, C.L. Woodcock, B.D. 
Dynlacht, and D. Reinberg. 2008. Ezh1 and Ezh2 maintain repressive chromatin 
through different mechanisms. Mol Cell. 32:503-18. 
•  Marion, R.M., K. Strati, H. Li, M. Murga, R. Blanco, S. Ortega, O. Fernandez-
Capetillo, M. Serrano, and M.A. Blasco. 2009. A p53-mediated DNA damage 
response  limits  reprogramming  to  ensure  iPS  cell  genomic  integrity.  Nature. 
460:1149-53. 
•  Martianov, I., A. Ramadass, A. Serra Barros, N. Chow, and A. Akoulitchev. 
2007. Repression of the human dihydrofolate reductase gene by a non-coding 
interfering transcript. Nature. 445:666-70. 
•  Martinez, A.M., B. Schuettengruber, S. Sakr, A. Janic, C. Gonzalez, and G. 
Cavalli.  2009.  Polyhomeotic  has  a  tumor  suppressor  activity  mediated  by 
repression of Notch signaling. Nat Genet. 
•  Masutomi, K., E.Y. Yu, S. Khurts, I. Ben-Porath, J.L. Currier, G.B. Metz, M.W. 
Brooks, S. Kaneko, S. Murakami, J.A. DeCaprio, R.A. Weinberg, S.A. Stewart, 
and  W.C.  Hahn.  2003.  Telomerase  maintains  telomere  structure  in  normal 
human cells. Cell. 114:241-53. 
•  Matheu,  A.,  C.  Pantoja,  A.  Efeyan,  L.M.  Criado,  J.  Martin-Caballero,  J.M. 
Flores,  P.  Klatt,  and  M.  Serrano.  2004.  Increased  gene  dosage  of  Ink4a/Arf 
results in cancer resistance and normal aging. Genes Dev. 18:2736-46. 
•  Matsuoka, S., B.A. Ballif, A. Smogorzewska, E.R. McDonald, 3rd, K.E. Hurov, 
J. Luo, C.E. Bakalarski, Z. Zhao, N. Solimini, Y. Lerenthal, Y. Shiloh, S.P. 
Gygi,  and  S.J.  Elledge.  2007.  ATM  and  ATR  substrate  analysis  reveals 
extensive protein networks responsive to DNA damage. Science. 316:1160-6. 
•  McPherson, R., A. Pertsemlidis, N. Kavaslar, A. Stewart, R. Roberts, D.R. Cox, 
D.A.  Hinds,  L.A.  Pennacchio,  A.  Tybjaerg-Hansen,  A.R.  Folsom,  E.   190 
Boerwinkle,  H.H.  Hobbs,  and  J.C.  Cohen.  2007.  A  common  allele  on 
chromosome 9 associated with coronary heart disease. Science. 316:1488-91. 
•  Michaloglou,  C.,  L.C.  Vredeveld,  M.S.  Soengas,  C.  Denoyelle,  T.  Kuilman, 
C.M. van der Horst, D.M. Majoor, J.W. Shay, W.J. Mooi, and D.S. Peeper. 
2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. 
Nature. 436:720-4. 
•  Miki, J., Y. Fujimura, H. Koseki, and T. Kamijo. 2007. Polycomb complexes 
regulate cellular senescence by repression of ARF in cooperation with E2F3. 
Genes Cells. 12:1371-82. 
•  Mikkelsen, T.S., J. Hanna, X. Zhang, M. Ku, M. Wernig, P. Schorderet, B.E. 
Bernstein, R. Jaenisch, E.S. Lander, and A. Meissner. 2008. Dissecting direct 
reprogramming through integrative genomic analysis. Nature. 454:49-55. 
•  Mikkelsen, T.S., M. Ku, D.B. Jaffe, B. Issac, E. Lieberman, G. Giannoukos, P. 
Alvarez,  W.  Brockman,  T.K.  Kim,  R.P.  Koche,  W.  Lee,  E.  Mendenhall,  A. 
O'Donovan, A. Presser, C. Russ, X. Xie, A. Meissner, M. Wernig, R. Jaenisch, 
C. Nusbaum, E.S. Lander, and B.E. Bernstein. 2007. Genome-wide maps of 
chromatin state in pluripotent and lineage-committed cells. Nature. 448:553-60. 
•  Min, J., Y. Zhang, and R.M. Xu. 2003. Structural basis for specific binding of 
Polycomb  chromodomain  to  histone  H3  methylated  at  Lys  27.  Genes  Dev. 
17:1823-8. 
•  Mo,  J.Y.,  H.  Maki,  and  M.  Sekiguchi.  1992.  Hydrolytic  elimination  of  a 
mutagenic nucleotide, 8-oxodGTP, by human 18-kilodalton protein: sanitization 
of nucleotide pool. Proc Natl Acad Sci U S A. 89:11021-5. 
•  Mollaaghababa, R., L. Sipos, S.Y. Tiong, O. Papoulas, J.A. Armstrong, J.W. 
Tamkun, and W. Bender. 2001. Mutations in Drosophila heat shock cognate 4 
are enhancers of Polycomb. Proc Natl Acad Sci U S A. 98:3958-63. 
•  Molofsky,  A.V.,  R.  Pardal,  T.  Iwashita,  I.K.  Park,  M.F.  Clarke,  and  S.J. 
Morrison. 2003. Bmi-1 dependence distinguishes neural stem cell self-renewal 
from progenitor proliferation. Nature. 425:962-7. 
•  Molofsky, A.V., S.G. Slutsky, N.M. Joseph, S. He, R. Pardal, J. Krishnamurthy, 
N.E.  Sharpless,  and  S.J.  Morrison.  2006.  Increasing  p16INK4a  expression 
decreases  forebrain  progenitors  and  neurogenesis  during  ageing.  Nature. 
443:448-52.   191 
•  Montgomery, N.D., D. Yee, A. Chen, S. Kalantry, S.J. Chamberlain, A.P. Otte, 
and T. Magnuson. 2005. The murine polycomb group protein Eed is required for 
global histone H3 lysine-27 methylation. Curr Biol. 15:942-7. 
•  Muller, J., C.M. Hart, N.J. Francis, M.L. Vargas, A. Sengupta, B. Wild, E.L. 
Miller,  M.B.  O'Connor,  R.E.  Kingston,  and  J.A.  Simon.  2002.  Histone 
methyltransferase activity of a Drosophila Polycomb group repressor complex. 
Cell. 111:197-208. 
•  Murga, M., I. Jaco, Y. Fan, R. Soria, B. Martinez-Pastor, M. Cuadrado, S.M. 
Yang, M.A. Blasco, A.I. Skoultchi, and O. Fernandez-Capetillo. 2007. Global 
chromatin compaction limits the strength of the DNA damage response. J Cell 
Biol. 178:1101-8. 
•  Myohanen, S., and S.B. Baylin. 2001. Sequence-specific DNA binding activity 
of RNA helicase A to the p16INK4a promoter. J Biol Chem. 276:1634-42. 
•  Nakabeppu, Y., K. Kajitani, K. Sakamoto, H. Yamaguchi, and D. Tsuchimoto. 
2006.  MTH1,  an  oxidized  purine  nucleoside  triphosphatase,  prevents  the 
cytotoxicity  and  neurotoxicity  of  oxidized  purine  nucleotides.  DNA  Repair 
(Amst). 5:761-72. 
•  Nekrasov, M., B. Wild, and J. Muller. 2005. Nucleosome binding and histone 
methyltransferase activity of Drosophila PRC2. EMBO Rep. 6:348-53. 
•  Ng, J., C.M. Hart, K. Morgan, and J.A. Simon. 2000. A Drosophila ESC-E(Z) 
protein complex is distinct from other polycomb group complexes and contains 
covalently modified ESC. Mol Cell Biol. 20:3069-78. 
•  Nguyen, N., X. Zhang, N. Olashaw, and E. Seto. 2004. Molecular cloning and 
functional  characterization  of  the  transcription  factor  YY2.  J  Biol  Chem. 
279:25927-34. 
•  Nicholls,  J.  2006.  Investigating  protein  complexes  that  are  involved  in  the 
function and regulation of the human INK4a/ARF locus. PhD Thesis, University 
College London, UK. 
•  Nomura, M., Y. Takihara, and K. Shimada. 1994. Isolation and characterization 
of retinoic acid-inducible cDNA clones in F9 cells: one of the early inducible 
clones encodes a novel protein sharing several highly homologous regions with 
a Drosophila polyhomeotic protein. Differentiation. 57:39-50. 
•  O'Carroll, D., S. Erhardt, M. Pagani, S.C. Barton, M.A. Surani, and T. Jenuwein. 
2001. The polycomb-group gene Ezh2 is required for early mouse development. 
Mol Cell Biol. 21:4330-6.   192 
•  Ogawa, H., K. Ishiguro, S. Gaubatz, D.M. Livingston, and Y. Nakatani. 2002. A 
complex  with  chromatin  modifiers  that  occupies  E2F-  and  Myc-responsive 
genes in G0 cells. Science. 296:1132-6. 
•  Ohno, K., D. McCabe, B. Czermin, A. Imhof, and V. Pirrotta. 2008. ESC, ESCL 
and their roles in Polycomb Group mechanisms. Mech Dev. 125:527-41. 
•  Ohta, H., A. Sawada, J.Y. Kim, S. Tokimasa, S. Nishiguchi, R.K. Humphries, J. 
Hara,  and  Y.  Takihara.  2002.  Polycomb  group  gene  rae28  is  required  for 
sustaining activity of hematopoietic stem cells. J Exp Med. 195:759-70. 
•  Orford, K.W., and D.T. Scadden. 2008. Deconstructing stem cell self-renewal: 
genetic insights into cell-cycle regulation. Nat Rev Genet. 9:115-28. 
•  Pandey, R.R., T. Mondal, F. Mohammad, S. Enroth, L. Redrup, J. Komorowski, 
T.  Nagano,  D.  Mancini-Dinardo,  and  C.  Kanduri.  2008.  Kcnq1ot1  antisense 
noncoding  RNA  mediates  lineage-specific  transcriptional  silencing  through 
chromatin-level regulation. Mol Cell. 32:232-46. 
•  Pandya-Jones,  A.,  and  D.L.  Black.  2009.  Co-transcriptional  splicing  of 
constitutive and alternative exons. Rna. 15:1896-908. 
•  Papp, B., and J. Muller. 2006. Histone trimethylation and the maintenance of 
transcriptional  ON  and  OFF  states  by  trxG  and  PcG  proteins.  Genes  Dev. 
20:2041-54. 
•  Park, I.K., D. Qian, M. Kiel, M.W. Becker, M. Pihalja, I.L. Weissman, S.J. 
Morrison, and M.F. Clarke. 2003. Bmi-1 is required for maintenance of adult 
self-renewing haematopoietic stem cells. Nature. 423:302-5. 
•  Parrinello, S., E. Samper, A. Krtolica, J. Goldstein, S. Melov, and J. Campisi. 
2003.  Oxygen  sensitivity  severely  limits  the  replicative  lifespan  of  murine 
fibroblasts. Nat Cell Biol. 5:741-7. 
•  Pasini, D., A.P. Bracken, J.B. Hansen, M. Capillo, and K. Helin. 2007. The 
polycomb  group  protein  Suz12  is  required  for  embryonic  stem  cell 
differentiation. Mol Cell Biol. 27:3769-79. 
•  Pasini, D., A.P. Bracken, M.R. Jensen, E. Lazzerini Denchi, and K. Helin. 2004. 
Suz12  is  essential  for  mouse  development  and  for  EZH2  histone 
methyltransferase activity. Embo J. 23:4061-71. 
•  Pasmant, E., I. Laurendeau, D. Heron, M. Vidaud, D. Vidaud, and I. Bieche. 
2007. Characterization of a germ-line deletion, including the entire INK4/ARF 
locus, in a melanoma-neural system tumor family: identification of ANRIL, an   193 
antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 
67:3963-9. 
•  Pear, W.S., G.P. Nolan, M.L. Scott, and D. Baltimore. 1993. Production of high-
titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 
90:8392-6. 
•  Peters, G. 2008. Tumor suppression for ARFicionados: the relative contributions 
of p16INK4a and p14ARF in melanoma. J Natl Cancer Inst. 100:757-9. 
•  Peterson, A.J., M. Kyba, D. Bornemann, K. Morgan, H.W. Brock, and J. Simon. 
1997. A domain shared by the Polycomb group proteins Scm and ph mediates 
heterotypic and homotypic interactions. Mol Cell Biol. 17:6683-92. 
•  Plath, K., D. Talbot, K.M. Hamer, A.P. Otte, T.P. Yang, R. Jaenisch, and B. 
Panning. 2004. Developmentally regulated alterations in Polycomb repressive 
complex 1 proteins on the inactive X chromosome. J Cell Biol. 167:1025-35. 
•  Poux, S., R. Melfi, and V. Pirrotta. 2001. Establishment of Polycomb silencing 
requires a transient interaction between PC and ESC. Genes Dev. 15:2509-14. 
•  Quelle, D.E., F. Zindy, R.A. Ashmun, and C.J. Sherr. 1995. Alternative reading 
frames  of  the  INK4a  tumor  suppressor  gene  encode  two  unrelated  proteins 
capable of inducing cell cycle arrest. Cell. 83:993-1000. 
•  Rai, P., T.T. Onder, J.J. Young, J.L. McFaline, B. Pang, P.C. Dedon, and R.A. 
Weinberg. 2009. Continuous elimination of oxidized nucleotides is necessary to 
prevent rapid onset of cellular senescence. Proc Natl Acad Sci U S A. 106:169-
74. 
•  Ramirez, R.D., C.P. Morales, B.S. Herbert, J.M. Rohde, C. Passons, J.W. Shay, 
and  W.E.  Wright.  2001.  Putative  telomere-independent  mechanisms  of 
replicative aging reflect inadequate growth conditions. Genes Dev. 15:398-403. 
•  Rea,  S.,  F.  Eisenhaber,  D.  O'Carroll,  B.D.  Strahl,  Z.W.  Sun,  M.  Schmid,  S. 
Opravil,  K.  Mechtler,  C.P.  Ponting,  C.D.  Allis,  and  T.  Jenuwein.  2000. 
Regulation  of  chromatin  structure  by  site-specific  histone  H3 
methyltransferases. Nature. 406:593-9. 
•  Ressler, S., J. Bartkova, H. Niederegger, J. Bartek, K. Scharffetter-Kochanek, P. 
Jansen-Durr, and M. Wlaschek. 2006. p16INK4A is a robust in vivo biomarker 
of cellular aging in human skin. Aging Cell. 5:379-89. 
•  Reya,  T.,  S.J.  Morrison,  M.F.  Clarke,  and  I.L. Weissman.  2001.  Stem  cells, 
cancer, and cancer stem cells. Nature. 414:105-11.   194 
•  Rigaut, G., A. Shevchenko, B. Rutz, M. Wilm, M. Mann, and B. Seraphin. 1999. 
A generic protein purification method for protein complex characterization and 
proteome exploration. Nat Biotechnol. 17:1030-2. 
•  Ringrose, L. 2007. Polycomb comes of age: genome-wide profiling of target 
sites. Curr Opin Cell Biol. 19:290-7. 
•  Ringrose, L., H. Ehret, and R. Paro. 2004. Distinct contributions of histone H3 
lysine 9 and 27 methylation to locus-specific stability of polycomb complexes. 
Mol Cell. 16:641-53. 
•  Rinn, J.L., M. Kertesz, J.K. Wang, S.L. Squazzo, X. Xu, S.A. Brugmann, L.H. 
Goodnough,  J.A.  Helms,  P.J.  Farnham,  E.  Segal,  and  H.Y.  Chang.  2007. 
Functional demarcation of active and silent chromatin domains in human HOX 
loci by noncoding RNAs. Cell. 129:1311-23. 
•  Rodier, F., J.P. Coppe, C.K. Patil, W.A. Hoeijmakers, D.P. Munoz, S.R. Raza, 
A. Freund, E. Campeau, A.R. Davalos, and J. Campisi. 2009. Persistent DNA 
damage  signalling  triggers  senescence-associated  inflammatory  cytokine 
secretion. Nat Cell Biol. 11:973-9. 
•  Rohozinski,  J.,  and  C.E.  Bishop.  2004.  The  mouse  juvenile  spermatogonial 
depletion  (jsd)  phenotype  is  due  to  a  mutation  in  the  X-derived  retrogene, 
mUtp14b. Proc Natl Acad Sci U S A. 101:11695-700. 
•  Roy,  N.,  A.  Van  Eynde,  L.  Beke,  M.  Nuytten,  and  M.  Bollen.  2007.  The 
transcriptional repression by NIPP1 is mediated by Polycomb group proteins. 
Biochim Biophys Acta. 1769:541-5. 
•  Ruas, M., and G. Peters. 1998. The p16INK4a/CDKN2A tumor suppressor and 
its relatives. Biochim Biophys Acta. 1378:F115-77. 
•  Sakamoto, Y., S. Watanabe, T. Ichimura, M. Kawasuji, H. Koseki, H. Baba, and 
M.  Nakao.  2007.  Overlapping  roles  of  the  methylated  DNA-binding  protein 
MBD1  and  polycomb  group  proteins  in  transcriptional  repression  of  HOXA 
genes and heterochromatin foci formation. J Biol Chem. 282:16391-400. 
•  Sancho,  M.,  E.  Diani,  M.  Beato,  and  A.  Jordan.  2008.  Depletion  of  human 
histone H1 variants uncovers specific roles in gene expression and cell growth. 
PLoS Genet. 4:e1000227. 
•  Sandler, L., D.L. Lindsley, B. Nicoletti, and G. Trippa. 1968. Mutants affecting 
meiosis in natural populations of Drosophila melanogaster. Genetics. 60:525-58.   195 
•  Sasaki, M., J. Yamaguchi, K. Itatsu, H. Ikeda, and Y. Nakanuma. 2008. Over-
expression of polycomb group protein EZH2 relates to decreased expression of 
p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol. 215:175-83. 
•  Satijn,  D.P.,  M.J.  Gunster,  J.  van  der  Vlag,  K.M.  Hamer,  W.  Schul,  M.J. 
Alkema, A.J. Saurin, P.S. Freemont, R. van Driel, and A.P. Otte. 1997. RING1 
is  associated  with  the  polycomb  group  protein  complex  and  acts  as  a 
transcriptional repressor. Mol Cell Biol. 17:4105-13. 
•  Satijn, D.P., K.M. Hamer, J. den Blaauwen, and A.P. Otte. 2001. The polycomb 
group protein EED interacts with YY1, and both proteins induce neural tissue in 
Xenopus embryos. Mol Cell Biol. 21:1360-9. 
•  Saurin, A.J., Z. Shao, H. Erdjument-Bromage, P. Tempst, and R.E. Kingston. 
2001.  A  Drosophila  Polycomb  group  complex  includes  Zeste  and  dTAFII 
proteins. Nature. 412:655-60. 
•  Saurin, A.J., C. Shiels, J. Williamson, D.P. Satijn, A.P. Otte, D. Sheer, and P.S. 
Freemont.  1998.  The  human  polycomb  group  complex  associates  with 
pericentromeric heterochromatin to form a novel nuclear domain. J Cell Biol. 
142:887-98. 
•  Saxena, R., B.F. Voight, V. Lyssenko, N.P. Burtt, P.I. de Bakker, H. Chen, J.J. 
Roix, S. Kathiresan, J.N. Hirschhorn, M.J. Daly, T.E. Hughes, L. Groop, D. 
Altshuler, P. Almgren, J.C. Florez, J. Meyer, K. Ardlie, K. Bengtsson Bostrom, 
B. Isomaa, G. Lettre, U. Lindblad, H.N. Lyon, O. Melander, C. Newton-Cheh, 
P. Nilsson, M. Orho-Melander, L. Rastam, E.K. Speliotes, M.R. Taskinen, T. 
Tuomi, C. Guiducci, A. Berglund, J. Carlson, L. Gianniny, R. Hackett, L. Hall, 
J. Holmkvist, E. Laurila, M. Sjogren, M. Sterner, A. Surti, M. Svensson, M. 
Svensson, R. Tewhey, B. Blumenstiel, M. Parkin, M. Defelice, R. Barry, W. 
Brodeur, J. Camarata, N. Chia, M. Fava, J. Gibbons, B. Handsaker, C. Healy, K. 
Nguyen, C. Gates, C. Sougnez, D. Gage, M. Nizzari, S.B. Gabriel, G.W. Chirn, 
Q. Ma, H. Parikh, D. Richardson, D. Ricke, and S. Purcell. 2007. Genome-wide 
association analysis identifies loci for type 2 diabetes and triglyceride levels. 
Science. 316:1331-6. 
•  Schlesinger, Y., R. Straussman, I. Keshet, S. Farkash, M. Hecht, J. Zimmerman, 
E. Eden, Z. Yakhini, E. Ben-Shushan, B.E. Reubinoff, Y. Bergman, I. Simon, 
and H. Cedar. 2007. Polycomb-mediated methylation on Lys27 of histone H3 
pre-marks genes for de novo methylation in cancer. Nat Genet. 39:232-6.   196 
•  Schmitt, S., M. Prestel, and R. Paro. 2005. Intergenic transcription through a 
polycomb group response element counteracts silencing. Genes Dev. 19:697-
708. 
•  Schoeftner, S., A.K. Sengupta, S. Kubicek, K. Mechtler, L. Spahn, H. Koseki, T. 
Jenuwein, and A. Wutz. 2006. Recruitment of PRC1 function at the initiation of 
X inactivation independent of PRC2 and silencing. Embo J. 25:3110-22. 
•  Schotta,  G.,  M.  Lachner,  K.  Sarma,  A.  Ebert,  R.  Sengupta,  G.  Reuter,  D. 
Reinberg, and T. Jenuwein. 2004. A silencing pathway to induce H3-K9 and 
H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 18:1251-62. 
•  Schuettengruber, B., D. Chourrout, M. Vervoort, B. Leblanc, and G. Cavalli. 
2007. Genome regulation by polycomb and trithorax proteins. Cell. 128:735-45. 
•  Schumacher,  A.,  C.  Faust,  and  T.  Magnuson.  1996.  Positional  cloning  of  a 
global regulator of anterior-posterior patterning in mice. Nature. 384:648. 
•  Schwartz, S., E. Meshorer, and G. Ast. 2009. Chromatin organization marks 
exon-intron structure. Nat Struct Mol Biol. 16:990-5. 
•  Schwartz, Y.B., T.G. Kahn, D.A. Nix, X.Y. Li, R. Bourgon, M. Biggin, and V. 
Pirrotta.  2006.  Genome-wide  analysis  of  Polycomb  targets  in  Drosophila 
melanogaster. Nat Genet. 38:700-5. 
•  Schwartz, Y.B., and V. Pirrotta. 2007. Polycomb silencing mechanisms and the 
management of genomic programmes. Nat Rev Genet. 8:9-22. 
•  Schwartz,  Y.B.,  and  V.  Pirrotta.  2008.  Polycomb  complexes  and  epigenetic 
states. Curr Opin Cell Biol. 20:266-73. 
•  Schwermann,  J.,  C.  Rathinam,  M.  Schubert,  S.  Schumacher,  F.  Noyan,  H. 
Koseki, A. Kotlyarov, C. Klein, and M. Gaestel. 2009. MAPKAP kinase MK2 
maintains self-renewal capacity of haematopoietic stem cells. Embo J. 28:1392-
406. 
•  Scott, C.L., J. Gil, E. Hernando, J. Teruya-Feldstein, M. Narita, D. Martinez, T. 
Visakorpi,  D.  Mu,  C.  Cordon-Cardo,  G.  Peters,  D.  Beach,  and  S.W.  Lowe. 
2007a. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl 
Acad Sci U S A. 104:5389-94. 
•  Scott, L.J.,  K.L.  Mohlke, L.L.  Bonnycastle,  C.J.  Willer,  Y.  Li,  W.L.  Duren, 
M.R. Erdos, H.M. Stringham, P.S. Chines, A.U. Jackson, L. Prokunina-Olsson, 
C.J.  Ding,  A.J.  Swift,  N.  Narisu,  T.  Hu,  R.  Pruim,  R.  Xiao,  X.Y.  Li,  K.N. 
Conneely, N.L. Riebow, A.G. Sprau, M. Tong, P.P. White, K.N. Hetrick, M.W. 
Barnhart, C.W. Bark, J.L. Goldstein, L. Watkins, F. Xiang, J. Saramies, T.A.   197 
Buchanan, R.M. Watanabe, T.T. Valle, L. Kinnunen, G.R. Abecasis, E.W. Pugh, 
K.F.  Doheny,  R.N.  Bergman,  J.  Tuomilehto,  F.S.  Collins,  and  M.  Boehnke. 
2007b. A genome-wide association study of type 2 diabetes in Finns detects 
multiple susceptibility variants. Science. 316:1341-5. 
•  Serrano,  M.,  A.W.  Lin,  M.E.  McCurrach,  D.  Beach,  and  S.W.  Lowe.  1997. 
Oncogenic ras provokes premature cell senescence associated with accumulation 
of p53 and p16INK4a. Cell. 88:593-602. 
•  Sessa, L., A. Breiling, G. Lavorgna, L. Silvestri, G. Casari, and V. Orlando. 
2007.  Noncoding  RNA  synthesis  and  loss  of  Polycomb  group  repression 
accompanies the colinear activation of the human HOXA cluster. Rna. 13:223-
39. 
•  Sewalt, R.G., J. van der Vlag, M.J. Gunster, K.M. Hamer, J.L. den Blaauwen, 
D.P. Satijn, T. Hendrix, R. van Driel, and A.P. Otte. 1998. Characterization of 
interactions between the mammalian polycomb-group proteins Enx1/EZH2 and 
EED  suggests  the  existence  of  different  mammalian  polycomb-group  protein 
complexes. Mol Cell Biol. 18:3586-95. 
•  Shao, Z., F. Raible, R. Mollaaghababa, J.R. Guyon, C.T. Wu, W. Bender, and 
R.E. Kingston. 1999. Stabilization of chromatin structure by PRC1, a Polycomb 
complex. Cell. 98:37-46. 
•  Sharpless, N.E. 2005. INK4a/ARF: a multifunctional tumor suppressor locus. 
Mutat Res. 576:22-38. 
•  Sharpless,  N.E.,  N.  Bardeesy,  K.H.  Lee,  D.  Carrasco,  D.H.  Castrillon,  A.J. 
Aguirre, E.A. Wu, J.W. Horner, and R.A. DePinho. 2001. Loss of p16Ink4a 
with retention of p19Arf predisposes mice to tumorigenesis. Nature. 413:86-91. 
•  Shen, X., Y. Liu, Y.J. Hsu, Y. Fujiwara, J. Kim, X. Mao, G.C. Yuan, and S.H. 
Orkin.  2008.  EZH1  mediates  methylation  on  histone  H3  lysine  27  and 
complements  EZH2  in  maintaining  stem  cell  identity  and  executing 
pluripotency. Mol Cell. 32:491-502. 
•  Shi, Y., E. Seto, L.S. Chang, and T. Shenk. 1991. Transcriptional repression by 
YY1,  a  human  GLI-Kruppel-related  protein,  and  relief  of  repression  by 
adenovirus E1A protein. Cell. 67:377-88. 
•  Silva, J., W. Mak, I. Zvetkova, R. Appanah, T.B. Nesterova, Z. Webster, A.H. 
Peters,  T.  Jenuwein,  A.P.  Otte,  and  N.  Brockdorff.  2003.  Establishment  of 
histone  h3  methylation  on  the  inactive  X  chromosome  requires  transient 
recruitment of Eed-Enx1 polycomb group complexes. Dev Cell. 4:481-95.   198 
•  Simon, J.A., and R.E. Kingston. 2009. Mechanisms of Polycomb gene silencing: 
knowns and unknowns. Nat Rev Mol Cell Biol. 
•  Sing, A., D. Pannell, A. Karaiskakis, K. Sturgeon, M. Djabali, J. Ellis, H.D. 
Lipshitz,  and  S.P.  Cordes.  2009.  A  vertebrate  Polycomb  response  element 
governs segmentation of the posterior hindbrain. Cell. 138:885-97. 
•  Singh, S.K., I.D. Clarke, M. Terasaki, V.E. Bonn, C. Hawkins, J. Squire, and 
P.B. Dirks. 2003. Identification of a cancer stem cell in human brain tumors. 
Cancer Res. 63:5821-8. 
•  Sleutels,  F.,  R.  Zwart,  and  D.P.  Barlow.  2002. The  non-coding  Air  RNA  is 
required for silencing autosomal imprinted genes. Nature. 415:810-3. 
•  Sparmann, A., and M. van Lohuizen. 2006. Polycomb silencers control cell fate, 
development and cancer. Nat Rev Cancer. 6:846-56. 
•  Sridhar, V.V., A. Kapoor, K. Zhang, J. Zhu, T. Zhou, P.M. Hasegawa, R.A. 
Bressan, and J.K. Zhu. 2007. Control of DNA methylation and heterochromatic 
silencing by histone H2B deubiquitination. Nature. 447:735-8. 
•  Stewart, S.A., and R.A. Weinberg. 2006. Telomeres: cancer to human aging. 
Annu Rev Cell Dev Biol. 22:531-57. 
•  Stock, J.K., S. Giadrossi, M. Casanova, E. Brookes, M. Vidal, H. Koseki, N. 
Brockdorff, A.G. Fisher, and A. Pombo. 2007. Ring1-mediated ubiquitination of 
H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. 
Nat Cell Biol. 9:1428-35. 
•  Su, I.H., A. Basavaraj, A.N. Krutchinsky, O. Hobert, A. Ullrich, B.T. Chait, and 
A. Tarakhovsky. 2003. Ezh2 controls B cell development through histone H3 
methylation and Igh rearrangement. Nat Immunol. 4:124-31. 
•  Su,  I.H.,  M.W.  Dobenecker,  E.  Dickinson,  M.  Oser,  A.  Basavaraj,  R. 
Marqueron,  A.  Viale,  D.  Reinberg,  C.  Wulfing,  and  A.  Tarakhovsky.  2005. 
Polycomb group protein ezh2 controls actin polymerization and cell signaling. 
Cell. 121:425-36. 
•  Sui, Y., Z. Yang, S. Xiong, L. Zhang, K.L. Blanchard, S.C. Peiper, W.S. Dynan, 
D.  Tuan,  and  L.  Ko.  2007.  Gene  amplification  and  associated  loss  of  5' 
regulatory sequences of CoAA in human cancers. Oncogene. 26:822-35. 
•  Suzuki, M., Y. Mizutani-Koseki, Y. Fujimura, H. Miyagishima, T. Kaneko, Y. 
Takada, T. Akasaka, H. Tanzawa, Y. Takihara, M. Nakano, H. Masumoto, M. 
Vidal, K. Isono, and H. Koseki. 2002. Involvement of the Polycomb-group gene   199 
Ring1B in the specification of the anterior-posterior axis in mice. Development. 
129:4171-83. 
•  Swigut,  T.,  and  J.  Wysocka.  2007.  H3K27  demethylases,  at  long  last.  Cell. 
131:29-32. 
•  Takahashi, K., and S. Yamanaka. 2006. Induction of pluripotent stem cells from 
mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663-
76. 
•  Takihara,  Y.,  D.  Tomotsune,  M.  Shirai,  Y.  Katoh-Fukui,  K.  Nishii,  M.A. 
Motaleb, M. Nomura, R. Tsuchiya, Y. Fujita, Y. Shibata, T. Higashinakagawa, 
and  K.  Shimada.  1997.  Targeted  disruption  of  the  mouse  homologue  of  the 
Drosophila polyhomeotic gene leads to altered anteroposterior patterning and 
neural crest defects. Development. 124:3673-82. 
•  Tanuma, N., S.E. Kim, M. Beullens, Y. Tsubaki, S. Mitsuhashi, M. Nomura, T. 
Kawamura, K. Isono, H. Koseki, M. Sato, M. Bollen, K. Kikuchi, and H. Shima. 
2008.  Nuclear  inhibitor  of  protein  phosphatase-1  (NIPP1)  directs  protein 
phosphatase-1 (PP1) to dephosphorylate the U2 small nuclear ribonucleoprotein 
particle  (snRNP)  component,  spliceosome-associated  protein  155  (Sap155).  J 
Biol Chem. 283:35805-14. 
•  Terranova, R., S. Yokobayashi, M.B. Stadler, A.P. Otte, M. van Lohuizen, S.H. 
Orkin, and A.H. Peters. 2008. Polycomb group proteins Ezh2 and Rnf2 direct 
genomic  contraction  and  imprinted  repression  in  early  mouse  embryos.  Dev 
Cell. 15:668-79. 
•  Tetsu,  O.,  H.  Ishihara,  R.  Kanno,  M.  Kamiyasu,  H.  Inoue,  T.  Tokuhisa,  M. 
Taniguchi,  and  M.  Kanno.  1998.  mel-18  negatively  regulates  cell  cycle 
progression upon B cell antigen receptor stimulation through a cascade leading 
to c-myc/cdc25. Immunity. 9:439-48. 
•  Tie,  F.,  T.  Furuyama,  J.  Prasad-Sinha,  E.  Jane,  and  P.J.  Harte.  2001.  The 
Drosophila Polycomb Group proteins ESC and E(Z) are present in a complex 
containing the histone-binding protein p55 and the histone deacetylase RPD3. 
Development. 128:275-86. 
•  Tie, F., C.A. Stratton, R.L. Kurzhals, and P.J. Harte. 2007. The N terminus of 
Drosophila ESC binds directly to histone H3 and is required for E(Z)-dependent 
trimethylation of H3 lysine 27. Mol Cell Biol. 27:2014-26.   200 
•  Tilgner, H., C. Nikolaou, S. Althammer, M. Sammeth, M. Beato, J. Valcarcel, 
and  R.  Guigo.  2009.  Nucleosome  positioning  as  a  determinant  of  exon 
recognition. Nat Struct Mol Biol. 16:996-1001. 
•  Tiwari, V.K., L. Cope, K.M. McGarvey, J.E. Ohm, and S.B. Baylin. 2008. A 
novel  6C  assay  uncovers  Polycomb-mediated  higher  order  chromatin 
conformations. Genome Res. 18:1171-9. 
•  Tokimasa, S., H. Ohta, A. Sawada, Y. Matsuda, J.Y. Kim, S. Nishiguchi, J. 
Hara, and Y. Takihara. 2001. Lack of the Polycomb-group gene rae28 causes 
maturation arrest at the early B-cell developmental stage. Exp Hematol. 29:93-
103. 
•  Tolhuis, B., E. de Wit, I. Muijrers, H. Teunissen, W. Talhout, B. van Steensel, 
and  M.  van  Lohuizen.  2006.  Genome-wide  profiling  of  PRC1  and  PRC2 
Polycomb chromatin binding in Drosophila melanogaster. Nat Genet. 38:694-9. 
•  Tonkin,  E.,  D.M.  Hagan,  W.  Li,  and  T.  Strachan.  2002.  Identification  and 
characterisation  of  novel  mammalian  homologues  of  Drosophila 
polyhomeoticpermits new insights into relationships between members of the 
polyhomeotic family. Hum Genet. 111:435-42. 
•  Trimarchi,  J.M.,  B.  Fairchild,  J.  Wen,  and  J.A.  Lees.  2001.  The  E2F6 
transcription  factor  is  a  component  of  the  mammalian  Bmi1-containing 
polycomb complex. Proc Natl Acad Sci U S A. 98:1519-24. 
•  Trinkle-Mulcahy,  L.,  S.  Boulon,  Y.W.  Lam,  R.  Urcia,  F.M.  Boisvert,  F. 
Vandermoere,  N.A.  Morrice,  S.  Swift,  U.  Rothbauer,  H.  Leonhardt,  and  A. 
Lamond.  2008.  Identifying  specific  protein  interaction  partners  using 
quantitative mass spectrometry and bead proteomes. J Cell Biol. 183:223-39. 
•  Ulke-Lemee, A., L. Trinkle-Mulcahy, S. Chaulk, N.K. Bernstein, N. Morrice, 
M. Glover, A.I. Lamond, and G.B. Moorhead. 2007. The nuclear PP1 interacting 
protein  ZAP3  (ZAP)  is  a  putative  nucleoside  kinase  that  complexes  with 
SAM68, CIA, NF110/45, and HNRNP-G. Biochim Biophys Acta. 1774:1339-
50. 
•  Utama,  B.,  D.  Kennedy,  K.  Ru,  and  J.S.  Mattick.  2002.  Isolation  and 
characterization of a new nucleolar protein, Nrap, that is conserved from yeast to 
humans. Genes Cells. 7:115-32. 
•  Vakoc, C.R., S.A. Mandat, B.A. Olenchock, and G.A. Blobel. 2005. Histone H3 
lysine  9  methylation  and  HP1gamma  are  associated  with  transcription 
elongation through mammalian chromatin. Mol Cell. 19:381-91.   201 
•  Valk-Lingbeek, M.E., S.W. Bruggeman, and M. van Lohuizen. 2004. Stem cells 
and cancer; the polycomb connection. Cell. 118:409-18. 
•  van der Knaap, J.A., B.R. Kumar, Y.M. Moshkin, K. Langenberg, J. Krijgsveld, 
A.J.  Heck,  F.  Karch,  and  C.P.  Verrijzer.  2005.  GMP  synthetase  stimulates 
histone  H2B  deubiquitylation  by  the  epigenetic  silencer  USP7.  Mol  Cell. 
17:695-707. 
•  van der Lugt, N.M., J. Domen, K. Linders, M. van Roon, E. Robanus-Maandag, 
H. te Riele, M. van der Valk, J. Deschamps, M. Sofroniew, M. van Lohuizen, 
and et al. 1994. Posterior transformation, neurological abnormalities, and severe 
hematopoietic  defects  in  mice  with  a  targeted  deletion  of  the  bmi-1  proto-
oncogene. Genes Dev. 8:757-69. 
•  van der Vlag, J., and A.P. Otte. 1999. Transcriptional repression mediated by the 
human polycomb-group protein EED involves histone deacetylation. Nat Genet. 
23:474-8. 
•  van Lohuizen, M., M. Tijms, J.W. Voncken, A. Schumacher, T. Magnuson, and 
E. Wientjens. 1998. Interaction of mouse polycomb-group (Pc-G) proteins Enx1 
and Enx2 with Eed: indication for separate Pc-G complexes. Mol Cell  Biol. 
18:3572-9. 
•  van Lohuizen, M., S. Verbeek, B. Scheijen, E. Wientjens, H. van der Gulden, 
and  A.  Berns.  1991.  Identification  of  cooperating  oncogenes  in  E  mu-myc 
transgenic mice by provirus tagging. Cell. 65:737-52. 
•  Varambally, S., S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, 
M.G. Sanda, D. Ghosh, K.J. Pienta, R.G. Sewalt, A.P. Otte, M.A. Rubin, and 
A.M.  Chinnaiyan.  2002.  The  polycomb  group  protein  EZH2  is  involved  in 
progression of prostate cancer. Nature. 419:624-9. 
•  Vincenz, C., and T.K. Kerppola. 2008. Different polycomb group CBX family 
proteins  associate  with  distinct  regions  of  chromatin  using  nonhomologous 
protein sequences. Proc Natl Acad Sci U S A. 105:16572-7. 
•  Vire, E., C. Brenner, R. Deplus, L. Blanchon, M. Fraga, C. Didelot, L. Morey, 
A. Van Eynde, D. Bernard, J.M. Vanderwinden, M. Bollen, M. Esteller, L. Di 
Croce, Y. de Launoit, and F. Fuks. 2006. The Polycomb group protein EZH2 
directly controls DNA methylation. Nature. 439:871-4. 
•  Voncken,  J.W.,  H.  Niessen,  B.  Neufeld,  U.  Rennefahrt,  V.  Dahlmans,  N. 
Kubben, B. Holzer, S. Ludwig, and U.R. Rapp. 2005. MAPKAP kinase 3pK   202 
phosphorylates  and  regulates  chromatin  association  of  the  polycomb  group 
protein Bmi1. J Biol Chem. 280:5178-87. 
•  Voncken, J.W., B.A. Roelen, M. Roefs, S. de Vries, E. Verhoeven, S. Marino, J. 
Deschamps,  and  M.  van  Lohuizen.  2003.  Rnf2  (Ring1b)  deficiency  causes 
gastrulation  arrest  and  cell  cycle  inhibition.  Proc  Natl  Acad  Sci  U  S  A. 
100:2468-73. 
•  Voncken, J.W., D. Schweizer, L. Aagaard, L. Sattler, M.F. Jantsch, and M. van 
Lohuizen. 1999. Chromatin-association of the Polycomb group protein BMI1 is 
cell cycle-regulated and correlates with its phosphorylation status. J Cell Sci. 
112 ( Pt 24):4627-39. 
•  Vonlanthen, S., J. Heighway, H.J. Altermatt, M. Gugger, A. Kappeler, M.M. 
Borner, M. van Lohuizen, and D.C. Betticher. 2001. The bmi-1 oncoprotein is 
differentially  expressed  in  non-small  cell  lung  cancer  and  correlates  with 
INK4A-ARF locus expression. Br J Cancer. 84:1372-6. 
•  Vousden,  K.H.,  and  C.  Prives.  2009.  Blinded  by  the  Light:  The  Growing 
Complexity of p53. Cell. 137:413-31. 
•  Wang,  E.T.,  R.  Sandberg, S. Luo,  I.  Khrebtukova,  L. Zhang,  C.  Mayr, S.F. 
Kingsmore, G.P. Schroth, and C.B. Burge. 2008. Alternative isoform regulation 
in human tissue transcriptomes. Nature. 456:470-6. 
•  Wang, H., L. Wang, H. Erdjument-Bromage, M. Vidal, P. Tempst, R.S. Jones, 
and  Y.  Zhang.  2004a.  Role  of  histone  H2A  ubiquitination  in  Polycomb 
silencing. Nature. 431:873-8. 
•  Wang, L., J.L. Brown, R. Cao, Y. Zhang, J.A. Kassis, and R.S. Jones. 2004b. 
Hierarchical  recruitment  of  polycomb  group  silencing  complexes.  Mol  Cell. 
14:637-46. 
•  Wang,  Y.J.,  and  H.W.  Brock.  2003.  Polyhomeotic  stably  associates  with 
molecular  chaperones  Hsc4  and  Droj2  in  Drosophila  Kc1  cells.  Dev  Biol. 
262:350-60. 
•  Whitcomb, S.J., A. Basu, C.D. Allis, and E. Bernstein. 2007. Polycomb Group 
proteins: an evolutionary perspective. Trends Genet. 23:494-502. 
•  Wierstra, I. 2008. Sp1: emerging roles--beyond constitutive activation of TATA-
less housekeeping genes. Biochem Biophys Res Commun. 372:1-13. 
•  Yamaki, M., K. Isono, Y. Takada, K. Abe, T. Akasaka, H. Tanzawa, and H. 
Koseki. 2002. The mouse Edr2 (Mph2) gene has two forms of mRNA encoding 
90- and 36-kDa polypeptides. Gene. 288:103-10.   203 
•  Yannoni,  Y.M.,  M.  Gaestel,  and  L.L.  Lin.  2004.  P66(ShcA)  interacts  with 
MAPKAP kinase 2 and regulates its activity. FEBS Lett. 564:205-11. 
•  Yu, W., D. Gius, P. Onyango, K. Muldoon-Jacobs, J. Karp, A.P. Feinberg, and 
H.  Cui.  2008.  Epigenetic  silencing  of  tumour  suppressor  gene  p15  by  its 
antisense RNA. Nature. 451:202-6. 
•  Zeggini,  E.,  M.N.  Weedon,  C.M.  Lindgren,  T.M.  Frayling,  K.S.  Elliott,  H. 
Lango, N.J. Timpson, J.R. Perry, N.W. Rayner, R.M. Freathy, J.C. Barrett, B. 
Shields, A.P. Morris, S. Ellard, C.J. Groves, L.W. Harries, J.L. Marchini, K.R. 
Owen, B. Knight, L.R. Cardon, M. Walker, G.A. Hitman, A.D. Morris, A.S. 
Doney, M.I. McCarthy, and A.T. Hattersley. 2007. Replication of genome-wide 
association signals in UK samples reveals risk loci for type 2 diabetes. Science. 
316:1336-41. 
•  Zhang, H., A. Christoforou, L. Aravind, S.W. Emmons, S. van den Heuvel, and 
D.A.  Haber.  2004.  The  C.  elegans  Polycomb  gene  SOP-2  encodes  an  RNA 
binding protein. Mol Cell. 14:841-7. 
•  Zhang, T., Y. Sun, E. Tian, H. Deng, Y. Zhang, X. Luo, Q. Cai, H. Wang, J. 
Chai, and H. Zhang. 2006. RNA-binding proteins SOP-2 and SOR-1 form a 
novel PcG-like complex in C. elegans. Development. 133:1023-33. 
•  Zhao, J., B.K. Sun, J.A. Erwin, J.J. Song, and J.T. Lee. 2008. Polycomb proteins 
targeted by a short repeat RNA to the mouse X chromosome. Science. 322:750-
6. 
•  Zhu, J., D. Woods, M. McMahon, and J.M. Bishop. 1998. Senescence of human 
fibroblasts induced by oncogenic Raf. Genes Dev. 12:2997-3007. 
 
 